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Chapter 1 
General Introduction 
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Major depressive disorder (MDD) is a common mental health problem (American Psy-
chiatric Association, 1994). Most clinicians have treated numerous clients suffering 
from MDD. Depression influences 18 million people in the United States alone (Schrof, 
1999). It is estimated that between 3 and 20 percent of the adult population have met 
criteria for MDD at some point in their lives, with 20 to 50 percent of these people ex-
periencing more than one episode. Life time prevalence rates among women are 
about twice as high as among men (see for a review Kuehner, 2003). No gender differ-
ence in rates of recurrence has been reported in adult samples (Kuehner, 2003), but 
the recurrence rate of depression is twice as high in girls compared to boys in late ado-
lescent (Curry et al., 2010). In short, it can be concluded that high depression rates and 
recurrence rates among people from all ages can pose a significant social problem that 
should be taken seriously.  
 Much research and clinical expertise has been dedicated to try to understand and 
treat MDD. Effective psychological and pharmacological treatments for treating MDD 
are developed. Beck’s cognitive approach (1967, 1979) is one of the most influential 
models of conceptualization and treatment of depression. In recent years, interest in 
behavioural approaches such as Behavioural Activation (BA) in the treatment of de-
pression has been rapidly increasing. Clinical studies of BA have offered evidence that 
the early behavioural approach of Lewinsohn (1974) and colleagues (Lewinsohn et al., 
1976) was on the correct track in treating depression. It is worth remembering that the 
findings of Jacobson and colleagues’ component analysis study (1996) that BA did as 
well as cognitive therapy were replicated in Dimidjian and colleagues’ treatment for 
depression study (2006). Both of the mentioned studies were conducted at Washing-
ton University where BA was developed. Until now, only one study outside the BA’s 
developers site was published (Ekers et al., 2011). This study compared BA with treat-
ment as usual in a routine clinical setting in England (BA delivered by nurse practition-
ers). BA in the study was superior to treatment as usual. The evidence base for the 
effectiveness of a treatment is increased if results are replicated in other settings, with 
new therapists and patients. BA seems to be a very effective treatment based on a 
rather simple model and using techniques that appeal as easy to learn to non-specialist 
mental health care providers. This makes BA an attractive candidate for implementa-
tion in usual health care, even in countries with limited resources. However, the evi-
dence base for this is still limited and needs more empirical tests. 
Definition of Behavioural Activation  
The BA approach we used was based on two manuals (Martell et al., 2001, 2010). BA 
interventions are behaviourally based and specific cognitive interventions are prohibit-
ed. BA is an idiographic and functional approach. By means of functional analysis of 
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behaviours therapists try to find with the patients the functions of their behaviours 
and the contingencies that may maintain the behaviours. The focus of BA model is on 
activation, and on the barriers to activation. BA does not include cognitive treatment; 
BA therapists help patients to break the avoidance patterns and to schedule activities 
that will support them to move toward their goals in life. 
Behavioural Activation  
As said, in BA, interventions are behaviourally based and specific cognitive interven-
tions are prohibited. BA pays attention to the participant’s behaviours and the envi-
ronmental context in which the behaviours take place; acting according to goals, not to 
feelings; and using an activity chart to schedule people’s activities and monitor the 
relationship between activity and mood. Identifying secondary problems such as 
avoidance patterns and depressive ruminations are important because they play a role 
in maintaining and exacerbating depression. Most depressed individuals withdraw 
from social activities, thereby minimizing distress in the short-term but creating long-
term difficulties. BA tries to break down the pattern of avoidance and utilizes behav-
ioural techniques to target depressive ruminations. BA therapists deal with ruminating 
as behaviour rather than exploring or challenging the contents of ruminative thoughts. 
 Beck and colleagues (1979) also used behavioural activation in the treatment 
manual for cognitive therapy for depressed patients. In the early stages of cognitive 
therapy for individuals who are more severely depressed, behavioural activation is 
used. For severely depressed individuals, behavioural activation can be used as the 
primary strategy more than cognitive intervention. Behavioural activation in cognitive 
therapy involves first teaching the patients to monitor their behaviours through an 
activity schedule. Patients should rate their mood during each hour on the activity 
schedule or provide an overall rating for the whole day. After several days of monitor-
ing, the therapist and the patient evaluate the activity schedule and the patient is 
helped to draw conclusions about the relationship between the activity level and 
mood. 
 After the patient has learned to monitor activity, the therapist offers a list of activ-
ities to the patients that may provide a sense of either mastery or pleasure (or both). 
In cognitive therapy, these activity schedules and mastery/pleasure ratings are consid-
ered as homework. As patient’s mood improves, standard cognitive interventions are 
applied and the patient is taught to use the dysfunctional thought record (Beck et al., 
1979) to record automatic thoughts (Beck, 1976) and to explore and find alternative 
responses to the automatic thoughts. 
 The Behavioural activation goal in our study is activating patients, not changing or 
modifying cognitions. In this model, it is believed that a behavioural formulation is suf-
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ficient without offering underlying structures such as core beliefs or schemas. Accord-
ing to Ferster (1973), there is a strong theoretical rationale for increasing activities that 
will allow patients to break through a passive approach to life and help them to in-
crease contact with positive, natural reinforcement. BA therapists try to help the pa-
tients to increase the opportunity for behaviours to be reinforced positively. However, 
BA therapists do not look for a full cause-and-effect relationship to explain how de-
pression originated and is maintained in the patient’s life. Most schools of treatment 
for psychological disorders follow the basic philosophy that they look for a working 
mechanism inside the depressed patient and try to influence that alleged mechanism 
to lessen the depression. Cognitive, psychodynamic, and biological therapists with very 
different theoretical orientations share this basic philosophy of mechanism and try to 
find the solution for solving psychological problems inside the individual (e.g, changing 
cognitions, unresolved conflicts or biological deficits). BA and other contextual thera-
pists on the other hand look at the whole life of the person and the context in which 
the person lives (environment), try to reengage the person in the events of her or his 
life and pay less attention to what is going on inside the person (Martell et al., 2001). 
 The reasons for choosing BA and its comparison condition ADM as treatments of 
depression are as follows. The first one was the availability of a new psychological 
treatment (BA) for treating MDD with high effectiveness. This approach had not been 
tested in other countries than the United States and Great Britain, and only one study 
was published testing its effectiveness outside the site where BA was developed. This 
promising new approach inspired us to test its application in Iran. The second reason 
was the expectancy that the strategies and techniques in this approach could be deliv-
ered by non-expert professionals in clinical settings, and would therefore be easy to 
implement. 
 The most accessible and widely available treatment for psychological disorders 
throughout Iran (and perhaps the whole world) is medication treatment. Thus, in Iran 
the usual treatment for MDD in mental hospitals and private practice by psychiatrists is 
ADM. Therefore, we chose to compare BA to ADM.  
 A randomized control trial (RCT) is the most rigorous and important method of 
determining whether a cause-effect relation exist between treatment and outcome 
and also for evaluating cost-effectiveness of a treatment. Non-RCTs can find associa-
tions between an intervention and an outcome (Sibbald, B., & Roland, M., 1998), but 
they cannot detect the probability that the association was caused by a third factor 
related to intervention and outcome. An RCT guaranties no systemic differences be-
tween factors associated with participants, specified or non-specified, that may influ-
ence outcome. Therefore, we chose the RCT as our method to test BA vs ADM for de-
pression in an Iranian context to prevent the influence of such third factors in the 
treatment and outcome of the study. 
12 
 Many studies concluded that personality pathology comorbid with depression 
negatively affects the treatment of MDD (Hardy et al., 1995; Newton-Howes, Tyrer, & 
Johnson, 2006; Sato, Sakado, Sato, & Morikawa, 1994). However, two recent reviews 
reported that comorbidity of personality disorder with MDD does not have a negative 
influence on treatment outcome (Kool et al., 2005; Mulder, 2002). Until now, there has 
been a controversy among clinicians and researchers in this field over whether comor-
bidity of personality disorder with MDD has or does not have a negative influence on 
depression treatment. Therefore, we tested the influence of personality disorder 
comorbid with MDD in our participants on the outcome of treatment conditions. 
 
Concerning the influence of patient preferences for psychological or medication condi-
tions in treatment of MDD, the literature reports mixed results. Some studies did not 
find an association between preference and outcome of depression treatment (Bedi et 
al., 2000; Dunlop et al., 2012; Kwan, Dimijian, & Rezvi, 2010), while others found an 
association between preference and outcome of depression treatment (Kocsis et al., 
2009; Mergl et al., 2011; Patricia et al., 2005). To help to further clarify this issue, we 
tested patients’ preference for psychological or medication treatments on the influ-
ence of treatment outcome. 
 
The final question addressed in this dissertation is the influence of patients’ attribu-
tions of the immediate effect of depression treatment on long-term effectiveness of 
BA and ADM. One important study by Basoglu et al. (1994) investigated attributions 
that patients with panic disorder and agoraphobia made for their improvement. At 
follow-up in week 43, those patients who at week 8 attributed their improvement to 
medication reported more severe problems and relapse in comparison to those pa-
tients who attributed their improvement to their own efforts. Another study by Biondi 
and Picardi, (2003) that investigated panic disorder with agoraphobia produced the 
same findings. It is hypothesized that similar attributional processes play a role in the 
differential long-term effects of CBT vs. ADM in depression treatment. So far, no previ-
ous study tested this hypothesis. In our study, we tested the influence of patients’ at-
tributions of the immediate effect of depression treatment on long-term effectiveness 
of BA and ADM and then investigated whether attributions also mediated the long-
term difference between BA and ADM. 
Main aims of the dissertation  
The first aim of the present dissertation was to investigate whether behavioural activa-
tion would be a viable alternative for ADM for depressed people. We compared BA to 
ADM (Treatment As Usual in Iran) in terms of dropout rates, effectiveness in reducing 
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depressive symptoms, response and remission rates, and relapse at approximately one 
year. The second aim was whether depressed participants with co-morbid PD differ in 
symptom reduction over time compared to those without comorbid PD, and whether 
BA and ADM differ in this respect. The third aim was to investigate whether depressed 
patients’ preference for and attitudes towards psychological treatment and ADM in-
fluence symptom reduction in the course of one year and dropout from treatment. The 
final purpose was whether the attribution of treatment effects to the self predicts bet-
ter long-term effects of treatment, even when controlled of the short-term effects of 
treatment; and whether attributions to medication would predict relatively worse 
long-term effects. 
Outline of the dissertation 
As this study was the first study in a non-Western country to compare BA and ADM, 
chapter 2 covers an evaluation of the effectiveness of BA and treatment as usual 
(ADM) for MDD in routine clinical practice in Iran. More specifically, the study reported 
in chapter 2 aimed to test BA versus ADM in terms of dropout rates, effectiveness in 
reducing depressive symptoms, response and remission rates, and relapse at approxi-
mately one year. We also assessed whether initial depression severity would moderate 
condition differences. 
 The findings of the study investigating effects of comorbid personality disorder 
(PD) are presented in chapter 3. We investigated whether depressed participants with 
comorbid PD differ in symptom reduction over time compared to those without 
comorbid PD, and whether BA and ADM differ in this respect. We also compared par-
ticipants with comorbid PD to those without PD in terms of dropout rates, and reduc-
tion of depressive symptoms during and after short-term treatments and at approxi-
mately one year. Furthermore, we examined the association of the number of PD-
traits with dropout and outcome. 
 Chapter 4 addresses the influence of patients’ preferences/attitudes towards psy-
chological treatment or antidepressant medication. Our focus was on whether de-
pressed patients’ preference for and attitudes towards psychological treatment and 
ADM influence symptom reduction in the course of one year and dropout from treat-
ment. If so, this would have important implications for optimal matching of treatments 
and patients. 
 Chapter 5 covers the results of attribution of treatment effects to the self and to 
medication. We studied whether attribution of treatment effects to the self predicts 
better long-term effects of treatment, even when controlled of the short-term effects 
of treatment and whether attributions mediated the long-term difference between BA 
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and ADM. Similarly, we investigated whether attribution to medication predicts long-
term effects and mediates the long-term differences between the two conditions. 
 Chapter 6 offers a general discussion and summary of the findings presented in 
chapters 2-5. The chapter commences with a summary and integration of the findings 
of the four studies. Next, a critical discussion is offered, including a discussion of the 
limitations of the studies, scientific, clinical and societal implications, and future pro-
spects. The dissertation ends with a general summary. 
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Chapter 2 
Behavioural activation and antidepressant 
medication for treating depression in Iran: 
randomized trial1 
  
                                                                
1 Published as: Moradveisi, L., Huibers, M. J., Renner, F., Arasteh, M., & Arntz, A. (2013). Behavioural activa-
tion v. antidepressant medication for treating depression in Iran: randomised trial. The British Journal of 
Psychiatry, 202(3), 204-211. 
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Abstract 
Background 
Behavioural activation (BA) might be a viable alternative to antidepressant medication 
(ADM) for major depressive disorder (MDD). 
Aims 
To compare the effectiveness of behavioural activation and treatment as usual (TAU, 
antidepressant medication) for major depressive disorder in routine clinical practice in 
Iran. 
Method 
Patients with major depressive disorder (N = 100) were randomized to 16 sessions of 
behavioural activation (n = 50) or antidepressant medication (n = 50) (IRCT1388071-
92573N1). The main outcome was depression, measured with the Beck Depression 
Inventory (BDI) and the Hamilton Rating Scale for Depression (HRSD), and assessed at 
0, 4, 13 and 49 weeks. 
Results 
Symptom reduction was stronger in behavioural activation group than in the TAU 
group on both the BDI and the HRSD at 13 and 49 weeks in multilevel analysis. Baseline 
depression severity was a moderator, with relatively better effects of behavioural acti-
vation who were more severely depressed. Also, there was better retention in the be-
havioural activation than in the TAU group. 
Conclusions 
Behavioural activation is a viable and effective treatment for people with major de-
pressive disorder, especially for those who are more severely depressed, and it can 
successfully be disseminated into routine practice settings in a non-Western country 
such as Iran. 
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Introduction 
Major Depressive Disorder is a common mental health problem1 and there are many 
studies that have demonstrated the effectiveness of antidepressant medication in 
treating it.2,5 Thus, antidepressants have become the standard treatment for depres-
sion6,7, despite their limitations such as problems with side-effects, refusal by patients, 
and considerable relapse after discontinuation. Psychological treatments might offer a 
viable alternative.8,10 In non-Western countries, the use of antidepressant medication 
is even more common, due to the limited availability of psychotherapy. This means 
there is a need for better dissemination of relatively simple but effective psychological 
treatments. Behavioural Activation is such a candidate, given its effectiveness and rela-
tively simple protocol. 
 Behavioural activation is based on the behavioural component of cognitive behav-
iour therapy (CBT) for treating depression.11 A study by Jacobson et al12 found that BA 
was as effective as the full CBT-package for treating depression. In a subsequent trial 
by the same research group, Dimidjian et al. compared behavioural activation with 
antidepressant medication and CBT.13 They found that behavioural activation was as 
effective as antidepressant medication, and even outperformed CBT, especially in indi-
vidual who were more severely depressed. Moreover, participants originally treated 
with antidepressant medication and later a pill-placebo experienced more relapse at 
the 2-year follow-up than individuals treated with behavioural activation or CBT.8 Thus, 
for prevention of recurrence, behavioural activation and CBT were superior to medica-
tion discontinuation. Finally, more recently, two meta-analyses unanimously found 
that behavioural activation interventions are as effective as CBT.14, 15 
 One study by Ekers et al16 compared behavioural activation (delivered by nurse 
practitioners) with treatment as usual (TAU) in a routine clinical setting. The behav-
ioural activation was superior to TAU and the authors concluded that it might be easily 
delivered by mental health professionals. 
 The present study was set up to document the effectiveness of behavioural activa-
tion when implemented in clinical practice in Iran after a short period of training. We 
reasoned that there is a need for psychological treatment for depression in Iran as an 
alternative to antidepressant medication, which although readably available is not very 
popular due to its association with mental illness (creating stigma) and because of side 
effects. From the effective psychological treatments available, behavioural activation 
seemed the most easy to implement. Training and treatment were based on the pub-
lished behavioural activation protocol17,18, and none of the developers of behavioural 
activation or specialists were involved. 
 Thus, the study’s aim was to investigate whether a simple psychological treat-
ment, behavioural activation, would be a viable alternative to antidepressant medica-
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tion for people with depression, when implemented in a non-Western country. We 
compared behavioural activation to antidepressant medication (TAU) in Iran including 
drop-out rates, effectiveness in reducing depressive symptoms, response and remis-
sion rates, and relapse at approximately 1 year. We also assessed whether initial de-
pression severity would moderate condition differences. 
Method 
Participants 
Participants included 100 people with depression between the ages of 18 to 70 years, 
selected from 174 referrals. Inclusion criteria were: a primary diagnosis of MDD ac-
cording to the DSM-IV-TR19, confirmed by the Structured Clinical Interview for the 
DSM-IV-TR (SCID-CT) 20; a score of ≥ 19 on the Beck Depression Inventory (BDI-II) 21 and 
≥ 14 on the 17-item Hamilton Rating Scale for Depression (HRSD); 22 written consent to 
participate in the study. Exclusion criteria were: a life-time diagnosis of bipolar disor-
der or psychosis; organic brain syndrome; intellectual disability; substantial and immi-
nent suicide risk; a current (within the past six months) diagnosis of alcohol or drug 
misuse or dependence, or a positive toxicology screen; a primary diagnosis other than 
major depressive disorder; unfavourable antidepressant medication response within 
the preceding year; unstable medical condition; medication use that would complicate 
antidepressant medication administration; known allergy to antidepressant medica-
tion/Sertraline; pregnancy or a plan to become pregnant; inability to read and under-
stand the study’s instruments. 
 Participants were recruited through the media and poster advertisements (n = 45; 
45%), word of mouth (n = 8; 8%), and referral from other mental health clinics (n = 28; 
28%), and general practitioners (n = 19; 19%). Participants diagnosed with major de-
pressive disorder through telephone screening were referred to the Mental Health 
Clinic for further assessment. Psychiatrists confirmed diagnoses and checked the eligi-
bility of participants who completed the assessment. When eligibility was confirmed, 
participants were randomized by an independent coordinator using a computer-
generated list based on blocks of four, created by an independent statistician at Kurdi-
stan University of Medical Science. Fifty participants were randomly assigned to each 
condition (IRCT138807192573N1). Baseline HRSD was used as severity-index. Partici-
pants were allocated to therapists and psychiatrists based on their availability. 
 The study was powered to detect a medium to large effect between conditions 
with 80% power and a 0.05 level of significance. To compensate for participants drop-
ping-outs, the original N = 80 on which the power analysis was based was extended to 
N=100. The study was approved by the local Medical Ethics Committee of Kurdistan 
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University of Medical Science. Participants were treated at Ghods Psychiatric Hospital 
and the Mental Health Clinic in Sanandaj, Kurdistan Province. The study was conducted 
from November 2009 to September 2011. 
Therapists  
Behavioural activation was conducted by two counsellor psychologists and the first 
author (L.M); they had six years clinical experience on average. Training in behavioural 
activation was provided by L.M., a master-level psychologist, in 20 h over 2 weeks. 
Therapists participated in an on-site consultation meeting held almost twice a week, 
led by L.M. Four psychiatrists provided TAU (antidepressant medication); all were certi-
fied with an average of approximately five years of clinical experience. Training and 
supervision was provided by (M.A.). 
Treatments 
Behavioural activation 
The behaviour activation model we used was based on the two behavioural activation 
manuals by Martell et al.17,18 Behavioural activation interventions are behavioural 
based and specific cognitive interventions are prohibited. The focus is on the partici-
pant’s behaviours and the environmental context in which the behaviours take place; 
acting according to goals, not to feelings; and using an activity chart to schedule peo-
ple’s activities and follow the relationship between activity and mood. Identifying sec-
ondary problems such as avoidance patterns and depressive ruminations are im-
portant because they play a role in maintaining depression. Most depressed individuals 
withdraw from social activities, thereby minimizing distress in short-term but creating 
long-term difficulties. Behavioural activation tries to break down the pattern of avoid-
ance and utilises behavioural techniques to target depressive ruminations. BA thera-
pists deal with ruminating as a behaviour rather than engaging or challenging the con-
tents of ruminative thoughts. 
 Participants received 16 sessions during 12 weeks (as opposed to the earlier trials 
by Jacobson and Dimidjian12,13 in which patients received 24 sessions in 4 months). For 
the first 4 weeks there were two sessions per week, and for the following 8 weeks 
there was one session per week. 
Treatment As Usual (antidepressant medication) 
For TAU, we chose Sertraline, a selective serotonin reuptake inhibitor (SSRI), the major 
reason being the availability of it in Iran. The participants in the TAU group were not 
offered any psychotherapeutic interventions by their psychiatrists but they established 
treatment rapport to support the continuation of treatment. For the first 4 weeks of 
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the treatment, participants received one session per week and for the next 8 weeks 
they received one session every 2 weeks. For the first session, psychiatrists saw partic-
ipants for 20 min and the following sessions lasted approximately 10 min to monitor 
pharmacotherapy and side-effects. The maximum dosage of Sertraline was 100 mg per 
day. In week 1, participants in the TAU group received 25 mg/daily of Sertraline, the 
dosage in week 2 increased to 50 mg, 75 mg in week 4, and 100 mg in week 6 up to 
week 12. Psychiatrists could reduce the dosage temporarily in the case of side-effects 
and then increase the dosage to the previous level. The maximum dosage was 100 mg 
because as a rule, higher dosages do not increase antidepressant efficacy, but may 
increase the risk of adverse effects.23 All decisions about the dosage were made by the 
supervising psychiatrist (M.A). After 12 weeks, it was up to participants whether they 
continued or stopped antidepressant medication. In case of continuation, participants 
had to pay for their medication. 
Measures 
Diagnostic measures (baseline) 
We used SCID-I, 20 which is a semi-structured clinical interview to evaluate DSM-IV-TR 
axis-I diagnoses. We used SCID-II24 for diagnosing personality disorders (effects are 
reported separately). 
Outcome measures 
The modified 17-item HRSD and the 21-item BDI-II), both assessing depressive symp-
toms, were outcome measures. The HRSD was taken by evaluators who were masked 
to group. Assessments were conducted at baseline, and at 4, 13 and 49 weeks. In ac-
cordance with the Dimidjian study13, each session was preceded by the HRSD (TAU 
group) and the BDI-II (Behavioural activation group), administered by assistants who 
were masked to group; for participants who dropped out of treatment we used these 
data as the last observation in the analysis (see statistical analysis). 
Baseline severity 
The baseline HRSD was used as the depression severity measure. 
Response, remission, and relapse criteria 
Response indicates substantial symptomatic improvement, whereas remission means 
that symptoms lie within the normal range. Response was defined as at least 50% re-
duction from baseline on both the HRSD and BDI-II. Remission was defined as scores of 
≤ 7 on the HRSD and ≤ 10 on BDI. Relapse was defined as no longer meeting the remis-
sion criterion at 49 weeks in patients who remitted at 13 weeks. 
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Statistical Analysis 
Multilevel analysis was used to estimate change in depression severity over time. We 
applied intention-to-treat analysis, with the HRSD and BDI as dependent variables, by 
including all available scores. Visual inspection suggested linear and quadratic time 
effects; we therefore modelled time linearly and quadratically. We used an unstruc-
tured covariance structure for repeated measures, with time, time-squared and condi-
tion as fixed effects. We computed effect sizes for continuous outcomes (Cohen’s d 
and r)2 from the multilevel estimates (Cohen’s d = (baseline mean- mean at time i)/(√ 
baseline variance) for within-condition change; d = (difference between means of con-
dition at time i)/ √ (residual variance at time i) for differences between conditions; r = √ 
(F / (F + d.f)) . For participants who dropped out of treatment, we used the last obser-
vation with the associated time, and estimated missing HRSD scores (for those in be-
havioural activation group) from changes on the BDI, and missing BDI scores (for those 
in the TAU) from changes on the HRSD, using regression derived equations (1 BDI 
unit=1.3 HRSD unit). All treatment drop-out took place before the mid-treatment as-
sessment. We repeated the analyses without these estimates as a sensitivity analysis. 
 For the test of moderation by baseline symptom severity, we entered time, time-
squared, the standardized baseline severity score and condition as covariates in the 
model. There was only one baseline assessment and therefore we included HRSD and 
BDI scores at weeks 4, 13 and 49 as dependent variables in the analyses. The baseline 
severity X condition and the time X baseline severity X treatment condition interac-
tions are of primary interest in this analysis. In all models, treatment condition was 
centred at -½ and ½. Analyses were conducted using SPSS19 for windows. 
Results 
Participant Enrolment 
Figure 1 shows the flow of participants. Of 174 participants originally recruited, 74 did 
not meet selection criteria: 20 did not meet selection criteria for major depressive dis-
order, 9 had too low severity on the HRSD or BDI-II, 37 had other primary diagno-
ses/problems (generalized anxiety disorder (n = 10), medical problems (n = 6), PTSD (n 
= 1), bipolar disorder (n = 5), substance dependence (n = 3), OCD (n = 8), positive alco-
hol screen (n = 3), opiate addiction more than four years (n = 1)), antidepressant use 
unsuccessfully for more than 2 years (n = 5), and 3 were pregnant. The remaining 100 
were randomised. 
                                                                
2 Cohen's d = (Baseline mean – mean at time i) / (SQRT baseline variance); r = SQRT (F / (F + df)) 
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Baseline 
Table 1 presents baseline sample demographic and clinical characteristics. Treatment 
groups were not significantly different on any of the variables. 
Drop out 
Five participants (10%) dropped out of behavioural activation, as opposed to 15 partic-
ipants (30%) from TAU group. In the behavioural activation group, two people were 
dissatisfied with behavioural activation and three had personal reasons (one due to 
participant’s business; two moved to another city). In TAU group, 12 participants were 
dissatisfied with medication (3 due to medication side-effects), 2 distrusted privacy of 
participation, and 1 believed no one could solve their problem. The difference in drop-
out rate was significant, χ² (1, N = 100) = 6.25, p = 0.012, OR = 3.86 (95%CI [1.28, 
11.64]). 
Change in depression severity over time 
Table 2 and 3 summarizes the multilevel analyses results. In the primary analyses (Ta-
ble 2), there were significant interactions between time and condition (HRSD r = 0.29; 
BDI r = 0.25) and between time-squared and condition (HRSD r = 0.29; BDI r = 0.22). 
Figure 2 shows the stronger symptom reduction over time on the HRSD and BDI in BA 
at 13 weeks. 
 Within condition changes (all p<0.001; Cohen’s d’s with baseline SD) are present-
ed in table 4. Response to behavioural activation differed from TAU at 13 weeks (mean 
HRSD-change difference 3.09, (95%CI 1.71; 4.47), d = 0.88, p < 0.001; mean BDI-change 
difference 3.34 (95%CI 1.63; 5.05), d = 0.76, p < 0.001) and at 49 weeks (mean HRSD-
change difference 2.34 (95%CI 0.84; 3.84), d = 0.61,p < 0.001; mean BDI-change differ-
ence 3.67 (95%CI 2.10; 5.23), d = 0.92, p < 0.001); statistics based on residual variances 
at 13 and 49 weeks respectively. 
 Sensitivity analyses yielded comparable results (Table 2). We also tested whether 
referral type influenced the results by adding referral (self-referral vs. professional-
referral) as covariate (Table DS1 and Figure DS1). The table reports results after delet-
ing NS higher order effects involving referral. In short, referral did not change the con-
dition by time (squared) effects, but professionally referred patients had a steeper 
decrease in depressive symptoms in the behavioural activation than self-referred pa-
tients, with no (HRSD) or the opposite effect (BDI) in the TAU group. 
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Figure1. Participant flow CONSORT 2010 Flow Diagram 
 
  
Assessed for eligibility (n=174)
Excluded (n= 74)
- Not meeting inclusion criteria (n=74)
- Declined to participate (n=0)
- Other reasons (n= 0)
Analysed (n=50) 
- Excluded from analysis (n= 0)
Lost to follow-up (n=5)
- 5 treatment discontinuers refused further 
participation
Discontinued intervention (n= 5)
- 2 patients were dissatisfied with BA
- 3 for personal reasons (1 due to business 
requirements; 2 moved to other city)
Allocated to BA (n=50)
- Received allocated intervention (n=50)
- Did not receive allocated intervention (n= 0)
Lost to follow-up (n=15)
- 15 treatment discontinuers refused further 
participation
Discontinued intervention (n=15) 
- 12 dissatisfied with medication (3 because of 
medication side effects)
- 3 others (2 because of distrust in privacy of 
participation; 1 believed no one could solve her 
problem).
Allocated to TAU (n=50)
- Received allocated intervention (n= 50)
- Did not receive allocated intervention (n= 0)
Analysed (n=50) 
- Excluded from analysis (n=0)
Allocation
Analysis
Follow-Up
Randomized (n=100)
Enrolment
Lost to follow-up after 1year (n=6)
- 6 refused participation
- 3 moved to other city
- 2 could not be accessed 
- 1 because of the business 
Lost to follow-up after 1year (n=7)
- 7 refused participation
- 2 moved to other city
- 4 could not be accessed
- 1 due to distrust in privacy of participation
Follow-Up 
after 1 year
Assessed after one year (n=87)
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Table 1. Baseline Characteristics of Participants in two conditions 
 Full sample 
(N=100) 
Medication 
Treatment 
(50) 
Behavioural 
Activation 
(50) 
Test statistic 
χ2 (df) t (d.f) U 
P  
(2-tailed) 
Baseline characteristics      
Gender: n (female)  85 (85·0) 40 (80·0) 45 (90·0) χ2 (1) = 1·96 0·16 
Age (years): M(SD) 31·37 (8·97) 32·62 (10·17) 30·12 (7·47) t (98) = 1·4 0·16 
Currently married or cohabiting: n (%) 48(48·0) 25 (50·0) 23 (46·0) χ2 (1) = 0·04 0·84 
College graduate: n (%) 40 (40·0) 19 (38·0) 21 (42·0) χ2 (1) = 0·37 0·54 
College student: n (%) 23 (23·0) 10 (20·0) 13 (26·0) χ2 (1) = 2·68 0·10 
Employed outside home: n (%) 35 (35·0) 19 (38·0) 16 (32·0) χ2 (1) = 0·38 0·58 
Current episode length (months): M(SD) 5·87 (2·14) 5·69 (1·97) 6·06 (2·31) t (98) = 1·01 0·31 
Severity      
HRSD Overall M(SD) 21·37 (5·32) 21·62 (5·42) 21·12 (5·26) t (98) = -0·47 0·64 
Number of prior episode: M(SD) 1·03 (0·80) 1·00 (0·72) 1·06 (0·88) U = 1222·5 0·63 
Recurrent depression: n (%) 73 (73·0) 38 (76·0) 35 (70·0) χ2 (1) = 0·45 0·49 
Pre psychiatric hospitalization: n (%) 2 (2·0) 0 2 (4·0) Fisher Exact Test 0·49a 
Any current Axis I diagnosis: n (%) 11 (11.0) 4(8·0) 7 (14.00) Fisher Exact Test 0·52a 
Personality disorders: n (%) 20 (20.0) 12 (24·0) 8 (16.0) χ2 (1) = 0·54 0·46 
Any current anxiety diagnosis: n (%) 11 (11·0) 4(8·0) 7 (14.0) Fisher Exact Test 0·52a 
HRSD, Hamilton Rating Scale for Depression. 
a.Fisher Excat test. 
 
 Baseline to Week 13 Baseline to Week 49 
HRSD BDI  HRSD BDI 
m SD d  m SD d  m SD d  m SD d 
Behavioural activation -17.31 3.52 3.24 -22.28 4.51 3.51 -13.58 3.83 2.54 -18.79 3.99 2.96 
Treatment as usual -14.22 5.32 2.66 -18.94 4.37 2.99 -11.25 3.83 2.11 -15.12 3.99 2.39 
HRSD, Hamilton Rating scale or depression; BDI, beck depression inventory. 
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Table 2. Results of mixed regression analyses of outcome analysis 
Hamilton Rating Scale for 
Depression 
B 95% CI (B) F  d.f.  ra p 
Primary analysis 
Intercept 21.39 20.34;22.44 1630.67 98.26 0.97 <0.001 
Time -1.56 -1.67; -1.46 885.78 87.95 0.95 <0.001 
Time-Squared  0.03 0.02; 0 .03 797.22 83.20 0.95 <0.001 
Condition -0.72 -2.82; 1.38 0.46 98.26 0.06 0.499 
Time x Condition -0.31 -0.51; -0.10 8.56 87.95 0.29 0.004 
Time-Squared x Condition 0.00 0.00; 0.00 7.83 83.20 0.29 0.006 
Beck Depression inventory       
Intercept 27.87 26.64; 29.10 2028.61 98.17 0.97 <0.001 
Time -2.03 -2.16; -1.91 1000.78 91.56 0.95 <0.001 
Time-Squared 0.03 0.03; 0.03 907.91 88.02 0.95 <0.001 
Condition -1.95 -4.40; 0.50 2.48 98.17 0.15 0.118 
Time x Condition -0.32 -0.57; 0.06 6.31 91.56 0.25 0.014 
Time-Squared x Condition 0.00 0.00; 0.00 4.90 88.02 0.22 0.029 
Sensitivity analyses outcome 
Intercept 21.46 20.41; 22.52 1620.34 98.47 0.97 <0.001  
Time -1.56 -1.66; -1.46 926.95 92.05 0.95  <0.001 
Time-Squared  0.02 0.02; 0.03 843.77 89.70 0.95  <0.001 
Condition -0.72 -2.83; 1.40 0.45 98.47 0.06  0.503 
Time x Condition -0.29 -0.49; -0.08 7.76 92.05 0.27  0.006 
Time-Squared x Condition 0.00 0.00; 0.01 6.97 89.70 0.26  0.010  
Beck Depression Inventory       
Intercept 27.67 26.45; 28.90 2012.54 98.21 0.97  <0.001 
Time -2.03 -2.15; 1.90 990.07 90.91 0.95  <0.001 
Time-Squared 0.03 0.03; 0.04 897.95 87.16 0.95  <0.001 
Condition -1.80 -4.24; 0.66 2.11 98.21 0.14 0.150 
Time x Condition -0.31 -0.67; 0.06 5.88 90.91 0.24  0.017 
Time-Squared x Condition 0.00 0.00; 0.01 4.31 87.16 0.21 0.041 
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Table 3. Results of moderation analysis, testing whether baseline severity (assessed with the Hamilton Rat-
ing Scale for Depression) moderates condition effects on outcome  
Hamilton Rating scale for 
Depression 
 B  95% CI (B) F  d.f.  ra p 
Moderation       
Intercept 21.42 20.39; 22.45 1701.45 85.90 0.97 <0.001 
Time -1.56 -1.69; -1.44 641.20 71.65 0.94 <0.001 
Time-Squared 0.03 0.02; 0.03 619.70 74.44 0.94 <0.001 
Condition -0.14 -2.21; 1.92 0.01 85.80 0.01 0.889 
Baseline Severity 4.62 3.55; 5.70 73.32 87.70 0.67 <0.001 
Time x Condition -0.36 -0.60; -0.10 8.31 71.21 0.32 <0.005 
Time-Squared x Condition 0.00 0.00; 0.01 8.18 74.04 0.31 0.006 
Time x Baseline severity -0.30 -0.43; -0.17 2131 74.91 0.47 <0.001 
Time-Squared x Baseline severity 0.00 0.00; 0.00 17.86 76.62 0.43 <0.001 
Condition x Baseline severity -2.57 -4.04; -1.10 12.11 77.32 0.36 <0.001 
Beck Depression Inventory       
Intercept 26.33 24.55; 28.10 867.20 95.97 0.94 <0.001 
Time -1.88 -2.08; -1.68 360.04 93.80 0.89 <0.001 
Time-Squared 0.03 0.03; 0.03 361.43 19.01 0.97 <0.001 
Condition -8.62 -12.17; -5.07 23.23 95.90 0.44 <0.001 
Baseline Severity 3.37 1.52; 5.20 13.14 96.93 0.34 <0.001 
Time x Condition 0.36 -0.03; 0.75 3.26 93.47 0.18 0.074 
Time-Squared x Condition -0.01 -0.01; 0.00 3.02 92.07 0.17 0.086 
Time x Baseline severity -0.17 -0.37; 0.03 2.65 97.28 0.16 0.107 
Time-Squared x Baseline severity 0.00 -0.00; 0.00 2.23 95.03 0.15 0.139 
Condition x Baseline severity -2.20 -3.40; -1.00 13.25 92.85 0.35 <0.001 
1 Effect size r = √(F/(F+df))  
 
Moderation by baseline severity 
The three-way interactions between time (respectively time-squared), condition and 
baseline severity were not significant; linear time-effect: F(1, 75.85) = 1.49, p = 0.17 for 
the HRSD, and F(1, 97.20) = 1.03, p = 0.31 for the BDI; quadratic time-effect: F(1, 75.85) 
= 1.49, p = 0.23 for the HRSD and F(1, 94.80) = 0.96, p = 0.33 for the BDI (results not 
shown in table). After removing the three-way interactions from the model, there 
were significant interactions between treatment condition and baseline severity (Table 
3) indicating that baseline severity moderated treatment outcome at 4, 13 and 49 
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weeks. As is shown in Figure 3, participants with higher baseline severity had relatively 
lower HRSD and BDI scores in the behavioural activation group than in the TAU group. 
Remission and response 
Among study completers, remission and response rates for the behavioural activation 
group at 13 weeks were 41 out of 45 (91.1%) and 44 out of 45 (97.8%) participants. For 
the TAU group, these rates were 24 out of 35 (68.6%) and 33 out of 35 (94.3%). Behav-
ioural activation differed significantly from TAU in remission rate; χ²(1, N = 80) = 6.93, 
p < 0.01, OR = 4.69 (95%CI [1.35, 16.40); but not in response rate; χ²(1, N = 80) = 0.67, 
p = 0.42, OR = 2.66 (95%CI [0.23, 30.67]). 
Remission, response and relapse at 49 weeks 
A total of 87 participants were available for assessment at 49 weeks. Remission and 
response rates for the behavioural activation were 29 out of 44 (65.9%) and 39 out of 
44 (88.6%) participants; and for the TAU group, 12 out of 43 (27.9%) and 20 out of 43 
(46.5%). Behavioural activation differed significantly from TAU in remission rate, χ²(1, 
N = 87) =12.60, p < 0.001, OR = 4.99 (95%CI [2.01, 12.44]); and in response rate, χ²(1, N 
= 87) = 17.69, p < 0.001, OR = 8.97, (95%CI [2.96, 27.14]). From those that remitted at 
13 weeks, 10 out of 36 (27.8% behavioural activation group) and 12 out of 20 (60.0% 
TAU group) relapsed at 49 weeks. This difference was also significant, χ²(1, N = 56) = 
5.60, p = 0.018, OR = 3.90 (95%CI [1.23, 12.37]). At 49 weeks, 3 out of 44 (6.8%) in the 
behavioural activation group and 11 out of 43 (25.6%) in the TAU group used ADM, 
χ²(1, N = 87) = 5.67, p = 0.017. 
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Figure 2. Mixed regression-based 
estimated means and 95% CI of 
Hamilton Rating Scale for Depres-
sion (HRSD) and Beck Depression 
Inventory (BDI) at baseline, 4, 13 
and 49 weeks for Behavioural 
Activation (BA) and Treatment as 
usual (TAU). 
 
  
Figure 3: Moderation of condition effects by baseline severity (Hamilton Rating Scale for Depression score at 
baseline) at 4, 13 and 49 weeks assessments on the (a) HRSD and (b) Beck Depression Inventory: fixed pre-
dicted scores from mixed regression analyses.  
Individuals in the behavioural activation (BA) group had on average lower HRSD and BDI scores, but the 
higher the baseline severity, the stronger the difference between Behavioural activation and Treatment as 
usual (TAU). HRSDcov, HRSD score at baseline, representing baseline severity.  
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Table DS1. Results of mixed regression analyses of outcome controlled by referral on BDI and HDRS 
Primary analyses outcome 
HRSD B 95% CI (B) F df r1 p 
Intercept 21.36 20.31; 22.42 1614.85 98.19 0.97 <0.001 
Time -1.56 -1.66; -1.45 875.45 85.99 0.95 <0.001 
Time-Squared  0.03 0.02; 0.03 788.08 81.79 0.95 <0.001 
Condition -0.73 -2.84; 1.37 0.48 98.19 0.06 0.491 
Referral  -0.86 -2.47; 0.75 1.12 82.52 0.11 0.293 
Time x Condition -0.32 -0.53; -0.11 8.98 85.99 0.30 0.004 
Time-Squared x Condition 0.01 0.00; 0.01 8.44 81.79 0.30 0.005 
Referral x Condition -2.16 -5.38; 1.07 1.77 82.52 0.14 0.187 
Referral x Time 0.04 -0.00; 0.07 3.93 83.72 0.21 0.051 
Referral x Condition x Time 0.11 0.03; 0.18 8.54 83.72 0.30 0.004 
BDI       
Intercept 27.77 26.55; 28.98 2062.60 97.61 0.97 <0.001 
Time -2.03 -2.16; -1.90 1006.16 90.04 0.95 <0.001 
Time-Squared 0.03 0.03; 0.04 901.27 86.14 0.95 <0.001 
Condition -2.01 -4.43; 0.42 2.69 97.61 0.07 0.104 
Referral  -.73 -2.67; 1.21 0.56 91.31 0.07 0.455 
Time x Condition -0.32 -0.58; -0.07 6.48 90.04 0.25 0.013 
Time-Squared x Condition 0.06 0.00; 0.01 5.28 86.14 0.24 0.024 
Referral x Condition -4.05 -7.93; -0.16 4.29 91.31 0.21 0.041 
Referral x Time 0.03 -0.02; 0.08 1.74 86.35 0.14 0.191 
Referral x Condition x Time 0.14 0.05; 0.23 9.48 86.35 0.31 0.003 
Sensitivity analyses outcome 
HRSD        
Intercept 21.43 20.37; 22.49 1605.72 98.30 0.97 <0.001 
Time -1.56 -1.66; -1.46 928.18 91.01 0.95 <0.001 
Time-Squared  0.02 0.02; 0.03 841.43 88.68 0.95  <0.001 
Condition -0.75 -2.87; 1.38 0.49 98.30 0.07 0.487 
Referral  -0.67 -2.31; 0.96 0.67 80.29 0.09 0.416 
Time x Condition -0.29 -0.50; -0.09 8.20 91.01 0.28 0.005 
Time-Squared x Condition 0.01 0.00; 0.01 7.61 88.68 0.28 0.007 
Referral x Condition -1.73 -5.00; 1.54 1.11 82.90 0.11 0.296 
Referral x Time 0.03 -0.00; 0.07 3.32 82.90 0.19 0.072 
Referral x Condition x Time 0.10 0.03; 0.18 7.56 8290 0.28 0.007 
BDI       
Intercept 27.57 26.36; 28.78 2047.75 97.51 0.97 <0.001  
Time -2.03 -2.15;-1.90 994.28 89.46 0.95 <0.001 
Time-Squared  .03 0.03; 0.04 890.89 85.38 0.95  <0.001 
Condition -1.84 -4.28; 0.58 2.28 97.51 0.08 0.134 
Referral  -0.77 -2.71; 1.16 0.63 91.88 0.08 0.430 
Time x Condition -0.32 -0.57; -0.63 6.13 89.46 0.25 0.015 
Time-Squared x Condition 0.01 0.00; 0.01 4.71 85.38 0.22 0.033 
Referral x Condition -3.99 -7.85; -0.11 4.17 91.88 0.20 0.044 
Referral x Time 0.03 -0.02; 0.08 1.74 86.52 0.29 0.191 
Referral x Condition x Time 0.14 0.05; 0.23 8.10 86.52 0.29 0.004 
1 Effect size r = √(F/(F+df))        
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Figure DS1. Mixed regression-based estimated means BDI and HRSD at baseline, mid-treatment, post-
treatment and 1 year follow-up for those participants who recruited by self-referral and referral by other 
professionals. 
Discussion 
The findings of this study indicate that behavioural activation is superior to antidepres-
sant medication in terms of effectiveness, especially in those with severe depression, 
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and the prevention of relapse. The lower drop out in the behavioural activation group 
suggests that behavioural activation was better tolerated than medication. As it was 
also more effective, behavioural activation might offer a viable alternative to medica-
tion, especially for those who prefer non-pharmacological treatment. The results repli-
cate and extend findings of three earlier trials12,13,16 and emphasise the value of simple 
behavioural strategies in the treatment of depression.  
 Until now, behavioural activation has been tested by the developers12,13 and by 
only one independent study16. In our study, behavioural activation therapists were not 
trained and supervised by behavioural activation experts but by a non-expert using the 
published protocol, which is encouraging regarding the feasibility of its dissemination 
around the globe. Behavioural activation interventions are relatively simple and easy 
to understand for depressed participants, and do not require difficult or complex skills 
from participants and therapists.25 It could therefore be considered as a first choice 
treatment, with potentially good cost-effectiveness. 
 In the Dimidjian et al’s study13 behavioural activation was conducted over 24 ses-
sions over a 4- month period, as opposed to the 16 sessions in our study. Remission 
and response rates were higher in our study (remission and response rates in the be-
havioural activation group of 91.1%, and 97.8% respectively) compared with the rates 
in the high severity group in the Dimidjian et al study13 (remission and response rates 
in the behavioural activation group of 52%-56% and 60%-76% respectively). Reasons 
for the striking effectiveness of behavioural activation in our study might be that be-
havioural activation fits particularly well with the Iranian culture. Although avoidance 
and rumination are typical responses observed in all depressed participants, they 
might be even more typical in the Iranian context. The behavioural activation thera-
pists had the impression that behavioural activation strategies that tackle rumination 
led to a strong reduction in depressive symptoms. In Iran, psychological treatment 
seems more acceptable than pharmacological treatment, because seeing a psycholo-
gist is more accepted (as the reason is that one merely has “life problems”), whereas 
pharmacological treatment is associated with having “mental disease” which has a 
heavy cultural stigma, especially for men. 
 Several studies have reported substantial relapse after discontinuation of antide-
pressant medication.10,26,27 From a behavioural activation perspective, a likely reason is 
that people who are treated with antidepressants and then relapse did not change 
their coping skills. Patterns of avoidance, environmental punishment, lack of rein-
forcement, and depressive rumination might still exist, although their effect on mood 
might have been temporarily reduced through the use of antidepressants. In contrast, 
behavioural activation equips individuals with healthy behavioural skills and thus the 
probability of relapse is reduced. 
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 The difference in effectiveness between behavioural activation and antidepres-
sant medication also points to differential pathways of change. Behavioural activation 
and antidepressants are obviously likely to work through different mechanisms, but 
this study provides further evidence that activation is needed crucial element that 
leads to improvement in psychotherapy for depression. The original study by Jacobson 
et al12 was set up to identify the active components of CBT, and found that behavioural 
activation was at least as effective as the complete package of CBT. Dimidjian et al13 
replicated this finding, and found behavioural activation to be even more effective 
than CBT in severe depression. Although behavioural activation in our study is not 
compared with CBT, the findings underline that simple activation strategies in psycho-
therapy are essential. It should be noted, however, that this study provides merely 
indirect evidence for a causal link between activation and recovery in depression and 
that experimental studies are needed to reveal the working mechanisms of behaviour-
al activation. 
Limitations 
A number of limitations should be mentioned. First, the fact that therapists were not 
trained by BA experts might have led to suboptimal application of the behavioural ac-
tivation techniques. Furthermore, participants had to pay for antidepressant medica-
tion after 3 months, which might have contributed to discontinuation. However, these 
two limitations can also be considered as strengths from the point of view of effective-
ness research, which addresses how the two approaches compare in routine practice 
settings. A third limitation is the high proportion of participants recruited by advertis-
ing and word of mouth. It is unclear to what degree the sample is different from regu-
lar clinical samples in Iran. Fourth, the rate of attrition in the antidepressant medica-
tion group was relatively high and this could have influenced the results. Fifth, we did 
not change the prescribed drug for the patients, Sertraline, in case of non-response. 
However, this was the same for behavioural activation. Sixth, independent assess-
ments of treatment integrity and reliability checks of the HRSD interviews were not 
done because of financial constraints. Seventh, the sample may have been biased in 
that the study especially attracted participants preferring psychological treatment, 
which is not widely available in Iran. Eighth, the absence of a non-treatment or placebo 
condition is another limitation. Ninth, we did not control for the amount of attention 
participants received from their therapists. The weaker effects of antidepressant medi-
cation might be partially explained by this. Tenth, the majority of our sample was fe-
male, and although this reflects clinical practice in Iran, further studies are needed into 
non-Western male samples. 
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Future research 
Our finding that behavioural activation was superior to antidepressant medication, and 
even more so in the more severely depressed subgroup should be replicated by other 
groups and in other settings. Subsequent trials in which the effectiveness and cost-
effectiveness of behavioural activation, antidepressant medication and other psycho-
logical treatments such as cognitive therapy are investigated are indicated. 
 Another issue pertains to mechanisms of change that are accountable for the su-
perior effects of behavioural activation. Understanding the (differential) causal path-
ways that lead to recovery in behavioural activation and antidepressant medication 
might illuminate important insights that help to improve treatment strategies in de-
pression, and future research is warranted here.  
Implications of this study 
The findings of our study suggest that behavioural activation is a simple and effective 
intervention for depression that can be easily disseminated to routine practice set-
tings, similar to what has been demonstrated in Western countries.16 Especially the 
fact that behavioural activation was delivered effectively by therapists with a minimum 
of training and supervision is very promising, taken together with the superior effects 
in the subgroup of participants with more severe depression, it speaks for timely dis-
semination to other routine practice settings as well. Moreover, behavioural activation 
might be a very cost-effective intervention. Although our study did not include a for-
mal economic evaluation, we calculated that the total direct treatment costs for be-
havioural activation participants amounted to €128 per patient, while the total direct 
treatment costs for ADM patients were €198 per patient on average, depending on the 
number of follow-up consultations. It has even been suggested that behavioural acti-
vation can be provided by health care professionals who had no previous experience 
with providing psychotherapy16, which further increases possibilities for its implemen-
tation. 
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Chapter 3 
The influence of comorbid personality disorder on 
the effects of behavioural activation vs. 
antidepressant medication for major depressive 
disorder: results from a randomized trial in Iran3 
  
                                                                
3 Published as: Moradveisi, L., Huibers, M. J., Renner, F., Arasteh, M., & Arntz, A. (2013). The influence of 
comorbid personality disorder on the effects of behavioural activation vs. antidepressant medication for 
major depressive disorder: Results from a randomized trial in Iran. Behaviour Research and Therapy, 51(8), 
499-506. 
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Abstract 
There is a disagreement about the impact of personality disorder (PD) on treatment 
outcome for patients with major depressive disorder (MDD). 100 out-patients with 
MDD were randomized to 16 sessions of behavioural activation (BA) (n = 50) or antide-
pressant medication (ADM) (n = 50) in Iran. Main outcome was depression severity, 
measured with the Beck Depression Inventory (BDI-II) and the Hamilton Rating Scale 
for Depression (HRSD), and assessed at 0, 4, 13 and 49 weeks. Participants with 
comorbid PDs had higher scores on BDI and HRSD at baseline and throughout the 
study than participants without comorbid PD. Participants in both treatment groups 
responded equally to the short-term treatment and this trend continued through one 
year of follow-up. Overall, BA was better in reducing symptoms in patients but this 
effect was not influenced by comorbid PD. Similar effects were found for a dimension-
al PD-measure. Only cluster-C PD-traits turned out to be associated with overall de-
pression severity. Cluster-A PD-traits predicted poorer long-term treatment response 
to ADM and BA, but only on the BDI, not on the HRSD. No effects of cluster-B PD-traits 
were found. However, PD was associated with higher dropout. The general conclusion 
is that comorbid PD pathology, especially from cluster-C, is associated with higher de-
pression severity, but not with less response to treatment. Comorbid PD did predict 
increased chance of dropout. 
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Introduction 
Many clinicians and researchers share the view that co-morbidity of personality disor-
der (PD) interferes with the treatment of depression (Shea, Widiger, & Klein 1992). 
Several studies indeed reported that comorbid personality pathology negatively influ-
ences treatment of major depressive disorder (MDD) (Hardy, Barkham, Shapiro, Rees, 
Stiles & Reynolds, 1995; Sato et al., 1994; Newton-Howes et al., 2006). However, re-
cent reviews have challenged this notion (Mulder, 2002; Kool et al., 2005). One review 
reported that co-morbidity of personality pathology does not have a negative effect on 
the treatment results for MDD and concluded that those studies that used structural 
clinical interviews and randomized designs (so that treatment allocation was unbiased) 
found the least evidence that personality pathology adversely influences treatment 
outcome (Mulder, 2002). Another meta-analysis on the effects of comorbid PD on 
pharmacological treatment of MDD included six randomized controlled trials. This 
study reported little effect of PD on response to treatment (Kool et al., 2005). 
 Effects of comorbid PDs might depend on treatment modality. For instance, 
(Tyrer, Seivewright, Ferguson, Murphy & Johnson, 1993) reported that depressed par-
ticipants with PD responded better to medication than to psychotherapy. Another re-
cent study found that ADM was more effective than cognitive therapy in reducing de-
pressive symptoms in patients with co-morbid personality pathology, while the re-
versed difference was found for patients without PD (Fournier, 2008). The PD effect 
seemed to be caused particularly by cluster-B PD-pathology. 
 Behavioural activation (BA) is a relatively new treatment model for patients with 
depression. As far as we know, no study to date investigated the effects of comorbid 
PD on treatment effects of BA in comparison to ADM for participants with MDD. The 
data presented in this paper are drawn from a randomized controlled trial comparing 
BA and Sertraline for patients with MDD (Moradveisi, Huibers, Renner, Arasteh & 
Arntz, 2013). Our focus is on whether depressed participants with co-morbid PD differ 
in symptom reduction over time compared to those without comorbid PD, and wheth-
er BA and Sertraline differ in this respect. We compared participants with co-morbid 
PD to those without PD in terms of drop-out rates, and reduction of depressive symp-
toms during and after short-term treatments and at approximately one year. Given the 
dimensional nature of PDs, we also explored the association of the number of PD-traits 
with dropout and outcome. As Fournier et al (2008) found a specific effect for cluster-B 
PD-pathology, we also explored whether cluster A, B, or C PD-traits moderated out-
come. 
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Method 
Main treatment outcome results and the sample characteristics of the study have been 
reported elsewhere (Moradveisi et al., 2013). Participants were 100 depressed pa-
tients from Sanandaj, Iran, between the ages of 18 to 60 years (mean 31.37, SD 8.97), 
85 women, with a primary diagnosis of MDD according to the Diagnostic and Statistical 
Manual of Mental Disorders DSM-IV-TR (American Psychiatric Association, 2000) con-
firmed by the Structured Clinical Interview for the DSM-IV-TR Axis-I Disorders Clinical 
Trials Version (SCID-CT) First, Williams, Spitzer & Gibbon (2007); and a score of ≥ 19 on 
the Beck Depression Inventory, second edition (BDI-II) Beck, Steer & Brown (1996) and 
≥ 14 on the 17-item Hamilton Rating Scale for Depression (HRSD) Hamilton (1960). The 
Structured Clinical Interview for DSM-IV Axis II PDs (SCID-II, First, Spitzer, Gibbons, Wil-
liams & Benjamin, 1996) was used at baseline to diagnose PDs. Among all participants, 
20 were diagnosed to have at least one comorbid PD. The following PDs were diag-
nosed: 6 Avoidant; 6 Dependent; 2 Borderline; 2 Paranoid, and 4 Obsessive-
compulsive. None of the PDs was an exclusion criterion. Eight out of 50 participants 
randomized to BA and 12 out of 50 to treatment as usual (ADM) conditions had a co-
morbid PD.4 The study was approved by the local Committee of Medical Ethics, Second 
Session. All participants signed written informed consent to participate in the study.  
Treatment 
One hundred participants were randomly assigned to receive BA (n = 50) or Sertraline 
(n = 50). Participants in the BA condition received sixteen 50-min sessions over 12 
weeks, for the first 4 weeks twice a week, and for the next 8 weeks once a week. In 
TAU participants were seen for the first 4 weeks of the treatment once a week and for 
the next 8 weeks once every two weeks. Psychiatrists saw each participant 20 min in 
the first session and in the subsequent sessions for approximately 10 min to monitor 
pharmacotherapy and side effects of the medication. BA and ADM were delivered in 
the same way to PD and non-PD comorbid patients, as the therapists and patients 
were blind for the results of the SCID-II.  
Outcome measures 
Depression severity was assessed with the modified 17-item version of the HRSD (Ham-
ilton, 1960) and the BDI-II (Beck et al., 1996). Both measures were administered at 
                                                                
1In the first draft of our study, there were three conditions, antidepressant medication, behavioural activa-
tion, and pill placebo; but the local Committee of Medical Ethics rejected the placebo condition. The study 
therefore had only two active conditions. 
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baseline, 4, 13, and 48 weeks of treatment. HRSD assessments were done by evalua-
tors blind to treatment conditions. Independent assessors took HRSD for TAU patients 
and BDI for BA patients, before every session and supplied therapists with the results. 
Statistical analyses 
The effect of PD on dropout rates was tested by means of a Chi-square test, whereas 
the combined effects of PD, condition, and their interaction were tested with logistic 
regression. Multilevel analysis was used to estimate effects of PD on change in depres-
sion severity over time. We applied intention-to-treat analysis, with the HRSD and BDI 
as dependent variables, by including all available scores. Visual inspection suggested 
linear and quadratic time effects; we therefore modelled time linearly and quadratical-
ly. We used multilevel analyses with an unstructured covariance structure for repeated 
measures, with time, time-squared, condition, time by condition, time-squared by 
condition, and PD as fixed effects. We also tested time (-squared) x PD, PD x condition, 
and time (-squared) x PD x condition interactions. The PD x time (-squared) and the 
main PD effects, and their interactions with condition are of primary interest in this 
analysis. Unstructured covariance structure for repeated measures does not allow for 
random slopes (as this is already represented in the unstructured covariance structure 
for repeated measures) and looking into the effects of PDs on slopes take depression 
severity at baseline into account. In all models, treatment condition was centred at -½ 
and ½. Non-significant interactions were removed stepwise from the model starting 
with the highest order interactions. Similar analyses were done with the standardized 
sum of PD-traits, total or by cluster, as predictor, instead of the dichotomous presence 
vs absence of PD variable. We computed effect sizes (r)5 for continuous outcomes from 
the multilevel estimates. For treatment dropouts who refused further assessments, we 
used the last observation with the associated time, and estimated missing HRSD scores 
(for BA-dropouts) from changes on the BDI, and missing BDI scores (for TAU-dropouts) 
from changes on the HRSD, using regression derived equations (1 BDI unit=1.3 HRSD 
unit). All treatment drop-out took place before the mid-treatment assessment. Anal-
yses were conducted using SPSS19.  
                                                                
5 r = √ (F / (F + df)) 
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Results 
Dropout 
The overall rate of participant’s dropout of the treatment was presented in the main 
publication (Moradveisi et al., 2013). Twenty participants dropped out of treatment, 8 
out of 20 (40%) had PD, compared to 12 out of 80 (15%) completers. The condition by 
PD interaction was NS (OR = 0.82 [0.07; 9.30]; p = 0.87). After deleting the interaction 
the main effects of condition (OR = 3.70 [1.17; 11.70], Wald (1) = 4.98, p = 0.026) and 
PD (OR = 0.20 [0.07; 0.63], Wald (1) = 7.63, p = 0.006) were significant, with lower 
dropout in BA and in participants without PD. Thus, there were more dropouts in par-
ticipants with PD than in those without PD. 
Drop-out with the PD-traits sum-scores 
The interaction between condition and the PD–traits sum-scores was not significant, 
OR = 1.06 [0.91; 1.24]; p = 0.47). After removing the interaction the main effects of 
condition (OR = 3.78 [1.23; 11.96], Wald (1) = 5.36, p = 0.021) and PD-sum-scores (OR = 
1.08 [1.00; 1.15], Wald (1) = 4.28, p = 0.039) were significant. Thus, patients with high-
er PD sum-scores were more likely to drop out than were patients with lower PD sum-
scores. 
Effects of PD on depression severity 
Table 1 presents results of the multilevel analyses. The three-way PD x time x condition 
and PD x time-squared x condition interactions were not significant for the BDI, F (1, 
141.41) = 1.30, p = 0.28, and F (1, 98.02) = 2.21, p = 0.14. The NS three-way interac-
tions were removed from the model. The two-way interaction between PD and condi-
tion was not significant for the BDI, F (1, 101.23) = 1.32, p = 0.25. The two-way interac-
tions between PD and time and PD and time–squared were (marginally) significant for 
the BDI, F (1, 102.65) = 3.25, p = 0.074, and F (1, 98.92) = 4.25, p = 0.042. In addition to 
significant condition by time effects, the PD main effect was significant, reflecting an 
overall higher BDI score for patients with comorbid PD over all assessments (p = 0.02). 
As can be seen from figure 1, more depressive symptom reduction in participants 
without PD than in those with PD was observed at mid-treatment and post treatment, 
but at 48-week follow-up this effect disappeared. After removing the PD by time and 
PD by time-squared interactions from the model, there was a main effect of PD: F (1, 
101.53) = 30.84, p < 0.001 for the BDI (Table 1), indicating higher depression levels 
throughout the study in participants with PD. 
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Figure 1. Mixed regression-based estimated means BDI(upper panel) and HRSD (low-
er panel) at baseline, mid-treatment, post-treatment and 1 year follow-up for those 
participants with and without PD, with PD by time and PD by squared time interac-
tion in the model. 
For the HRSD, the PD x time x condition and PD x time-squared x condition three-way 
interactions were not significant, F (1, 98.30) = 1.48, p = 0.27, and F (1, 94.43) = 1.86, p 
= 0.17. The NS three-way interactions were removed from the model. The two-way 
interaction between PD and condition was not significant for the HRSD, F (1, 95.19) = 
1.03, p = 0.31 and therefore removed. There were no two-way interactions between 
PD and time, and time–square, F (1, 100.11) = 0.87, p = 0.35; and F (1, 96.46) = 1.39, p 
= 0.24. After deleting these interactions, there was a main effect of PD: F (1, 95.95) = 
30.10, p < 0.001, indicating higher depression levels throughout the study in partici-
pants with PD (Figure 2). 
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Figure 2. Mixed regression-based estimated means BDI and HRSD at baseline, mid-
treatment, post-treatment and 1 year follow-up without PD by time interaction. 
Effects of PD-trait sum-scores on depression severity 
We also tested for moderation by the standardized total sum-scores on the SCID-II as a 
measure of PD severity. The total sum-scores x time x condition and total sum-scores x 
time-squared x condition three-way interactions were not significant for the BDI, F (1, 
78.04) = 0.04, p = 0.85, and F (1, 77.64) = 0.19, p = 0.66. The NS three-way interactions 
were removed from the model. The sum-scores x condition two-way interaction was 
not significant for the BDI, F (1, 90.35) = 2.24, p = 0.13. Also, the two-way interactions 
between sum-scores of the SCID-II and time and sum-scores and time-squared were 
not significant, F (1, 95.31) = 0.01, p = 0.91, and F (1, 91.09) = 0.09, p = 0.76. After re-
moving these interactions from the model, there was a main effect of the total SCID-II 
sum-scores: F (1, 91.15) = 8.15, p = 0.005, r = .22, indicating a higher depression level 
throughout the study in participants with a higher total score on the SCID-II. 
For the HRSD, the sum-scores x time x condition and sum-scores x time-squared x con-
dition three-way interactions were not significant, F (1, 70.37) = 0.02, p = 0.89, and F 
(1, 69.89) = 0.18, p = 0.67. The NS three-way interactions were removed from the 
model. The two-way interaction between sum-scores and condition was not significant 
for the HRSD, F (1, 88.19) = 2.45, p = 0.12. Also, there were no two-way interactions 
between sum-scores and time, and time-squared, F (1, 95.31) = 0.01, p = 0.91, and F (1, 
91.08) = 0. 08, p = 0.76. After deleting these interactions, there was a main effect of 
total sum-scores: F (1, 88.32) = 9.38, p = 0.003, r = .25, indicating a higher depression 
level throughout the study in participants with a high total score on the SCID-II. 
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Table1. Prediction of depressive symptoms by PD over time 
 B 95% CI (B) F df r1 p 
BDI with time x PD interaction       
Intercept 27.18 25.84;28.53 1607.09 97.06 0.97 <0.001 
Condition -1.13 -3.62; 1.37 0.80 106.36 0.08 0.374 
PD 3.33 0.31; 6.35 4.79 98.66 0.21 0.031 
Time -2.06 -2.20; -1.93 871.10 88.73 0.95 <0.001 
Time-Squared 0.04 0.03; 0.04 821.90 85.91 0.95 <0.001 
Time x Condition -0.32 -0.58; -0.07 6.45 91.51 0.25 0.013 
Time-Squared x Condition 0.01 0.00; 0.01 5.20 88.51 0.23 0.025 
Time x PD 0.31 -0.03; 0.65 3.25 102.65 0.17 0.074 
Time-Squared x PD -0.01 -0.01; -0.00 4.25 98.92 0.20 0.042 
Condition x PD -1.88 5.14; 1.37 1.32 101.23 0.11 0.253 
BDI without time x PD interaction 
Intercept 27.05 28.51;28.29 1875.91 107.70 0.97 <0.001 
Condition -1.26 -3.65; 1.14 1.08 98.51 0.10 0.301 
PD 4.43 2.85; 6.01  30.84 101.503 0.48 <0.001 
Time -2.03 -2.15; -1.90 1004.01 92.86 0.95 <0.001 
Time-Squared 0.03 0.03; 0.04 917.46 89.65 0.95 <0.001 
Time x Condition -0.34 -0.60; -0.09 7.17 92.85 0.26 0.009 
Time-Squared x Condition 0.01 0.00; 0.01 5.10 89.78 0.23 0.016 
HRSD with time x PD interaction 
Intercept 20.60 19.49;21.73 1324.07 97.00 0.96 <0.001 
Condition -0.12 -2.22; 1.97 0.01 106.97 0 0.910 
PD 3.67 1.14; 6.19 8.31 98.72 0.27 0.005 
Time -1.57 -1.68; -1.46 755.64 86.72 0.94 <0.001 
Time-Squared 0.03 0.02; 0.03 699.56 82.65 0.94 <0.001 
Time x Condition -0.31 -0.52; -0.10 8.91 89.36 0.30 0.004 
Time-Squared x Condition 0.01 0.00; 0.01 8.28 85.28 0.29 0.005 
Time x PD 0.13 -0.15; 0.40 0.88 100.11 0.09 0.352 
Time-Squared x PD -0.00 -0.01; 0.00 1.39 96.46 0.11 0.242 
Condition x PD -1.51 -.4.45; 1.44 1.03 95.19 0.10 0.313 
HRSD without time x PD interaction  
Intercept 20.57 19.53;21.61 1530.39 108.58 0.96 <0.001 
Condition -0.41 -2.41; 1.60 0.16 98.78 0.04 0.689 
PD 4.03 2.59; 5.47 30.10 95.95 0.48 <0.001 
Time -1.55 -1.65; 1.45 898.10 90.80 0.95 <0.001 
Time-Squared 0.03 0.02; 0.03 811.90 86.90 0.95 <0.001 
Time x Condition -0.31 -0.51; -0.10 8.89 90.79 0.29 0.004 
Time-Squared x Condition 0.01 0.00; 0.01 8.38 87.01 0.28 0.005 
1 Effect size r = √(F/(F+df)) 
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Effects of cluster-A PD-traits on depression severity 
Table 2 presents the results of the mixed regression of the full model and the final 
model of cluster-A PD-traits for HRSD and BDI, respectively. 
 BDI: Three-way Condition x Time (Squared) x cluster-A PD-traits interactions were 
not significant for the BDI (Table 2). After deleting of NS three-way interactions, there 
was a significant interaction between Time and cluster-A PD-traits, F (1, 94.57) = 4.49, 
p = 0.037, indicating that both treatments are increasingly less effective over time for 
those with high cluster-A PD-trait scores. This holds for both BA and ADM, and is espe-
cially clear at 1 year follow-up (Figure 3). Cluster-A PD-traits did not predict overall 
higher BDI scores. 
 HRSD. Three-way Condition x Time (Squared) x cluster-A PD-traits interactions 
were not significant for the HRSD (Table 2). Also, the two-way Condition x cluster-A 
PD-traits and Time (Squared) x cluster-A PD-traits interactions were not significant for 
the HRSD. Cluster-A PD-traits did not predict overall higher HRSD scores. 
 
 
Figure 3. Mixed regression-based estimated slopes of cluster-A PD traits (standardized; 
x-axis) with BDI (y-axis) at baseline, mid-treatment, post-treatment and 1 year follow-
up with cluster A traits by time interaction. 
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Table 2. Prediction of depressive symptoms by cluster-A PD-traits over time 
 B 95% CI (B) F df r1 p 
BDI with time x -cluster-A traits interaction 
Intercept 28.00 26.78; 29.24 2032.58 96.08 0.97 <0.001 
Condition -1.75 -4.22; 0.71 1.99 96.08 0.14 0.162 
cluster-A traits  -0.16 -1.41; 1.09 0.07 96.34 0.02 0.798 
Time -2.04 -2.17; -1.91 964.58 90.02 0.95 <0.001 
Time-Squared 0.03 0.03; 0.04 871.68 86.92 0.95 <0.001 
Time x Condition -0.34 -0.60; -0.07 6.71 90.02 0.26 0.011 
Time-Squared x Condition 0.01 0.01; 0.01 5.40 86.92 0.24 0.023 
Condition x cluster-A traits 1.70 -0.80; 4.21 1.82 96.34 0.13 0.180 
Time x cluster-A traits -0.02 -0.16; 0.12 0.08 94.10 0.02 0.784 
Time-Squared x cluster-A traits 0.002 -0.001;0.003 0.37 91.87 0.06 0.545 
Condition x Time x cluster-A traits -0.07 -0.34; 0.21 0.24 94.10 0.05 0.625 
Condition x Time -Squared x cluster-A 
traits 
0.001 -0.004; 0.01 0.08 91.87 0.02 0.774 
BDI without time x cluster-A interaction 
Intercept 27.83 26.60; 29.07 2006.70 97.37 0.97 <0.001 
Condition -2.21 -4.69; 0.26 3.15 97.80 0.17 0.079 
cluster-A traits -0.60 0.03; 0.04 1.43 87.27 0.12 0.235 
Time -2.03 -2.16; -1.90 984.22 90.17 0.95 <0.001 
Time-Squared 0.03 -1.62; 0.40 897.07 87.27 0.95 <0.001 
Time x Condition -0.31 -0.56; -0.05 5.65 90.18 0.24 0.020 
Time-Squared x Condition 0.004 0.002; 0.01 4.63 87.20 0.22 0.034 
Time x cluster-A traits 0.03 0.001; 0.05 4.49 94.57 0.21 0.037 
HRSD with time x cluster-A traits interaction 
Intercept 21.4 20.39; 22.50 1624.61 95.77 0.97 <0.001 
Condition -0.73 -2.84; 1.38 0.47 95.77 0.06 0.493 
cluster-A traits -0.03 -1.11; 1.04 0.004 96.28 0 0.950 
Time -1.56 -1.67; -1.45 864.53 87.24 0.95 <0.001 
Time-Squared 0.03 0.02; 0.03 777.51 82.75 0.95 <0.001 
Time x Condition -0.31 -0.52; -0.10 8.60 87.25 0.29 0.004 
Time-Squared x Condition 0.01 -.002; 0.01  7.98 82.75 0.29 0.006 
Condition x cluster-A traits 1.21 -0.94; 0.3.35 1.25 96.28 0.11 0.266 
Time x cluster-A traits -0.3 -0.14; 0.08 0.28 91.10 0.05 0.599 
Time-Squared x cluster-A traits 0.002 -0.001; 0.002 0.58 88.10 0.08 0.449 
Condition x Time x cluster-A traits -0.05 -0.27; 0.17 0.20 91.10 0.04 0.654 
Condition x Time -Squared x cluster-A 
traits 
0.002 -0.004; 0.004 0.04 88.10 0.02 0.847 
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 B 95% CI (B) F df r1 p 
HRSD without time x cluster-A traits interaction  
Intercept 21.39 20.33; 22.44 1624.31 98.10 0.97 <0.001 
Condition -0.73 -2.84; 1.39 0.47 98.55 0.06 0.496 
cluster-A traits -0.04 -0.69; 0.62 0.01 90.95 0.01 0.910 
Time -1.55 -1.66; -1.45 885.24 87.89 0.95 <0.001 
Time-Squared 0.03 0.02;0.03 796.65 83.14 0.95 <0.001 
Time x Condition -0.31 -0.52; -0.10 8.56 87.88 0.29 0.004 
Time-Squared x Condition 0.01 0.002; 0.01 7.83 83.11 0.29 0.006 
1 Effect size r = √(F/(F+df)) 
Effects of Cluster-B PD-traits on depression severity 
 BDI and HRSD. Cluster-B PD-traits did not moderate treatment or time effects on 
BDI and HRSD, neither did these traits predict overall higher depression scores (Table 
3). 
Effects of Cluster-C PD-traits on depression severity 
 BDI. Table 4 presents the results. After deleting the three-way interactions, the 
two-way Condition x cluster-C PD-traits interaction was significant, F (1, 91.80) = 4.95, 
p = 0.028, indicating a differential association between cluster-C PD-traits and BDI in 
the two treatment conditions. As this effect was already present at baseline, we refrain 
from interpreting it. The main effect of cluster-C PD-traits on the BDI was significant, F 
(1, 91.80) = 4.35, p = 0.040, indicating higher BDI-scores for those with more cluster-C 
PD-traits. 
 HRSD. The three-way Condition x Time (Squared) x cluster-C PD-traits interactions 
were not significant for the HRSD (Table 4). After removing the three-way interactions, 
the two-way Condition x cluster-C PD-traits and Time x cluster-C PD-traits interactions 
were significant, F (1, 88.82) = 6.36, p = 0.013 and F (1, 87.23) = p = 0.037. As the Con-
dition x cluster-C PD-traits interaction was already present at baseline, we refrain from 
interpreting it. The Time by Cluster-C PD-traits interaction reflects a weakening of the 
association between Cluster-C PD-traits and HRSD over time. The main effect of clus-
ter-C PD-traits on the HRSD was significant, F (1, 91.52) = 14.90, p = 0.001, indicating 
that cluster-C PD-traits were associated with overall higher HRSD scores. 
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Table 3. Prediction of depressive symptoms by cluster-B PD-traits over time 
 B 95% CI (B) F df r1 p 
BDI with time x cluster-B traits interaction       
Intercept 27.91 26.65; 29.16 1957.37 96.15 0.97 <0.001 
Condition -1.93 -4.43; 0.58 2.34 96.15 0.15 0.130 
cluster-B traits 0.04 -1.29; 1.38 0.004 95.94 0 0.949 
Time -2.03 -2.16; -1.90 991.02 89.07 0.95 <0.001 
Time-Squared 0.03 0.03; 0.04 904.58 85.51 0.95 <0.001 
Time x Condition -0.31 -0.56; -0.05 5.65 89.07 0.24 0.020 
Time-Squared x Condition 0.004 0.002; 0.01 4.33 85.51 0.21 0.040 
Condition x cluster-B traits 0.54 -2.14; 3.21 0.16 95.94 0.04 0.691 
Time x cluster-B traits 0.09 -0.05; 0.22 1.66 86.57 0.13 0.201 
Time-Squared x cluster-B traits -0.002 -0.004; 0.002 2.14 84.15 0.15 0.147 
Condition x Time x cluster-B traits 0.02 -0.25; 0.29 0.03 86.57 0.01 0.867 
Condition x Time -Squared x cluster-B traits -0.002 -0.01; 0.004 0.03 84.15 0.01 0.867 
BDI without time x cluster-B traits interaction 
Intercept 27.87 26.64; 29.10 2017.52 97.92 0.97 <0.001 
Condition -1.86 -4.33; 0.61 2.24 98.71 0.14 0.137 
cluster-B traits 0.28 -0.44; 0.10 0.59 94.48 0.07 0.444 
Time -2.03 -2.16; -1.91 1004.11 91.74 0.95 <0.001 
Time-Squared 0.03 0.03; 0.04 910.67 88.23 0.95 <0.001 
Time x Condition -0.32 -0.58; -0.07 6.37 91.74 0.05 0.013 
Time-Squared x Condition 0.01 0.002; 0.01 4.94 88.22 0.23 0.029 
HRSD with time x cluster-B traits interaction 
Intercept 21.42 20.35; 22.49 1582.24 96.22 0.97 <0.001 
Condition -0.81 -2.95; 1.32 0.57 96.22 0.07 0.452 
cluster-B traits -0.36 -1.50; 0.78 0.39 95.98 0.06 0.534 
Time -1.56 -1.66; -1.45 870.82 84.86 0.95 <0.001 
Time-Squared 0.03 0.02; 0.03 781.91 80.24 0.95 <0.001 
Time x Condition -0.29 -0.50; -0.08 7.66 84.86 0.28 0.007 
Time-Squared x Condition 0.01 0.002; 0.01 7.04 80.24 0.28 0.010 
Condition x cluster-B traits 0.46 -1.82; 2.74 0.16 95.98 0.04 0.688 
Time x cluster-B traits 0.07 -0.04;0.18 1.62 82.60 0.13 0.206 
Time-Squared x cluster-B traits  -0.002 -0.002; 0.004 1.39 78.97 0.02 0.241 
Condition x Time x cluster-B traits 0.02 -0.20; 0.24 0.05 82.60 0.01 0.833 
Condition x Time -Squared x cluster-B traits -0.002 -0.004; 0.002 0.03 78.97 0.01 0.870 
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 B 95% CI (B) F df r1 p 
HRSD without time x cluster-B traits interaction  
Intercept 21.39 20.33; 22.24 16.17 97.39 0.37 <0.001 
Condition -0.68 -2.80; 1.4 0.41 98.23 0.06 0.523 
cluster-B traits 0.13 -0.52; 0.78 0.16 88.03 0.04 0.687 
Time -1.56 -1.66; -1.45 886.75 88.02 0.95 <0.001 
Time-Squared 0.03 0.02; 0.03 798.13 83.29 0.95 <0.001 
Time x Condition -0.31 -0.52; -0.10 8.61 88.02 0.29 0.004 
Time-Squared x Condition 0.01 0.002; 0.01 7.87 83.28 0.29 0.006 
1 Effect size r = √(F/(F+df) 
 
Table 4. Prediction of depressive symptoms by cluster-C PD-traits over time 
 B 95% CI (B) F df r1 p 
BDI with time x cluster-C traits interaction 
Intercept 27.87 26.69; 29.06 2187.75 96.34 0.97 <0.001 
Condition -2.07 -4.43; 0.30 3.01 96.34 0.17 0.086 
Time -2.03 -2.16; -1.90 988.67 90.08 0.95 <0.001 
Time-Squared 0.03 0.03; 0.04 897.00 86.33 0.95 <0.001 
Time x Condition -0.33 -0.58; -0.07 6.50 90.08 0.25 0.012 
Time-Squared x Condition 0.01 0.004; 0.01 5.21 86.33 0.23 0.025 
cluster-C traits 0.75 -0.47; 1.98 1.48 96.69 0.12 0.226 
Condition x cluster-C traits -3.13 -5.58;-0.67 6.40 96.69 0.24 0.013 
Time x cluster-C traits 0.05 -0.09; 0.19 0.54 93.78 0.07 0.464 
Time-Squared x cluster-C traits -0.002 -0.002; 0.002  0.93 89.29 0.01 0.338 
Condition x Time x cluster-C traits 0.26 -0.01; 0.53 3.57 93.78 0.19 0.062 
Condition x Time -Squared x cluster-C traits -0.004 -0.01; 0.002 3.60 89.29 0.19 0.061 
BDI without time x cluster-C traits interaction 
Intercept 27.87 26.69; 29.05 2183.03 96.99 0.97 <0.001 
Condition -2.02 -4.39; 0.35 2.87 96.99 0.16 0.094 
Time -2.03 -2.15; -1.90 992.33 91.36 0.95 <0.001 
Time-Squared 0.03 0.03; 0.04 901.03 87.95 0.95 <0.001 
Time x Condition 0.34 -0.59; -0.08 6.90 91.36 0.26  0.010 
Time-Squared x Condition -0.01 0.004; 0.01 5.64 87.95 0.24 0.020 
cluster-C traits 0.73 0.03; 1.43 4.35 91.80 0.21 0.040 
Condition x cluster-C traits -1.56 -2.95; 0.17 4.95 91.80 0.22 0.028 
HRSD with time x cluster-C traits interaction 
Intercept 21.41 20.43; 22.39 1879.74 96.35 0.97 <0.001 
Condition -0.74 -2.70; 1.22 0.56 96.35 0.05 0.457 
Time -1.55 -1.66; -1.45 876.10 88.18 0.95 <0.001 
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 B 95% CI (B) F df r1 p 
Time-Squared 0.03 0.02; 0.03 785.19 83.52 0.95 <0.001 
Time x Condition -0.32 -0.53;-0.11 9.18 88.18 0.30 0.003 
Time-Squared x Condition 0.01 0.00; 0.01 8.58 83.52 0.30 0.004 
cluster-C traits 1.28 0.26; 2.29 6.22 96.66 0.24 0.014 
Condition x cluster-C traits -2.64 -4.68; -0.61 6.65 96.66 0.25 0.011 
Time x cluster-C traits 0.004 -0.11; 0.11 0.01 91.81 0.01 0.933 
Time-Squared x cluster-C traits -0.004 -0.002; 0.002 0.18 86.76 0.04 0.658 
Condition x Time x cluster-C traits 0.17 -0.05; 0.39 2.32 91.81 0.15 0.139 
Condition x Time -Squared x cluster-C traits -0.002 -0.01; 0.002 2.22 86.76 0.15 0.140 
HRSD without time x cluster-C trait interaction  
Intercept 21.40 20.42; 22.38 1877.63 97.04 0.97 <0.001 
Condition -0.75 -2.71; 1.21 0.58 97.04 0.07 0.449 
Time -1.55 -1.65; -1.45 879.89 88.80 0.95 <0.001 
Time-Squared 0.03 0.02; 0.03 790.51 84.54 0.95 <0.001 
Time x Condition -0.32 -0.53; -0.11 9.53 88.80 0.31 0.003 
Time-Squared x Condition 0.01 0.002; 0.01 8.99 84.57 0.30 0.004 
cluster-C traits 1.49 0.72; 2.26 14.90 91.52 0.37 <0.001 
Condition x cluster-C traits -1.57 -2.81; -0.33 6.36 88.82 0.25 0.013 
Time x cluster-C traits -0.02 -0.04; -0.002 4.51 87.23 0.22 0.037 
1 Effect size r = √(F/(F+df) 
Discussion 
The results of this study indicate that participants with comorbid PDs had higher scores 
on BDI and HRSD at baseline and throughout the study than participants without 
comorbid PD. Both groups responded equally well to the short term treatments in the 
acute phase, and this parallel development over time was still apparent at one year 
follow-up. The absence of PD x condition and PD x time x condition interactions indi-
cates that PD did not moderate the difference between the treatment conditions. 
Thus, BA was overall better in reducing symptoms in patients but this effect was not 
influenced by comorbid PD. For the BDI we found equivocal evidence that PD was as-
sociated with a somewhat less strong immediate response to treatment, but this effect 
disappeared at one year follow-up. The statistical evidence for this effect was weak, 
could not be detected in the HRSD, and most of the effects were explained by parallel 
development in the two groups. We repeated the analyses for PD-trait sum score and 
the findings were the same: PD-traits were associated with higher depressive symptom 
scores from baseline on throughout the study, but not with a reduced treatment ef-
fect. However, an important effect of PD (both in terms of diagnosis and trait sum 
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scores) was found in dropout rates, which were higher in those with comorbid PD (and 
with higher PD trait sum scores), independent of treatment condition. 
 Given the fact that Fournier et al. (2008) found that especially Cluster-B PD-
pathology was responsible for the moderation of treatment effects, we explored the 
effects of the three cluster scores. We did not find evidence for moderating effects of 
cluster scores on treatment differences. However, we found that cluster-C PD-traits 
were associated with generally higher levels of depression over the trial, whereas clus-
ter-A and B traits did not have this association. Moreover, for the HRSD this association 
became weaker over time, suggesting that over time the predictive power of cluster-C 
PD-traits reduces. Lastly, we found evidence that cluster-A PD-traits were associated 
with a poorer treatment response over time, for both BA and ADM, but only for the 
BDI. Given the fact that this was not found on the HRSD, this result should be inter-
preted with caution.  
 The findings of this study are consistent with Mulder (2002), Kool and et al (2005), 
and De Bolle et al (2010), in that general personality pathology does not have an effect 
on treatment outcome and is not an obstacle to good treatment response. In other 
words, it seems that well-designed studies with structural clinical interviews and with 
good statistical analyses do not support the hypothesis of effects of PD on treatment 
outcome in patients with MDD. Our findings are in contrast to Newton-Howes’s review 
(2006). An important methodological issue is whether baseline MDD severity is taken 
into account or not (Dreessen & Arntz, 1998). In the Newton-Howes’s meta-analysis 
baseline severity was not taken into account, so it cannot be excluded that the PD ef-
fects on depression scores found at follow-up in fact reflect differences already pre-
sent at baseline (Dreessen & Arntz, 1998). 
 In the meta-analysis by Kool et al, (2005) only two studies reported drop-out rates. 
Other meta-analyses did not report drop-out rates. No study so far found statistically 
significant differences in drop-out rates between patients with and without PDs. Sulli-
van’s (Sullivan, Joyce & Mulder, 1994) study reported 15% dropout in the group with-
out PD, and 15% for those with PD. Dropout rates in Kool, Dekker, Duijsens, De Jonghe 
& Puite (2003) study was 21.7% in the non-PD group and 22.4% in the PD group. Four-
nier et al (2008) found no overall difference in drop out between people with and 
without PD. In the antidepressant group the drop-out rate was 12% for people with PD 
and 21% for those without PD, and in the cognitive therapy group 12% for the people 
without PD and 22% for those with PD. Thus, the difference was not significant. In our 
study we found 8 out of 20 dropouts (40%) had PD, compared to 12 out of 80 (15%) 
completers, with no interaction with treatment condition. 
 Fournier et al, (2008) findings indicated that cognitive therapy did not do well in 
people with PD, but in our study BA was quite effective in treating people with PD and 
had less drop out than ADM. This raises the possibility that BA should be preferred 
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above CT in both patients with and without comorbid PD, at least for the acute treat-
ment phase. It should be noted however that apart from the different psychological 
treatments (CT vs BA), there were other differences between the studies. Whereas 
Fournier et al. used DSM-III-R PD criteria; we used DSM-IV-TR PD criteria. Moreover, 
cultural differences might have played a role. Note that Fournier et al found that the 
PD x treatment condition effect was driven by Cluster-B PD criteria. We did not find 
such an effect of cluster-B PD psychopathology. In fact none of the PD-
psychopathology indicators moderated condition differences on treatment outcome in 
our study.  
 Depressed participants with personality pathology bring more problems in addi-
tion to depression into therapy and these problems need more efforts by therapists in 
dealing with the problems, thereby exerting more stress on therapists (Dreessen & 
Arntz, 1999). This might be a reason for therapists feeling that depressed patients with 
co-morbid personality pathology respond less to treatment. Another reason for the 
belief that PD is associated with less response might be the higher levels of depression 
at the end of treatment – which are in fact not an indication of less response, but of a 
generally higher level of depression, already present at baseline. Still another reason 
might be that therapists might attribute lack of treatment response to alleged PD pa-
thology in the patient (Kool et al., 2003). At least one indication of increased problems 
in treating patients with comorbid PD is their higher dropout rate observed in the cur-
rent study. 
Limitations 
A number of limitations should be considered for the data presented in this publica-
tion. First, the categorical model of PD is subject to controversies, and dimensional 
models are proposed as better representing personality pathology (De Bolle et al., 
2010). However, we investigated the effects of dimensional measures of PD pathology 
and could not demonstrate any consistent moderation effects either. The only interac-
tions with time we observed (with cluster-A and cluster-C trait scores) were restricted 
to one outcome measure, and the lack of replication on the other measure obviously 
limits the meaning of these findings, which may have been accidental. Second, the 
sample size was not large enough to investigate individual PDs. However, we were able 
to investigate effects of cluster scores. Third, due to ethical regulations we had to skip 
the originally planned pill-placebo condition, which would have been helpful to sepa-
rate specific from non-specific effects. Fourth, the treatments were brief with regard 
to the durations suggested for people with depression with co-morbid personality pa-
thology (Fournier et al., 2008). MDD treatment might need more time to reach similar 
endpoints in patients with comorbid PD compared to patients without this comorbidi-
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ty. Alternatively, approaches that focus more on issues related to the comorbid PD 
might be needed for this. 
Future Research 
This is the first trial comparing BA to ADM in depressed participants that assessed ef-
fects of co-morbid PD on treatment retention and response. Future studies with larger 
samples are needed to investigate the effects of specific PDs on effects of BA, or other 
psychological treatments such as cognitive therapy, and ADM. 
Clinical implications 
Our conclusion is that depressed participants with co-morbid PD responded to BA and 
ADM parallel to those without PD. The only indication of an exception to this general 
effect was the long-term effect of cluster-A PD-traits on the BDI, suggesting a weaker 
response in those with elevated cluster-A traits. However, given the fact that a similar 
effect was not found on the HRSD it seems too early to draw clinical conclusions from 
this finding, which might have been accidental. Thus, depressed participants with PD 
can be treated by both BA and ADM treatment although BA is more effective. At the 
start of the treatment, people with comorbid PD had a higher score on BDI and HRSD 
than those without personality pathology, and they maintained relatively higher scores 
over the short-term and at 1 year follow-up. This effect was especially driven by clus-
ter-C PD-traits. To further decrease depression levels in patients with comorbid PD, 
longer treatment might be necessary. Comorbid PD does not seem to be an exclusion 
criterion for BA or ADM, although there is an increased risk of dropout from treatment. 
 
 
  
57 
References 
American Psychiatric Association (2000). Diagnostic and statistical manual of mental disorders (DSM-IV-TR.). 
Washington, DC: Author. 
Beck, A.T., Steer, R.A., & Brown, G.K. (1996). Manual for the BDI-II. San Antonio, TX: Psychological Corpora-
tion. 
De Bolle, M., De Fruyt, F., C. Quilty, L., Rolland, J.P., Decuyper, M., Bagby, R.M., et al. (2010). Does personali-
ty disorder co-morbidity impact treatment outcome forpatients with major depression? A multi-level 
analysis. Journal of Personality Disorders, 25 (1), 15. 
Dreessen, L., & Arntz, A. (1999). Personality Disorders have no excessively negative impact on therapist-
rated therapy process in the cognitive and behavioral treatment of Axis I Anxiety Disorders. Clinical 
Psychology & Psychotherapy, 6, 384-394. 
Dreessen, L., & Arntz, A. (1998). The impact of personality disorders on treatment outcome of anxiety disor-
ders: Best-evidence synthesis. Behaviour Research and Therapy, 36 (5), 483-504.-129. 
First, M.B., Williams, J.B., Spitzer, R.L., & Gibbon, M. (2007). Structured Clinical Interview for DSM-IV- TR Axis 
I Disorders, Clinical Trials Version (SCID-CT). New York: Biometrics Research, New York State Psychiatric 
Institute. 
First, M.B., Spitzer, R.L., Gibbons, M., Williams, J.B., & Benjamin, L. (1996). User’s guide for the Structured 
Clinical Interview for DSM–IV Axis II Personality Disorders (SCID-II). New York: New York State Psychiat-
ric Institute, Biometrics Research Department. 
Fournier, J.C., DeRubeis, R.J., Shelton, R.C., Gallop, R., Amsterdam, J.D., & Hollon, S.D. (2008). Antidepres-
sants medications v. cognitive therapy in people with depression with or without personality disorder. 
British Journal of Psychiatry, 192, 124. 
Hamilton, M. (1960). A rating scale for depression. Journal of Neurology Neurosurgery and Psychiatry, 23, 
56-61. 
Hardy, G.E., Barkham, M., Shapiro, D.A., Rees, A., Stiles, W.B., & Reynolds, S. (1995). Impact of cluster-c 
personality disorders on outcomes of contrasting brief psychotherapies for depression. Journal of Con-
sulting and Clinical Psychology, 63 (6), 997-1004.  
Kool, S., Dekker, J., Duijsens, I.J., De Jonghe, F., & Puite, B. (2003). Efficacy of combined therapy and pharma-
cotherapy for depressed patients with or without personality disorders. Harvard Review of Psychiatry, 
11 (3), 133-141. 
Kool, S., Schoevers, R., De Maat, S., Van, R., Molenaar, P., Vink, A., et al. (2005). Efficacy of pharmacotherapy 
in depressed patients with and without personality disorders: A systematic review and meta-analysis. 
Journal of Affective Disorders, 88, 269-79. 
Moradveisi, L., Huibers, M., Renner, F., Arasteh, M., & Arntz, A. (2013). Behavioural activation v. Antidepres-
sant Medication for depression in Iran: a Randomized Trial. British Journal of psychiatry, 202 (3) 204-
211. 
Mulder, R.T (2002). Personality pathology and treatment outcome in major depression: a review. American 
Journal of Psychiatry, 159, 359-371. Newton-Howes, G., Tyrer, P., & Johnson, T. (2006). Personality dis-
order and the outcome of depression: meta-analysis of published studies. British Journal of Psychiatry, 
188, 13-20. 
Sato, T., Sakado, K., Sato, S., & Morikawa, T. (1994). Cluster a personality disorder- A marker of worse treat-
ment outcome of major depression. Psychiatric Research, 53 (2), 153-159. 
Shea, M.T., Widiger, T.A., & Klein, M.H. (1992). Comorbidity of personality disorder and depression implica-
tions for treatment. Journal of Consulting and Clinical Psychology, 60 (6), 857-868. 
Sullivan, P.F., Joyce, P.R., & Mulder, R.T. (1994). Borderline personality disorder in major depression. Journal 
of Nervous and Mental Disease, 182 (9), 508-516. 
58 
Tyrer, P., Seivewright, N., Ferguson, B., Murphy, S., & Johnson, A.L. The Nottingham Study of Neurotic Disor-
der: effect of personality status on response to drug treatment, cognitive therapy and self-help over 
two years. British Journal of Psychiatry, 162, 219-225.  
 
 
  
59 
 
Chapter 4 
The influence of patients’ preference/attitude 
towards psychotherapy and antidepressant 
medication on the treatment of major depressive 
disorder6 
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Abstract 
Background and Objectives: Preferences and attitudes that patients hold towards the 
treatment they receive are important, as these can influence treatment outcome. In 
depression research, the influence of patients’ preference/attitudes on outcome and 
dropout has mainly been studied for antidepressant medication, and less for psycho-
logical treatments. We investigated the effects of patients’ preference and attitudes 
towards psychological treatment and antidepressant medication on treatment out-
come and dropout, and tested specificity of effects.  
 
Methods: Data are based on a randomized trial testing the effectiveness of behaviour-
al activation (BA) vs antidepressant medication (ADM) for major depression (MDD) in 
Iran. Patients with MDD (N = 100) were randomized to BA (N =50) or ADM (N = 50). 
Patients’ preference/attitudes towards psychotherapy and ADM were assessed at 
baseline and associated with dropout and treatment outcome using logistic regression 
and multilevel analysis.  
 
Results: High scores on psychotherapy preference/attitude and low scores on ADM 
preference/attitude predicted dropout in ADM, while no association between dropout 
and preference/attitude was found in BA. Psychotherapy preference/attitude moder-
ated the differential effect of BA and ADM on one outcome measure, although the 
association disappeared after one year.  
 
Limitations: Because in Iran most patients have only access to ADM, offering a psycho-
logical treatment for depression could attract especially those patients that prefer this 
newly available treatment.  
 
Conclusions: patients’ preferences and attitudes towards depression treatments influ-
ence dropout from ADM, and moderate the short-term difference in effectiveness be-
tween BA and ADM. The fact that dropout from BA was not affected by prefer-
ence/attitude speaks for its acceptability among patients. 
 
  
61 
1. Introduction 
Depressed patients generally come to treatment with a preference for psychological or 
medication treatment depending on what they think is effective for them (Khalsa, 
McCarthy, Sharpless, Barrett, & Barber, 2011). Patients with major depressive disorder 
(MDD) in primary care often receive antidepressant medication (ADM), and not psy-
chological treatment, because of the unavailability of psychotherapies (Van Schaik et 
al., 2004). There is a lack of specialist mental health care for depression in rural areas, 
compared to urban areas (Lambart, Agger, & Hartley, 1999), and especially the availa-
bility of psychotherapy is low in rural areas (Fortney, Harman, Xu, & Dong, 2009). 
There are also vast differences between countries, with Western countries having 
much more psychological treatments available than non-Western countries. The Me-
dian rate of psychologist per 100,000 population working in the mental health sector 
by WHO region is 0.04 for Africa, 1.29 for the Americans, 0.48 for the eastern Mediter-
ranean, 2.58 for Europe, 0.03 for South East Asia, and 0.00 for the Western Pacific 
(WHO-Mental Health Atlas, 2011). In Iran, for instance, the usual treatment for de-
pression is ADM, and psychological treatments are difficult to get. In rural areas, but 
even in most urban areas in Iran the supply of psychological treatment is very limited 
(WHO-AIMS Report, 2006). Sanandaj for instance, where the present study was con-
ducted, has a population of more than 500.000, but there are only five psychologists 
available for mental health care. If factors like preference for psychological treatment 
and negative attitudes towards ADM influence the acceptability and effectiveness of 
ADM, the limited availability of psychological treatment in many regions around the 
world is problematic as this will lead to suboptimal health care.  
 Previous research on the influence of patient preference has however yielded 
mixed results. A first issue is whether preference influences the take up, adherence 
and completion of a treatment. A meta-analysis by Van Schaik et al (2004) reported 
that patients with a strong preference for psychological treatment are probably disin-
clined to be randomized in clinical trials where they might receive antidepressant med-
ication. One study reported dropout and non-compliance in primary care to be related 
to being given non-preferred depression treatment (Schulberg, Magruder, & Gegruy, 
1996). A randomized controlled trial (Raue, schulberg, Heo, Klimstra, & Bruce, 2009) 
that studied influences of preference of depressed patients for interpersonal psycho-
therapy and ADM reported that preference was related to treatment initiation and 12-
weeks adherence rate. Thus, these studies indeed indicate that treatment preference 
influences take up, adherence, and completion of treatment. 
 A second issue is the degree to which outcomes of treatment are influenced by 
(dis) concordance of preference and the offered treatment. Seven studies found no 
association between preference and outcome of depression treatment (Raue et al., 
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2009; Bedi et al., 2000; Ward et al., 2000; Van et al.,2009; Dunlop et al., 2012; Kwan et 
al., 2010; Laykin et al., 2007). Two of these used a partially randomized patient-
preference design (Bedi et al., 2000; Ward et al., 2000) i.e. patients who did not accept 
randomization were offered the preferred treatment. Neither of these studies report-
ed significant differences in outcome between those who were randomized to psycho-
therapy and those who chose it, and preference for psychotherapy was not related to 
higher recovery rates at follow-up. Another study compared patient preference with 
random allocation in short-term psychodynamic supportive psychotherapy with indi-
cated addition of pharmacotherapy for depression and did not find preference to in-
fluence outcome (Van et al., 2009). 
 Four studies reported evidence for influences of preference on outcome (Patricia 
et al., 2005; Steidtmann et al., 2012; Kocsis et al., 2009; Mergl et al., 2011). The results 
of a trial (Patricia et al., 2005) that investigated patients’ preference for counselling or 
antidepressant medication indicated that those who received their preferred treat-
ment had better treatment outcome. Steidtmann et al (2012) conducted a large trial 
with a two-phase design; in phase I, all depressed participants were offered ADM, 
while in Phase II non-remitters were randomized to either cognitive-behavioural sys-
tem of psychotherapy (CBASP) plus ADM, brief supportive psychotherapy plus ADM, or 
ADM only. In phase I, participants without any preference had a higher rate of symp-
tom reduction than those with any preference, and those who preferred combined 
treatment showed less attrition than those who preferred medication. In phase II, 
treatment preference was not related to attrition or reduction of symptoms. Kocsis et 
al (2009) compared the effectiveness of nefazodone, CBASP, or combination therapy in 
patients with chronic MDD. They found that patients who received their treatment of 
choice had a higher remission rate and lower depression scores than those who re-
ceived the non-preferred reatment. Mergl et al (2011) investigated influences of 
treatment preference on effects of Sertraline and group-CBT for depression in de-
pressed primary care patients, and found that those receiving their preferred treat-
ment responded significantly better than those who did not receive their preferred 
therapy.  
 Renewed interest in behavioural strategies has led to the development of behav-
ioural activation (BA) as a relatively new treatment for patients with MDD (Jacobson et 
al., 1996). Earlier studies have shown that BA is an effective intervention for depres-
sion that might even be more effective than cognitive therapy in severely depressed 
patients (Dimidjian et al., 2006). To date, no study investigated the association of 
treatment preference with the effects of BA in comparison to ADM for patients with 
MDD. 
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1.1 Aims of the study 
The data presented in this paper are drawn from a randomized controlled trial com-
paring BA and Sertraline for patients with MDD, in which BA proved to be superior to 
ADM (Moradveisi et al., 2013). The focus of this paper is on whether depressed pa-
tients’ preference for and attitudes towards psychological treatment and ADM influ-
ence symptom reduction in the course of one year and dropout from treatment. 
 Studies into preference effects typically assess preference by a single question 
(e.g., Dunlop et al., 2012; Kocsis et al., 2009; Kwan et al., 2010; Leykin et al., 2007; 
Mergl et al., 2011; Steidtmann et al., 2012).We wanted to improve on that by using a 
questionnaire with multiple items assessing preferences for and attitudes towards 
ADM and psychotherapy. With this, we could assess basic psychometric properties, for 
instance whether preferences for and attitudes towards BA and ADM are one-
dimensional or multidimensional, and how reliable these assessments are - issues that 
cannot be addressed when a single question is used. We expected that preference for 
and attitudes towards BA and ADM would not load on a single dimension, as we ex-
pected that at least some people have relatively negative attitudes to both, others 
positive attitudes to both, and some people have no clearcut preference, whereas 
others do. Using dimensional variables and a multiple regression approach, it is possi-
ble to represent the probably multidimensional nature of treatment preferences and 
attitudes in the statistical analyses. 
2. Method  
2.1 Study design 
A randomized controlled trial (RCT) was conducted comparing BA and ADM (Sertraline) 
as treatment for MDD. There were two primary outcome measures: the Beck Depres-
sion Inventory (BDI) and the Hamilton Rating Scale for Depression (HRSD), assessed at 
0 (baseline), 4, 13 and 49 weeks. At baseline, a preference/attitude questionnaire was 
also completed. Main treatment outcome findings and the sample characteristics of 
the study have been reported elsewhere (Moradveisi et al., 2013). The study was regis-
tered in the International Clinical Trial register, IRCT138807192573N1. 
2.2. Participants and setting 
Participants were 100 depressed patients from Sanandaj, Iran, between the ages of 18 
to 60 years (mean 31.37, SD 8.97), 85 women, with a primary diagnosis of MDD ac-
cording to the Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR (Amer-
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ican Psychiatric Association, 2000) confirmed by the Structured Clinical Interview for 
the DSM-IV-TR Axis-I Disorders Clinical Trials Version (SCID-CT) (First, Williams, spritzer, 
& Gibbon, 2007). Participants had to have a score of ≥ 19 on the Beck Depression In-
ventory, second edition (BDI-II) (Beck steer, & Brown, 1996) and a score of ≥ 14 on the 
17-item Hamilton Rating Scale for Depression (HRSD) (Hamilton, 1960). Participants 
completed a preference/attitude questionnaire at baseline. The study was approved 
by the local Committee of Medical Ethics, Second Session of Kurdistan University of 
Medical Sciences. All participants signed written informed consent to participate in the 
study.  
2.3 Treatment Behavioural activation and antidepressant medication 
One hundred participants were randomly assigned to receive behavioural activation 
(BA, n = 50) or Sertraline (n = 50). Participants in the BA condition received sixteen 50-
min sessions over 12 weeks, for the first 4 weeks twice a week, and for the next 8 
weeks once a week. In the treatment as usual (TAU) condition, participants were seen 
for the first 4 weeks of the treatment once a week and for the next 8 weeks once every 
two weeks. Psychiatrists saw each participant 20 min in the first session and in the 
subsequent sessions for approximately 10 min to monitor pharmacotherapy and side 
effects of the medication.  
2.4 Measures and assessments 
2.4.1 Primary outcome 
Depression severity was assessed with the modified 17-item version of the HRSD 
(Hamilton, 1960) and the BDI-II (Beck et al., 1996). Both measures were administered 
at baseline, 4, 13, and 49 weeks of treatment. HRSD assessments were done by evalua-
tors blind to treatment conditions. In addition to these assessments, independent as-
sessors, not blind for the condition, took the HRSD for ADM patients before every ses-
sion and supplied therapists with the results, whereas BA patients completed the BDI-II 
before every session and the results were supplied to their therapists. These additional 
assessments where only used in the analysis as last observations in case of early drop-
out. 
2.4.2 Construction of the preference/attitude questionnaire 
The preference-attitude questionnaire was constructed by two authors (L.M and A.A). 
It had 15 items, organized in two sets: (1) psychotherapy preference/attitudes (items 
1, 2, 7, 9, 11, 13); (2) ADM preference/attitudes (items 3, 4, 5, 6, 8, 10, 12, 14, 15). The 
items were: 
1. I prefer psychotherapy above antidepressant medication in treating depression; 
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2. Psychotherapy is an effective way to treat depression; 
3. I avoid taking antidepressant medications due to the side effects; 
4. Depression usually improves by antidepressant medication; 
5. Depression is always caused by problems in people’s lives, thus antidepressant 
medication cannot help to improve depression; 
6. Antidepressant medications are addictive; 
7. Depression is a physiological problem and psychotherapy is not capable of treating 
that; 
8. Antidepressant medication is an effective way to treat depression; 
9. Psychotherapy can help people to solve problems in their lives, therefore I prefer 
it; 
10. When I was depressed in the past, antidepressants helped to improve my depres-
sion; 
11. People with depression find it difficult to talk; therefore, psychotherapy cannot 
help to improve depression; 
12. Depressed people are avoiding their daily routines and relationships with friends, 
therefore antidepressant cannot help to improve depression; 
13. Depression is caused by low self-esteem and faulty thoughts, therefore psycho-
therapy can improve it; 
14. I am more comfortable with taking antidepressant medication than psychological 
treatment; 
15. Most depressed people respond better to antidepressant medications than psy-
chological treatment. 
 Items were scored on 9-point Likert scales (0 = not at all; 8 = very much so). Prin-
cipal component analysis supported the structure of two scales: the scree-plot had an 
elbow at two components. The two components explained 49.53% of the variance. 
After oblimin rotation, the two components were clearly related to two sets described 
above: preference and positive attitudes to either ADM, or psychological treatment. 
Reliability analyses of the scales formed on the basis of these components (with re-
versed scorings of items 3, 5, 6, 7, 11) indicated too low contributions of items 12 and 
13. After deleting these items the subscales had acceptable internal consistencies 
(both α=.83). Mean (standard deviation) was 5.90 (1.71) for psychotherapy prefer-
ence/attitudes and 2.69 (1.51) for ADM preference/attitudes, respectively. The two 
scales correlated -.413 (p<.001) with each other. 
2.5 Statistical analysis 
Preference/attitude scores were centred by transformation into z-scores. The effects 
of preference/attitude, condition, and their interaction on treatment dropout were 
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tested with logistic regression. Multilevel analysis was used to estimate influences of 
preference/attitude on change in depression severity over time, alone and in interac-
tion with condition. As time was best fitted using a polynomial growth curve, we used 
time and time-squared in all analyses, as reported earlier (Moradveisi et al., 2013). We 
applied intention-to-treat analysis, with the HRSD and BDI as dependent variables, by 
including all available scores. We used multilevel analyses with an unstructured covari-
ance structure for repeated measures, with time, time-squared, condition, time by 
condition, time-squared by condition, and preference/attitude, and the interactions 
between preference/attitude, time(-squared) and condition as fixed effects. In all 
models, treatment condition was centred at -½ and ½. Non-significant interactions 
were removed stepwise from the model starting with the highest order interactions. 
We computed effect sizes r (= √ (F/F+df)) for continuous outcomes from the multilevel 
estimates. One extreme score on the ADM preference/attitude scale was pulled into 
+2 SD, to prevent the case becoming a leverage point. 
 For treatment dropouts who refused further assessments, we used the last obser-
vation with the associated time, and estimated missing HRSD scores (for BA-dropouts) 
from changes on the BDI, and missing BDI scores (for TAU-dropouts) from changes on 
the HRSD, using regression derived equations (1 BDI unit=1.3 HRSD unit). All treatment 
drop-out took place before the mid-treatment assessment. Analyses were conducted 
using SPSS19. 
Results 
Dropout 
The overall rate of participant’s dropout was detailed in the original publication (Mo-
radveisi et al., 2013). 20 participants dropped out of treatment, 5 in BA and 15 in the 
ADM condition. The two preference/attitudes scales were first analysed separately. As 
to psychotherapy preference/attitude, the condition by psychotherapy prefer-
ence/attitude interaction was significant (OR = 0.21 [0.05; 0.87]; p = 0.031), the main 
effect of psychotherapy preference/attitude was significant (OR = 5.01[1.86; 13.50]; p 
= 0.001) and the condition effect was not significant (OR = 0.31[0.09; 1.09]; p = 0.060). 
As to ADM preference/attitude, the condition by ADM preference/attitude interaction 
was also significant (OR = 9.85 [1.91; 50.75]; p = 0.006), the main effect of ADM pref-
erence/attitude was significant (OR= 0.11 [0.03; 0.38]; p = 0.001) and the condition 
was significant (OR = 0.21 [0.06; 0.78]; p = 0.019). As figure 1 illustrates, both high psy-
chotherapy preference/attitude and low ADM preference/attitude were associated 
with higher dropout from ADM, while dropout from BA was not associated with pref-
erence/attitudes. When both preference/attitude scales were put in the analyses, the 
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condition by psychotherapy preference/attitude interaction was no longer significant 
(p = 0.18). After stepwise removing non-significant predictors, the model contained the 
condition, ADM preference/attitude, and their interaction. 
 In conclusion, the results indicate that a high preference for and positive attitude 
towards psychotherapy was associated with a higher chance to drop out from ADM, as 
was a low preference for and negative attitude towards ADM. The ADM prefer-
ence/attitude score appeared to be the most important predictor of dropout from 
ADM. In contrast, both preference/attitude scales did not predict dropout from BA. 
 
  
Figure 1. Illustration of the effects of treatment preference/attitude on chance of dropout by condition. X-
axis: z-score of psychotherapy preference/attitude (left panel), respectively z-score of ADM prefer-
ence/attitude (right panel). Y-axis: chance of dropping out from treatment. Left panel: the regression lines 
depict the association between psychotherapy preference/attitudes and chance of dropout from ADM and 
BA treatments separately. There is a positive association for ADM, but not for BA, meaning that chance of 
dropout from ADM is higher when psychotherapy preference/attitude is higher, whereas there is no effect 
of this preference on chance to dropout from BA. Right panel: the regression lines depict the association 
between ADM preference/attitudes and chance of dropout from ADM and BA treatments separately. There is a 
negative association for ADM, but not for BA, meaning that chance of dropout from ADM is higher when ADM 
preference/attitude is lower, whereas there is no effect of this preference on chance to dropout from BA. 
Abbreviations: BDI = Beck Depression Inventory; HRSD = Hamilton Ratings Scale for Depression; ADM = 
antidepressant medication (Sertraline); BA = behavioural Activation.  
Effects of preference/attitude on BDI and HRSD 
Table 1 presents the results of the mixed regression of the full model, including all pre-
dictor variables and higher order interactions, for both HRSD and BDI. Table 2 gives an 
overview of the results after deletion of non-significant higher order interactions in-
volving the preference/attitude scales. 
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Table 1. Prediction of depressive symptoms by preference over time: mixed regression full model results. 
BDI B 95% CI (B) F df r1 p 
Intercept 27.74 26.45; 29.02 1831.99 103.04 0.97 <0.001 
Condition -2.57 -5.16; 0.03 3.85 105.18 0.18 0.052 
Preference psychotherapy 0.45 -0.65; 1.55 0.66 95.96 0.08 0.417 
Preference ADM  -0.60 -1.66; 0.45 1.30 88.86 0.12 0.257 
Time -1.98 -2.12; -1.84 838.17 92.51 0.94 <0.001 
Time-Squared 0.03 0.03; 0.04 732.25 87.09 0.94 <0.001 
Time x Condition -0.36 -0.62; -0.10 7.71 90.66 0.27 0.007 
Time-Squared x Condition 0.01 0.00; 0.01 6.45 88.12 0.26 0.013 
Condition x Preference psychotherapy 0.06 -2.55; 2.66 0.00 103.31 0 0.966 
Condition x Preference ADM 0.39 -1.26; 2.04 0.21 83.66 0.05 0.643 
Time x Preference psychotherapy -0.00 -0.03; 0.02 0.05 89.80 0.02 0.827 
Time-squared x Preference psychotherapy 0.00 -0.00; 0.00 0.353 87.79 0.06 0.554 
Time x Preference ADM 0.00 -0.00; 0.00 0.78 76.06 0.10 0.379 
Time-squared x Preference ADM 0.00 -0.00; 0.00 0.571 77.91 0.08 0.452 
Time x Condition x Preference psychotherapy -0.20 -0.47; 0.07 2.06 92.31 0.14 0.155 
Time –Squared x Condition x Preference 
psychotherapy 
0.00 -0.00; 0.01 2.14 87.17 0.15 0.148 
Time x Condition x Preference ADM 0.17 -0.15; 0.48 1.11 87.20 0.11 0.295 
Time –Squared x Condition x Preference ADM -0.00 -0.01; 0.00 0.58 82.39 0.08 0.449 
HRSD  
Intercept 21.56 20.45; 22.67 1495.24 103.66 0.96 <0.001 
Condition -1.50 -3.71; 0.72 1.80 105.51 0.12 0.183 
Preference psychotherapy 0.15 -0.74; 1.05 0.12 85.16 0.03 0.730 
Preference ADM   -0.93  -1.81; -0.06  4.50 77.28  0.23  0.036 
Time -1.50 -1.61; -1.40 774.37 93.94 0.94 <0.001 
Time-Squared 0.03 0.02;0.03  680.76 90.17 0.93 <0.001 
Time x Condition -0.37 -0.57; -0.16 12.56 91.66 0.34 <0.001 
Time-Squared x Condition 0.01 0.00; 0.01 13.16 90.48 0.35 <0.001 
Condition x Preference psychotherapy 0.59 -1.65; 2.84 0.28 104.56 0.05 0.601 
Condition x Preference ADM 0.81 -0.73; 2.35 1.09 77.81 0.11 0.300 
Time x Preference psychotherapy 0.01 -0.01; 0.03 0.44 85.42 0.07 0.508 
Time-squared x Preference psychotherapy 0.00 -0.00; 0.00 0.10 91.03 0.03 0.749 
Time x Preference ADM 0.00 7.47; 0.00 5.54 73.97 0.26 0.021 
Time-squared x Preference ADM 0.00 3.89; 0.00 4.75 74.28 0.24 0.032 
Time x Condition x Preference psychotherapy -0.23 -0.45; -0.02 4.52 93.89 0.21 0.036 
Time –Squared x Condition x Preference 
psychotherapy 
0.00 0.00; 0.01 5.45 90.40 0.23 0.022 
Time x Condition x Preference ADM 0.04 -0.21; 0.28 0.08 87.64 0.03 0.777 
Time –Squared x Condition x Preference ADM 1.70 -0.00; 0.00 0.00 83.77 0 0.994 
Abbreviations: BDI = Beck Depression Inventory; HRSD = Hamilton Ratings Scale for Depression; ADM = anti-
depressant medication (Sertraline). 1 Effect size r = √(F/(F+ df)).  
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Table 2. Mixed Regression results after deleting three-way and preference x time (squared) interaction 
BDI  B 95% CI (B) F df ra p 
Intercept 28.41 26.60; 30.21 970.46 110.48 0.94 <0.001 
Condition -1.77 -4.39; 0.84 1.80 116.43 0.12 0.182 
Time -1.87 -2.06; -1.68 392.69 95.20 0.89 <0.001 
Time-squared 0.03 0.03; 0.04 353.36 89.22 0.89 <0.001 
Condition x Time  -0.32 -0.57; -0.06 6.00 91.16 0.24 0.016 
Condition x Time-Squared 0.00 0.00; 0.00 4.36 86.31 0.21 0.040 
Preference psychotherapy 1.23 0.22; 2.25 5.85 95.71 0.24 0.018 
Preference ADM 0.91 -0.06; 1.88 3.48  84.00 0.19 0.066 
Preference psychotherapy x Condition -1.09 -2.53; 0.36 2.22 86.40 0.15 0.140 
Preference ADM x Condition -1.07 -2.86; 0.73 1.41 77.10 0.13 0.239 
HRSD  
Intercept 21.85 20.29; 23.42 765.89 108.25  0.93 <0.001 
Condition -0.80 -3.11; 1.49 0.49 115.82 0.06 0.487 
Time -1.41 -1.55; -1.26 349.91 95.49 0.88 <0.001 
Time-squared 0.02 0.02; 0.03 311.49 91.15 0.87 <0.001 
Condition x Time -0.29 -0.50; -0.09 8.14 90.87 0.28 0.005 
Condition x Time-Squared 0.01 0.00; 0.01 7.30 87.01 0.27 0.008 
Preference psychotherapy 0.94 -0.03; 1.91 3.74 89.69 0.20 0.056 
Preference ADM 0.39 -0.54; 1.32 0.70 78.29 0.09 0.404 
Preference psychotherapy x Condition -0.61 -0.00; 0.77  0.79 78.69 0.09 0.378 
Preference ADM x Condition -0.36 -2.08; 1.36 0.18 69.86 0.05 0.677 
Abbreviations: BDI = Beck Depression Inventory; HRSD = Hamilton Ratings Scale for Depression; ADM = anti-
depressant medication (Sertraline) 
a Effect size r = √(F/(F+ df)).  
 
 BDI. Three-way psychotherapy preference/attitude score x time (squared) x condi-
tion interactions were not significant for the BDI (Table 1). The same held for the 
three-way interaction of the ADM preference/attitude score (Table 1). The two-way 
psychological treatment preference/attitude x condition interaction was also non-
significant for the BDI, as was the two-way interaction of ADM preference/attitude and 
condition (Table 2). These findings indicate that preferences for and attitudes towards 
psychotherapy or ADM did not influence the overall condition effects or the condition 
effects on changes in the BDI over time 
 HRSD. Three-way psychological treatment preference/attitude x time (squared) x 
condition interactions were significant for the HRSD, F (1, 93.89) = 4.52, p = 0.036 and 
F (1, 90.40) = 5.45, p = 0.022, indicating that preference/attitude for psychological 
treatment moderated the difference between conditions in treatment effects (Table 
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1). Inspection of the difference between BA and ADM in the association between pref-
erence/attitude for psychological treatment and HRSD at the four assessments shows 
that the effect is caused by a temporary change in the association in the BA condition 
after acute phase treatment which disappears at 49 weeks (Fig. 2). Thus, BA partici-
pants, who preferred psychological treatment at baseline and received such a treat-
ment, initially responded better to this treatment than others (see negative slope for 
BA at week 13), but not at one year follow-up. In other words, preference/attitude for 
psychotherapy did not moderate the outcome at follow-up (Fig. 2).  
 Three-way ADM preference/attitude x time (squared) x condition interactions 
were not significant (Table 1), as was the ADM preference/attitude x condition interac-
tion (Table 2), indicating that ADM preference/attitudes did not moderate condition 
differences over time or general differences between conditions. 
 
 
Figure 2. Mixed regression based-estimated HRSD scores at baseline (0 weeks), during treatment (4 weeks), 
post-treatment (13 weeks) and at 49 weeks follow-up for the two conditions as a function of baseline psy-
chotherapy preference/attitude score (x-axis). The slopes depict the linear relationships between psycholog-
ical preference/attitudes (z-scores) and HRSD at the four assessments. The negative slope between this 
preference and HRSD at 13 weeks for BA indicates superior effects of BA for those with a high psychotherapy 
preference/attitude. This effect disappears at week 49 (parallel slopes; the distance between the slopes 
depicts the superior long term effects of BA above ADM). This difference between conditions in change of 
the relationship between baseline psychotherapy preference/attitude scores and HRSD over time is reflect-
ed in significant time (squared) x condition x psychotherapy preference interactions. 
Abbreviations: BDI = Beck Depression Inventory; HRSD = Hamilton Ratings Scale for Depression; ADM = 
antidepressant medication (Sertraline); BA = behavioural Activation. 
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Discussion 
We developed a self-report instrument to assess patients’ treatment preferences for 
and attitudes towards either psychotherapy or pharmacological treatment for depres-
sion. Preference and attitude items related to a treatment modality loaded on the 
same factor, but psychological and ADM treatment preferences/attitudes could be 
clearly distinguished, and showed only a modest correlation (-.41, i.e. shared variance 
= 17%). This indicates that a high (or a low) preference for/attitude towards one mo-
dality does not necessarily imply an opposite preference for and attitude towards the 
other modality. The scales turned out to be treatment-specific predictors. Firstly, 
dropout from ADM could be predicted by both preference/attitude scales, with the 
ADM preference scale being the strongest predictor. Secondly, preference for psycho-
logical treatment moderated the condition by time interaction effects on the HRSD 
caused by a specific effect on short-term response to BA. These findings will now be 
discussed in detail. 
 Participants with a lower ADM preference/attitude score showed more dropouts 
from the ADM condition. Those with a higher psychological preference/attitude score 
had also a higher chance of dropout from ADM. Of the two preference/attitude scales, 
the ADM scale was the most important, as the psychological preference/attitude scale 
had no additional contribution in predicting dropout from ADM. BA participants’ drop-
out was not influenced by preference/attitude. The influence of preference/attitude 
on dropout was not similar in the two conditions. Whereas a mismatch between pref-
erence and treatment predicted dropout from ADM, no mismatch was associated with 
dropout from BA. It seems that BA has higher acceptability than ADM even for those 
that prefer and have positive attitudes to ADM, and for those that have a low prefer-
ence for psychotherapy. 
 The existence of three-way preference/attitude psychological treatment x time 
(squared) x condition interactions for the HRSD indicates that preference/attitude for 
psychological treatment moderated the difference between treatment conditions. 
However, this difference disappeared after one year follow-up. This might point to-
ward some kind of placebo effect. People who believe that the treatment they receive 
works also report to get better, but only as long as they also receive that treatment. 
However, one would then also expect such an effect after 4 weeks of treatment, but 
no association between high psychological treatment preference/attitude and treat-
ment outcome was apparent in BA. Moreover, similar effects were not found on the 
BDI. Thus, we can conclude that we found some evidence for the short-term effects of 
preference/attitude on outcome, but in the long-run this effect disappeared. 
 The main outcomes of the RCT (Moradveisi et al., 2013) remained stable when 
controlled for treatment preference/attitudes. Dropout was higher from ADM than 
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from BA, and this effect remained significant after controlling for ADM prefer-
ence/attitudes and its interaction with condition (OR = 0.26 without controlling for 
preference/attitudes, OR = 0.21 after controlling). BA was more effective than ADM on 
the HRSD and BDI, and these effects remained stable after controlling for treatment 
preference/attitudes: the beta coefficients of the mixed regression estimates of the 
time effects, and the condition by time interactions are highly comparable with and 
without controlling for preference scores. This indicates that the main findings of the 
RCT are not dependent on specific treatment preferences and attitudes, and speaks for 
the applicability of BA as a highly acceptable and effective treatment for many de-
pressed patients. 
 Our results on the influence of preference on dropout are consistent with Van 
Schaik et al (2004), Schulberg et al (1996), and Raue et al (2009). Our study suggests a 
qualification, as the effect was only observed for pharmacological treatment, and not 
for psychological treatment, as dropout from BA was not influenced by preference. 
The finding that differences between BA and pharmacotherapy in outcome as assessed 
with the HRSD was moderated by preference are in line with four previous studies re-
porting effects of preference on outcome (Patricia et al., 2005; Steidtmann et al., 2012; 
Kocsis et al., 2009; Mergl et al., 2011), but in contrast to the seven studies that did not 
find such effects (Raue et al., 2009; Bedi et al., 2000; Ward et al., 2000; Van et al.,2009; 
Dunlop et al., 2012; Kwan et al., 2010; Laykin et al., 2007). It is unclear which factors 
might explain the different findings across studies, but these might include differences 
between samples (e.g., primary vs. secondary care), differences between treatments 
that were compared, differences in designs, and different assessment methods of 
preferences. It should be stressed however, that our moderation effect on outcome by 
preference was only temporary and only found in one of the two outcome instru-
ments. Consequently, our moderation effect does not seem to constitute strong evi-
dence for the effects of preference on treatment outcome.  
 The results suggested that the majority of our participants preferred psychological 
treatment above ADM. One explanation for this is that ADM is widely available in Iran, 
and most depressed patients have experience with ADM treatment. Thus, offering a 
new treatment such as BA may have attracted participants to our study, so that the 
sample might have been biased towards those that had positive attitudes towards psy-
chological treatment. On the other hand, preference for psychological treatment 
above ADM seems a fairly general phenomenon (Van Schaik et al., 2004; Laine and 
davidoff, 1996; Schulberg et al., 1996; Raue et al, 2009) and perhaps not so specific for 
our sample. 
 ADM is more easily available in most regions of the world than psychological 
treatment. The finding that dropout from ADM is influenced by preference and atti-
tudes towards it, whereas dropout from BA was lower and not influenced by prefer-
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ence and attitudes, and had better effects than ADM, is worrisome in that context. It 
indicates that simple psychological treatments like BA should be made more available 
around the globe, or that negative attitudes towards ADM should be addressed. 
Limitations 
A number of limitations should be mentioned with respect to the data presented in 
this study. Due to the fact that in Iran most patients have only access to ADM, offering 
a psychological treatment for depression could attract especially those patients that 
prefer this newly available treatment. Our results might therefore be subjected to se-
lection bias and only apply to Iran and the Iranian culture. Most participants with re-
current MDD have had already medication treatment. The most accessible treatment 
for psychological disorders in Iran is medication. Thus, those who previously sought 
help for depression likely received ADM from psychiatrists in the past rather than psy-
chological treatment by clinical psychologists. Unfortunately, we did not collect data 
on previous treatments in our sample so that we could not look into the possible ef-
fects of this. 
 However, several previous studies in Western cultures have reported a general 
preference for psychological treatment in depressed patients (Van Schaik et al., 2004; 
Laine and Davidoff, 1996; Schulberg et al., 1996; Raue et al, 2009). Another limitation 
is that we used a newly developed instrument that was not previously used in research 
to assess preferences and attitudes towards depression treatments. However, the 
straightforwardness of the items in combination with the results from our principal 
component analysis suggest our newly developed scales have ecological validity. As to 
the moderation of effectiveness by preference and attitude, a limitation is that this 
was only detected on the HRSD and not on the BDI, and our findings on moderation of 
effects should be interpreted with some caution. 
Conclusion 
In conclusion, our study found that those participants who received ADM and who at 
the same time had a low preference for or attitude towards ADM had a higher chance 
to drop out of treatment than those without such a preference/attitude. The fact that 
dropout from BA was not affected by preferences/attitude speaks for its high accepta-
bility. Moreover, psychotherapy preference had a positive effect on initial response to 
the psychological treatment. Our conclusion is therefore that taking patient preference 
into account may improve treatment retention and initial response. Future studies 
should investigate the effects of preference/attitude for BA and ADM in other clinical 
settings and cultures. 
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Chapter 5 
The influence of patients’ attributions of the 
immediate effects of treatment of depression on 
long-term effectiveness of behavioural activation 
and antidepressant medication7 
  
                                                                
7-  Moradveisi, L., Huibers, M. J., & Arntz, A. (2014). The influence of patients’ attributions of the immediate 
effects of treatment of depression on long-term effectiveness of behavioural activation and antidepres-
sant. Behaviour Research and Therapy, ’in revision’’. 
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Abstract 
Patients’ attributions of effects of treatment are important, as these can affect long-
term outcome. Most studies so far focused on the influence of attributions to medica-
tion for anxiety and depression disorders. We investigated the effects of patients’ at-
tributions made after acute treatment on the long-term outcome of antidepressant 
medication (ADM) and psychological treatment (behavioural activation, BA). Data are 
based on a randomized trial testing the effectiveness of BA vs. ADM for major depres-
sion (MDD) in Iran. Patients with MDD (N = 100) were randomized to BA (N = 50) or 
ADM (N = 50). Patients’ attributions were assessed at post-test (after completion of 
the treatments). Scores on an attribution questionnaire were factor analysed, and fac-
tor scores were retained as predictors of depressive symptoms at 1-year follow-up. 
Regression analysis was used to test whether attributions predicted depressive symp-
toms at 1-yr follow-up, controlling for symptom level, condition, and their interaction 
at post-test. Belief in coping was the only attribution factor significantly predicting 1-
year HRSD scores, controlling for condition, post-test HRSD and their interaction. It 
also mediated the condition differences at follow-up. Credits to self was the single at-
tribution factor that predicted BDI follow-up scores, controlling for condition, posttest 
BDI, and their interaction. It partially mediated the condition differences on the BDI at 
follow-up. Attribution to increased coping capacities and giving credits to the self ap-
pear essential. In the long-term (at 1 year follow-up), the difference in outcome be-
tween BA and ADM (with BA being superior to ADM) is at least partially mediated by 
attributions. 
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Introduction 
Antidepressant medication (ADM) is a standard treatment for depressed patients in 
current psychiatric guidelines (American Psychiatric Association, 2000; (Frank, et al. 
1990) and the most recent practice guideline for the initial treatment of patients with 
mild to moderate major depressive disorder (MDD) is antidepressant medication and 
depression-focused psychotherapy. For depressed patients with severe MDD with or 
without psychiatric features however, ADM is the first choice (American Psychiatric 
Association, 2010). The short-term effectiveness of ADM is well studied and compara-
ble to that of CBT and IPT, although dropout from ADM is higher (Cuijpers et al., 2008). 
Much less is known about the long-term effectiveness of ADM, and how it compares to 
that of psychological treatment. A recent meta-analysis reported a trend towards su-
periority in relapse prevention of CBT compared to maintenance of ADM over 5 studies 
(OR = 1.62; p = .07). The superiority of CBT over ADM became significant after exclu-
sion of one outlier, OR = 1.77, p < .05 (Cuijpers et al., 2013). The same meta-analysis 
reports clear evidence of superiority of CBT over ADM when ADM is discontinued after 
the acute treatment phase over eight studies, OR = 2.61, p < .001 (see also Imel et al., 
2008). Thus, when patients stop taking antidepressant medication, those who recov-
ered from their depressive episode are at a substantial risk for recurrence, whereas 
CBT appears to offer a better protection for future relapse. The superior effects of CBT 
over ADM in relapse prevention seem to hold for both the Beckian approaches (Hollon, 
et al. 2002); Hollon et al., 2005; Dobson et al., 2008) and for Behavioural Activation 
(BA) (Dobson et al., 2008; Moradveisi et al., 2013). 
 The important question then arises: what explains the apparent superior long-
term effects of psychological treatment over ADM? It has been argued before that 
where ADM only alleviates depression symptoms as long as the medication is used, 
patients in psychotherapy actually learn to get better and stay well (Paykel et al., 2006; 
Hollon et al., 2005). More specifically, it was found that the skills that patients acquire 
in CT actually predict the prevention of relapse after treatment (Strunk et al., 2007). 
From a behavioural activation point of view, a likely reason of relapse after discontinu-
ation medication is that patients did not change their coping skills. The lack of rein-
forcement, patterns of avoidance and rumination might still exist, although antide-
pressant medication might reduce temporarily their effects on mood. In contrast, 
those patients treated with behavioural activation have acquired healthy behavioural 
skills and new coping styles that might reduce relapse (Moradveisi et al., 2013). 
 Another explanation is that patients’ beliefs about why they recovered in therapy 
(attributions) impact the sustaining of gains. It has been postulated by Brewin and An-
taki (1982) that patients who attribute gains to their own efforts are more likely to 
sustain those gains compared to those who attribute improvement to external causes 
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such as a drug’s activity or a therapist’s charisma. A study by Basoglu et al. (1994) in-
vestigated attributions made by patients with panic disorder and agoraphobia who had 
participated in an RCT comparing 8 weeks of alprazolam or placebo (medication treat-
ment) plus exposure or relaxation (psychological treatment; relaxation being the “psy-
chological placebo”). At the end of 8 weeks of treatment, 40 patients who much/very 
much improved assessed how much they attributed their gains to medication or to 
their own efforts. At the treatment-free follow-up in week 43, those who at week 8 
had attributed their gains to medication and felt less confident about coping without 
medication had more severe withdrawal symptoms and a higher loss of gains in com-
parison to those who at week 8 had attributed their gains to their own efforts during 
treatment. Another study by Biondi and Picardi (2003) that investigated panic disorder 
with agoraphobia reported similar results. They found that 60% of the patients with 
panic disorder who attributed improvement to medication in a combined medication-
psychotherapy treatment relapsed, whilst those who attributed improvement to the 
self-reported no relapse. Although similar attributional processes have been hypothe-
sized to play a role in the differential long-term effects of CBT vs. ADM in depression 
treatment, no study so far assessed this to the best of the present authors’ knowledge.  
 Behavioural activation (BA) is a relatively new treatment for patients with major 
depressive disorder (MDD) (Jacobson et al., 1996). Recent studies have shown that BA 
is an effective treatment for depression that might even be more effective than cogni-
tive therapy in severely depressed patients (Dimijian et al., 2006). To date, no study 
investigated the effects of attribution to medication and attribution to the self on 
treatment effects of BA in comparison to antidepressant medication (ADM) for partici-
pants with MDD. The data presented in this paper are drawn from a randomized con-
trolled trial comparing BA and antidepressant medication (Sertraline) for patients with 
MDD, in which BA proved to be superior to ADM (Moradveisi et al., 2013). The focus of 
this paper is on whether depressed patients’ attributions of treatment effects (i.e. to 
the medication or to the self), impact the long-term effects of treatment, assessed 
after approximately one year. If it is true that CBT has better long-term effects than 
ADM because of attribution of improvement to controllable factors in the self instead 
of to external factors such as medication, two predictions follow. 
 
(1) Attribution of treatment effects to the self will predict better long-term effects of 
treatment, even after controlling for the short-term effects. In contrast, attribution of 
treatment effects to medication will not be associated, or negatively associated, with 
long-term treatment effects. 
 
(2) Attribution of treatment effects to the self will mediate the long-term differences 
between BA and ADM that were observed in our trial. 
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We tested the first prediction by assessing participants’ beliefs about factors explaining 
improvement after treatment, and testing their predictive power in explaining long-
term depressive complaints, assessed at 49 weeks, whilst controlling for the level of 
these complaints as assessed immediately after treatment (week 13). The second pre-
diction was tested by formal mediation tests, investigating whether attributions statis-
tically mediated the difference between conditions in long-term effects, even when 
controlling for the short-term effects of treatment. Implicated in the attribution medi-
ation hypothesis is that attributions that play a role in explaining the differences be-
tween BA and ADM on the long-term effects should differ significantly between condi-
tions; we therefore also tested whether attributions differed between BA and ADM. 
Methods 
Main treatment outcome findings and the sample characteristics of the study have 
been reported elsewhere (Moradveisi et al., 2013). The original sample consisted of 
100 depressed patients from Sanandaj, Iran, between the ages of 18 to 60 years (mean 
31.37, SD 8.97), 85 women, with a primary diagnosis of MDD according to the Diagnos-
tic and Statistical Manual of Mental Disorders DSM-IV-TR (American Psychiatric Associ-
ation, 2000), confirmed by the Structured Clinical Interview for the DSM-IV-TR Axis-I 
Disorders Clinical Trials Version (SCID-CT) (First et al., 2007). Participants had to have a 
score of ≥ 19 on the Beck Depression Inventory, second edition (BDI-II) (Beck et al., 
1996) and a score of ≥ 14 on the 17-item Hamilton Rating Scale for Depression (HRSD) 
(Hamilton, 1960). The present study reports on the 70 participants with complete data 
at the 3-months and 1-year follow-up assessments. These were all treatment complet-
ers. The study was approved by the local Committee of Medical Ethics, Second Session 
of Kurdistan University of Medical Sciences. All participants signed written informed 
consent to participate in the study.  
Treatments, measures and assessments 
Participants were randomized by an independent coordinator. Fifty participants were 
randomly assigned to each condition, behavioural activation (N= 50) and antidepres-
sant medication (N= 50). Participants in the BA group received 16 sessions over 12 
weeks. For the first 4 weeks they received two sessions per week, and for the following 
8 weeks one session per week. No patient in the BA group took medication during the 
three months of the treatment phase. 
 Patients in the ADM group received sertraline, which is the usual treatment in Iran 
for depression. In week 1, participants in the ADM group started with 25 mg/daily of 
sertraline, and the dosage in week 2 increased to 50 mg, 75 mg in week 4, and 100 mg 
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in week 6 up to week 12. Psychiatrists could reduce the dosage temporarily in case of 
side-effects and then increase the dosage to the previous level. The maximum dosage 
of sertraline was 100 mg per day. After 12 weeks, antidepressant medication use was 
discontinued.  
 Depression severity was assessed with the modified 17-item version of the HRSD 
(Hamilton, 1960) and the BDI-II (Beck et al., 1996). Both measures were administered 
at baseline, 4, 13 (three months of treatment), and 49 weeks (also referred to as 1 year 
follow-up). HRSD assessments were done by evaluators blind to treatment conditions. 
Independent assessors assessed the HRSD for TAU patients and the BDI for BA patients 
before every treatment session and supplied results to psychiatrists and therapists. 
 The attribution questionnaire was constructed by two authors (L.M and A.A) on 
the basis of Basoglu’s attribution questionnaire (Basoglu et al., 1994). We modified 
items to make them applicable to depression treatment, and replaced items 3, 4, 7, 9, 
and 14 to add more items with explicit attribution to psychological treatment. The 
questionnaire had 15 items (Table 1). Items were scored on 9-point Likert scales (0 = 
not at all; 8 = very much so). Participants filled out all items, they were instructed to 
use their subjective belief if they had no experience with what was asked. Item 14 
caused too many interpretation problems, probably because of the double negation, 
and was left out further analyses. It should be noted that most participants had previ-
ous experience with ADM before entering the trial. 
Statistical analysis 
The attribution items were subjected to a Principal Component Analyses, retrieving 
components with Eigenvalue > 1, also using the scree test to decide on the number of 
components to extract, followed by Oblimin rotation. Attribution scores were based on 
factor scores from the Principal Component Analysis, which are by definition centred. 
Regression analyses were used to estimate the influences of attribution on depression 
severity at week 49, controlling for depression severity at week 13 and the interaction 
between condition and depression severity at week 13, if significant. We used HRSD-
follow up and BDI-follow up as dependent variables, and centred predictors, by using 
Z-scores of BDI and HRSD at week 13, and treatment condition dummies -0.5 (ADM) 
and 0.5 (BA). Predictors were centred as main effects cannot be interpreted validly 
when interactions are included in the model. For each dependent variable, the follow-
ing predictors were forced into the model: z-score of the dependent variable at week 
13, condition, and their interaction (if significant); this was model 1. Next, the 4 factor 
scores of the belief questionnaire were entered, as well as their interactions with con-
dition. As none of these 
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interactions was significant, we will not report them. Thus, the second model we re-
port had all 4 factor scores as predictors in addition to the predictors of model 1. Next, 
non-significant predictors involving attribution factors were deleted backwards, using 
p<.05 as a criterion, leading to models 3, 4, etc., until only significant attribution pre-
dictors remained. The significant attribution factors were then tested as mediators of 
long-term differences between BA and ADM, controlling for post-test level of the de-
pendent variable (HRSD, respectively BDI) and its interaction with condition (if signifi-
cant). The mediation tests were executed using Hayes and Preacher’s (2013; see also 
Preacher & Hayes, 2004) bootstrap mediation test with the SPSS Macro “Mediate” 
(http://www.afhayes.com/spss-sas-and-mplus-macros-and-code.html, downloaded 
March 9, 2013), using 50,000 replications. This test allows multiple covariates in the 
model. We used a high number of replications to get more precise estimates (less es-
timation error) as the 95% CI intervals were near zero. Statisticians have criticized the 
use of relatively small numbers of replications in Monte Carlo tests like the bootstrap, 
and the underestimation of the error resulting from relatively small numbers of repli-
cations (Koehle, Brown & Haneuse, 2009). The higher the number of replications, the 
more precise the estimate becomes, and therefore practical aspects (computational 
time) and not statistical theory usually determines the number of replications. With 
the mediation test we assessed whether the difference between BA and ADM in de-
pression severity at 1-year follow-up is statistically explained by attributions. The me-
diation test examines whether the direct effect of condition on 1-year depression se-
verity is explained by an “indirect” effect through attribution, that is whether BA and 
ADM differ in attribution, and whether this difference accounts for the long-term dif-
ferences in depression severity. Mediation is inferred when (i) attribution differs be-
tween conditions (i.e., condition predicts attribution); (ii) attribution predicts 1-year 
depression severity; (iii) the effect of condition becomes non-significant after control-
ling for attribution; (iv) the indirect path from condition to 1-year depression severity 
through attribution is significant. Partial mediation is concluded when all criteria are 
fulfilled except (iii), that is the effect of condition remains significant (despite reducing 
in strength). As the indirect path effect is the product of the effects of condition on the 
mediator (i.e., attribution) and of the mediator on 1-year depression severity, the dis-
tribution of the indirect path effect is usually not normal (but highly skewed). Testing 
the indirect path is therefore done in the Preacher and Hayes (2004) approach by a 
bootstrap test; high numbers of samples (with replacement) of the same N as the em-
pirical sample are taken, the indirect path is calculated for every sample, and thereby a 
simulated distribution of the indirect path is created. From this simulated distribution 
the 95% confidence interval (CI) is derived and if it does not contain zero, significance 
at p<.05 of the indirect path is concluded. The mediation tests were controlled for the 
level of severity at 3 months as well as for the (significant) interaction of condition by 
85 
level of severity at 3 months. Figures 1-4 illustrate the mediation models that were 
tested. 
Results 
Structure of the attribution scale 
A Principal Component Analysis indicated 4 components with Eigenvalue > 1. The four 
components explained 72.43% of the variance. After Oblimin rotation three of the four 
components could be well interpreted: (1) belief in tablets; (2) belief in coping; (3) 
credits to self; whereas the fourth was provisionally labeled (4) indifference (to facili-
tate interpretation, the original loadings of factors 3 and 4 were reversed). Table 1 
presents the item’s factor loadings per factor in order of size, omitting loadings with an 
absolute value < .25. The factor inter-correlations ranged from -.37 to .22. For further 
computations, factor scores were retained (reversed for factors 3 and 4), with higher 
scores representing higher positions on the dimensions as listed above. As might be 
expected, BA participants scored higher on “belief in coping”, t(68) = 4.36, p < .001, 
and “credits to the self”, t(68) = 3.81, p < .001, compared to ADM participants. ADM 
participants scored higher on “belief in tablets”, t(68) = 11.24, p < .001, and “indiffer-
ence”, t(68) = 3.02, p = .004. 
Effects of attribution on BDI and HRSD 
Table 2 and 3 present the results of the regression analyses of the full model for HRSD 
and BDI, respectively. 
 HRSD. The two-way condition x zHRSD post interaction was significant for the 
HRSD in all models and therefore included in all (Table 2). The interaction reflected a 
positive association between HRSD at 3 months and 1 year in ADM (r=0.65, p < .001) 
and an absence of an association in BA (r=0.03, n.s.). Condition was significant in mod-
el 1, before entering the attribution factors, reflecting lower HRSD scores at 1-year 
follow-up in BA than in ADM. After backward deletion of the non-significant attribution 
factors, belief in coping remained as the single significant attribution factor predicting 
1-year HRSD scores, with higher scores predicting lower HRSD scores (Table 2, model 
5). In model 5, condition became non-significant (p=.074; Table 2), suggesting that the 
condition effect at 1-year follow-up was mediated to a large extent by the belief in 
coping attribution factor. 
The formal test of mediation with Hayes & Preacher’s (2013) bootstrap mediation test 
yielded positive evidence for mediation of the group effect on follow-up HRSD, as the 
direct effect of group on the mediator (“belief in coping”) was significant when con-
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trolling for posttest HRSD and group by posttest HRSD as covariates (Beta = 1.04, 
se=.25, t (66)= 4.24, p = .0001), and the bootstrap 95% confidence interval of the indi-
rect effect of condition through the mediator on 1-year HRSD (-.86; SE .63) did not con-
tain zero, 95%CI [-2.75; -0.05] (Figure 1). 
 BDI. The two-way condition x zBDI post interaction was significant in all analyses, 
and therefore retained in all models (Table 3). The interaction reflected a positive as-
sociation between BDI at 3 months and 1 year in ADM (r=0.58, p = .001) and an ab-
sence of an association in BA (r=0.01, ns). Condition was significant, reflecting superior 
effects of BA above ADM on BDI-scores at 1-year follow-up. After backward deletion of 
the non-significant attribution factors, credits to the self was found to be the single 
significant attribution factor predicting 1-year BDI scores, controlling for condition, 
posttest BDI and their interaction (model 5, Table 3). Credits to the self predicted low-
er BDI scores at 1-year follow-up. In model 5, condition remained significant, though 
there was a shrinkage in explanatory power, suggesting partial mediation of the condi-
tion effect by the credits to the self factor. 
 The formal test of mediation with Hayes & Preacher’s (2013) bootstrap mediation 
test yielded positive evidence for (partial) mediation of the group effect on follow-up 
BDI, as the effect of group on the mediator (“credits to the self”) was significant when 
controlling for posttest BDI and group by posttest BDI as covariates (Beta = -.59, 
se=.26, t(66)= -2.26.24, p = .027), and the bootstrap 95% confidence interval of the 
indirect effect of condition through the mediator on 1-year BDI (-.51; SE .32) did not 
contain zero, 95% CI [-1.52; -0.08] (Figure 2). 
 
  
87 
Table 2. Results of regression analyses testing effects of attributions after 13 weeks of treatment on 49 
weeks HRSD scores. 
 Predictor Unstandardized coefficients Standardized 
Beta 
t-value p-value 
 B S.E 
Model 1 (R2 = .45)  
Constant 7.90 0.37  21.43 < 0.001 
Condition  -2.32  0.74 -0.33 -3.15 0.002 
 z (HRSD Post) 1.12 0.36  0.33  3.07 0.003 
Condition* z (HRSD Post) -2.04 0.73 -0.27 -2.81 0.007 
Model 2 (R2 = .51)  
Constant  7.81 0.38  20.70 < 0.001 
Condition -1.56 1.40  -0.22 -1.11 0.27 
z (HRSD Post)  1.10 0.38  0.32  2.85 0.006 
Condition* z (HRSD Post) -2.17 0.76  -0.28 -2.87 0.006 
Belief in tablets  0.04 0.64  0.01  0.06 0.95 
Belief in coping -0.84 0.36  -0.24 -2.30 0.025 
Credits to self -0.27 0.37  -0.08 -0.74 0.46 
Indifference -0.43 0.35  -0.12 -1.25 0.22 
Model 3 (R2 = .51)  
Constant  7.82 0.36  21.88 < 0.001 
Condition -1.62 0.85  -0.23 -1.90 0.062 
z (HRSD Post)  1.09 0.37  0.32  2.92 0.005 
Condition* z (HRSD Post) -2.15 0.71  -0.28 -3.06 0.003 
Belief in coping -0.84 0.36  -0.24 -2.33 0.023 
Credits to self -0.27 0.36  -0.08 -0.75 0.46 
Indifference -0.44 0.34  -0.12 -1.27 0.21 
Model 4 (R2 = .51) 
Constant  7.83 0.36  22.04 < 0.001 
Condition -1.77 0.83  -0.25 -2.15 0.035 
z (HRSD Post)  1.17 0.35  0.35 3.34 0.001 
Condition* z (HRSD Post) -2.19 0.70  -0.29 -3.13 0.003 
Belief in coping -0.88 0.36  -0.25 -2.47 0.016 
Indifference -0.49 0.33  -0.14 -1.48 0.14 
Model 5 (R2 = .49)  
Constant  7.83 0.36  21.82 < 0.001 
Condition -1.46 0.81  -0.21 -1.82 0.074 
z (HRSD Post)  1.20 0.35  0.35  3.38 0.001 
Condition* z (HRSD Post) -2.12 0.71  -0.28 -3.01 0.004 
Belief in coping -0.83 0.36  -0.23 -2.31 0.024 
Note. Condition was centred with BA = .5 and TAU (ADM) = -.5. z (HRSD Post) = standardized HRSD score at 
post-test (13 weeks). The four factor scores (by definition centred) of the attribution questionnaire taken at 
post-test were labelled: (1) Belief in Tablets; (2) Belief in Coping; (3) Credits to Self; and (4) Indifference. 
Significant p-levels are printed bold. 
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Table 3. Results of regression analyses testing the effects of attributions after 13 weeks of treatment on 49 
weeks BDI scores. 
 Predictor Unstandardized coefficients Standardized 
Beta 
t-value p-value 
 B S.E 
Model 1 (R2 = .56)      
Constant 9.76 0.42  23.54 < 0.001 
Condition  -4.29 0.83 -0.49 -5.17 < 0.001 
 z (BDI Post) 1.15 0.41 0.27 2.79 0.007 
Condition* z (BDI Post) -2.21 0.82 -0.23 -2.69 0.009 
Model 2 (R2 = .62)      
Constant  9.79 0.43  22.91 < 0.001 
Condition -4.73 1.50 -0.54 -3.15 0.003 
z (BDI Post)  0.96 0.41 0.23 2.36 0.021 
Condition* z (BDI Post) -1.97 0.87 -0.20 -2.27 0.027 
Belief in tablets -0.72 0.69 -0.16 -1.04 0.30 
Belief in coping -0.69 0.39 -0.16 -1.76 0.083 
Credits to self -0.65 0.39 -0.16 -1.66 0.10 
Indifference -0.50 0.38 -0.12 -1.32 0.19 
Model 3 (R2 = .61)      
Constant  9.64 0.40  23.96 < 0.001 
Condition -3.50 0.93 -0.40 -3.75 < 0.001 
z (BDI Post)  0.98 0.41  0.23  2.41 0.019 
Condition* z (BDI Post) -2.34 0.79 -0.24 -2.95 0.004 
Belief in coping -0.67 0.39 -0.16 -1.72 0.091 
Credits to self -0.71 0.39 -0.17 -1.85 0.069 
Indifference -0.43 0.37 -0.10 -1.17 0.25 
Model 4 (R2 = .60)      
Constant  9.60 0.40  23.88 < 0.001 
Condition -3.20 0.90 -0.37 -3.56 <0.001 
z (BDI Post)  0.93 0.40  0.22  2.30 0.025 
Condition* z (BDI Post) -2.37 0.80 -0.25 -2.98 0.004 
Belief in coping -0.62 0.39  -0.14 -1.59 0.12 
Credits to Self  -0.81 0.38 -0.20 -2.17 0.034 
Model 5 (R2 = .59)      
Constant  9.69 0.40  24.02 < 0.001 
Condition -3.78 0.83 -0.43 -4.52 < 0.001  
z (BDI Post)  0.92 0.41  0.22  2.24 0.029 
Condition* z (BDI Post) -2.19 0.80 -0.23 -2.75 0.008 
Credits to Self -0.86 0.38 -0.21 -2.28 0.026 
Note. Condition was centred with BA = .5 and TAU (ADM) = -.5. z (BDI Post) = standardized BDI score at post-
test (13 weeks). The four factor scores (by definition centred) of the attribution questionnaire taken at post-
test were labelled: (1) Belief in Tablets; (2) Belief in Coping; (3) Credits to Self; and (4) Indifference. Signifi-
cant p-levels are printed bold. 
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Table 4. Factor loadings of the 6 items of the reduced attribution questionnaire. 
Item Factor 1 
Lack of Belief in 
Coping 
Factor 2 
Credits to Self 
8. I will not be able to cope all by myself when my treatment ends .947  
3. I can do things more easily because my efforts improved my feelings -.926  
5. I do not feel more confident in coping with my problem now .726 -.312 
2. I do not deserve any credit for the improvement I have made  -.846 
12. I like myself better for having achieved this improvement so far  .807 
11. I have learned things during my treatment that are helping me to 
cope better 
 .627 
Note. Factor loadings with absolute value < .25 are not displayed. 
 
Table 5. Results of regression analyses testing effects of attributions from the reduced attribution question-
naire after 13 weeks of treatment on 49 weeks HRSD scores. 
Predictor Unstandardized coefficients Standardized 
Beta 
t-value p-value 
 B S.E 
Model 1 (R2 = .45)      
Constant 7.90 0.37  21.43 < 0.001 
Condition  -2.32  0.74 -0.33 -3.15 0.002 
 z (HRSD Post) 1.12 0.36  0.33 3.07 0.003 
Condition* z (HRSD Post) -2.04 0.73 -0.27 -2.81 0.007 
Model 2 (R2 = .51)      
Constant 7.79 0.36    
Condition -0.97 0.86 -0.14 -1.13 0.26 
z (HRSD Post) 1.03 0.37 0.30 2.79 0.007 
Condition* z (HRSD Post) -2.12 0.70 -0.28 -3.03 0.004 
Lack of Belief in Coping 0.81 0.38 0.23 2.13 0.037 
Credits to Self -0.58 0.38 -1.54 -1.54 0.13 
Model 3 (R2 = .49)      
Constant 7.79 0.36  21.62 < 0.001 
Condition -1.24 0.85 -0.18 -1.46 0.15 
z (HRSD Post) 1.21 0.35 0.36 3.42 .001 
Condition* z (HRSD Post) -2.20 0.71 -0.29 -3.11 .003 
Lack of Belief in Coping 0.89 0.38 0.25 2.34 .023 
Note. Condition was centred with BA = .5 and TAU (ADM) = -.5. z (HRSD Post) = standardized HRSD score at 
post-test (13 weeks). The two factor scores (by definition centred) of the reduced attribution questionnaire 
(only items that did not refer to medication or psychological treatment) taken at post-test were labelled: (1) 
Lack of Belief in Coping; and (2) Credits to Self. Significant p-levels are printed bold. 
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Table 6. Results of regression analyses testing effects of attributions from the reduced attribution question-
naire after 13 weeks of treatment on 49 weeks BDI scores. 
 Predictor Unstandardized coefficients Standardized 
Beta 
t-value p-value 
 B S.E 
Model 1 (R2 = .56)      
Constant 9.76 0.42  23.54 < 0.001 
Condition  -4.29 0.83 -0.49 -5.17 < 0.001 
 z (BDI Post) 1.15 0.41 0.27 2.79 0.007 
Condition* z (BDI Post) -2.21 0.82 -0.23 -2.69 0.009 
Model 2 (R2 = .61)      
Constant 9.64 .40  23.98 <.001 
Condition -3.00 0.95 -0.35 -3.17 0.002 
z (BDI Post) 0.92 0.40 0.22 2.27 0.026 
Condition* z (BDI Post) -2.34 0.80 -0.24 -2.93 0.005 
Lack of Belief in Coping 0.54 0.42 0.23 1.30 0.20 
Credits to Self -0.99 0.40 -0.23 -2.48 0.016 
Model 3 (R2 = .60)      
Constant 9.73 0.40  24.46 < 0.001 
Condition -3.59 0.84 -0.41 -4.27 < 0.001 
z (BDI Post) 0.89 0.41 0.21 2.21 0.031 
Condition* z (BDI Post) -2.14 0.79 -0.22 -2.72 0.008 
Credits to Self -1.04 0.40 -0.24 -2.61 0.011 
Note. Condition was centred with BA = .5 and TAU (ADM) = -.5. z (HRSD Post) = standardized HRSD score at 
post-test (13 weeks). The two factor scores (by definition centred) of the reduced attribution questionnaire 
(only items that did not refer to medication or psychological treatment) taken at post-test were labelled: (1) 
Lack of Belief in Coping; and (2) Credits to Self. Significant p-levels are printed bold. 
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A. Unmediated model 
 
 
 
B. Mediation model 
 
Figure 1. Mediation of effects of treatment condition on 1-year depression assessed with the HRSD by at-
tribution factor “belief in coping”. 
 
Note. BA = behavioural Activation; ADM = Antidepressant Medication; z(HSRD post) = standardized score of 
the Hamilton Rating Scale for Depression at posttest (post-treatment); HRSD = Hamilton Rating Scale for 
Depression; a, b, c = unstandardized regression coefficients (with SE in brackets); NS p > .05; * p < .05; ** p < 
.01; *** p < .005; **** p < .001 
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Follow-up
c1 = -2.32 (0.74) ***
c2 = 1.12 (0.36) ***
c3 = -2.04 (0.73)**
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coping
Condition
(BA vs ADM)
HRSD at
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Follow-up
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X
Condition
(BA vs ADM)
c’2 = 1.20 (0.35)***
c'3 = -2.12 (0.71)***
b  = -0.83 (0.36)*
c’1 = -1.46 (0.81)NS
Mediation was significant: 
(i) a1 and b were significant; 
(ii) condition effect c’1 became nonsignificant (whereas c1 was significant in model A);
(iii) bootstrap 95%CI of the indirect effect did not contain zero [-2.75; -0.05] 
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A. Unmediated model 
 
 
 
B. Mediation model 
 
Figure 2. Partial mediation of effects of treatment condition on 1-year depression assessed with the BDI by 
attribution factor “credits to self”. 
 
Note. BA = behavioural Activation; ADM = Antidepressant Medication; z (BDI post) = standardized score of 
the Beck Depression Inventory at posttest (post-treatment); BDI = Beck Depression Inventory; a, b, c = un-
standardized regression coefficients (with SE in brackets); NS p > .05; * p < .05; ** p < .01; *** p < .005; **** 
p < .001 
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b  = -0.86 (0.38)*
c’1 = -3.78 (0.83)****
Partial mediation was significant: 
(i) a1 and b were significant; 
(ii) condition effect c’1 remained significant (c1 was significant in model A, but reduced 
in strength);
(iii) bootstrap 95%CI of the indirect effect did not contain zero [-1.52; -0.08] 
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A. Unmediated model 
 
 
 
B. Mediation model 
 
Figure 3. Mediation of effects of treatment condition on 1-year depression assessed with the HRSD by at-
tribution factor “lack of belief in coping” from the reduced attribution questionnaire (additional analyses). 
 
Note. BA = behavioural Activation; ADM = Antidepressant Medication; z(HSRD post) = standardized score of 
the Hamilton Rating Scale for Depression at posttest (post-treatment); HRSD = Hamilton Rating Scale for 
Depression; a, b, c = unstandardized regression coefficients (with SE in brackets); NS p > .05; * p < .05; ** p < 
.01; *** p < .005; **** p < .001 
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Mediation was significant: 
(i) a1 and b were significant; 
(ii) condition effect c’1 became nonsignificant in model B (whereas c1 was significant 
in model A);
(iii) bootstrap 95%CI of the indirect effect (-0.86) did not contain zero [-2.77; -0.007] 
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A. Unmediated model 
 
 
 
B. Mediation model 
 
Figure 4. Partial mediation of effects of treatment condition on 1-year depression assessed with the BDI by 
attribution factor “credits to self” from the reduced attribution questionnaire (additional analyses). 
 
Note. BA = behavioural Activation; ADM = Antidepressant Medication; z (BDI post) = standardized score of 
the Beck Depression Inventory at posttest (post-treatment); BDI = Beck Depression Inventory; a, b, c = un-
standardized regression coefficients (with SE in brackets); NS p > .05; * p < .05; ** p < .01; *** p < .005; **** 
p < .001 
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z (BDI post)
z (BDI post) X
Condition
(BA vs ADM)
c’2 = 0.89 (0.40)*
c'3 = -2.14 (0.79)**
b  = -1.04 (0.40)*
c’1 = -3.59 (0.84)****
Partial mediation was significant: 
(i) a1 and b were significant; 
(ii) condition effect c’1 remained significant (c1 was significant in model A, but reduced 
in strength in model B);
(iii) bootstrap 95%CI of the indirect effect (-0.70) did not contain zero [-1.73; -0.16] 
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Additional analyses 
The analyses so far may be criticized as the attribution questionnaire contained items 
that might have been difficult to rate for participants not receiving the type of treat-
ment the items refer to. We therefore checked attributional effects within each condi-
tion by construing ad-hoc attribution scales from item subsets that did not refer to the 
other treatment. For ADM, items 1,2,3,5,6,8,9,10,11,12,13 and 15 were considered as 
none referred to psychological treatment (reversed scoring when indicated). Based on 
a reliability analysis, items 5, 8, and 13 were deleted. The subscale had (within the 
ADM subgroup) an internal consistency of .53 (Cronbach’s alpha) and correlated signif-
icantly with change from 3-month to 1-year follow-up changes in HRSD (r=.37, p=.046) 
and BDI (r=.36, p=.049), indicating that higher attributions to medication and lower 
attributions to skills and the self predicted increases in depression severity from 3-
months to one year. Similarly, we considered items 2,3,4,5,7,8,11 and 12 for the BA 
condition, as none referred to medication. Based on a reliability analysis items 3,4,5,7 
and 8 were retained (Cronbach alpha = .91). Correlations with changes from 3-month 
to 1-year follow-up failed to reach significance for HRSD (r = -.22, p=.17) and BDI (r = -
.002, p=.99). 
 Lastly, the main analyses were repeated using only items of the attribution ques-
tionnaire that did not refer to medication or psychological treatment, that is items 
2,3,5,8,11 and 12. A principal component analyses yielded two components with ei-
genvalue > 1 (total variance explained 71.5%), and the scree plot also supported a two-
factor solution. After Oblimin rotation, the two factors were interpreted as “lack of 
belief in coping” and “credits to the self”, see table 4 for factor loadings. The factor 
intercorrelation was -. 31. Factor scores were retained for further computations. The 
conditions differed significantly in mean factor scores; on “lack of belief in coping” 
means (SD) were for ADM .63 (.65) vs. for BA -.47 (.96), t(68) = 5.10, p<.001; and on 
“credits to the self” for ADM -.53 (1.02) vs. for BA .40 (.78), t(68) = 4.34, p<.001. Using 
the same regression procedures as above, factor 1 scores significantly added to the 
prediction of HRSD scores at 1-year follow-up, controlling for condition, 3-months 
HRSD and their interaction (Table 5). The prediction by condition became non-
significant, indicating mediation of the condition differences on HRSD at 1-year follow-
up by “lack of belief in coping”. This was confirmed by a formal mediation test, see 
figures 3 and 4. In short, condition significantly predicted the mediator, the mediator 
significantly predicted the HRSD at follow-up, the direct effect of condition on 1-year 
follow-up HRSD became non-significant after controlling for the mediator, and the 95% 
CI of the indirect effect of condition (beta = -.86) through the mediator did not contain 
zero (-2.7708; -.0067). 
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 Similar findings as from the primary analyses were found for the prediction of 1-
year BDI by the revised attribution questionnaire’s factors. As is shown in Table 6, fac-
tor 2 (Credits to Self), but not factor 1, predicted 1-year BDI controlling for condition, 
3-months BDI, and their interaction. Similarly as in the primary analysis, adding factor 2 
reduced the contribution of condition, but did not make it non-significant. A formal 
mediation analysis demonstrated that the (partial) mediation of the condition effect by 
factor 2 was significant, as condition significantly predicted factor 2, and the indirect 
effect of condition through the mediator (beta = -0.70) was significant (the 95% CI did 
not contain zero: (-1.73; -0.16)). 
Discussion 
We used a self-report instrument to assess patients’ treatment attribution towards 
either psychotherapy or pharmacological treatment for depression. The instrument 
was a modification of the instrument constructed by Basoglu et al. (1994), adapted to 
depression and to represent not only medication but also psychological treatment. The 
four components of the instrument explained 72.43% of the variance, and were la-
belled: (1) belief in tablets; (2) belief in coping; (3) credits to self; and (4) indifference. 
The results of the study indicated that BA and ADM treatment conditions differentially 
influenced the attribution types. ADM treatment led to relatively stronger beliefs in 
medication and to stronger indifference compared to BA, whereas BA conduced to 
relatively stronger beliefs in own coping capabilities and to stronger crediting the self 
for improvement. It is likely that increased belief in medication was due to improve-
ment of depression symptoms in the ADM condition attributed to the medication par-
ticipants took, but the higher scores on factor 4 (labelled “indifference”) are more dif-
ficult to interpret. By hindsight, the label of factor 4 might be wrong, and for instance 
“unconditional preference for medication above psychological treatment” is a better 
description. Perhaps a cognitive dissonance reduction process might have played a role 
here, with (some) ADM participants placing stronger trust in medication and not in 
psychological treatment because they were randomized to ADM. In any case, this at-
tribution factor did not appear to be important as a mediator, and can be ignored in 
that sense. Stronger beliefs in coping and stronger crediting the self for improvement 
in BA than in ADM is probably directly related to learning new strategies and skills in 
treatment to cope with problems, and the direct experience that one’s own actions 
lead to overcoming problems and improvement in mood. However, we did not assess 
the degree of skill acquisition and actual application, so we cannot test this interpreta-
tion. 
 Long-term effects were predicted by attributional factors. Attribution of effects to 
medication does not seem to play a role, but attribution to increased coping capacities 
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and giving credits to the self appear essential. The difference between BA and ADM 
treatment (with BA > ADM) in the long-term (at 1 year follow-up) is at least partially 
mediated by attributions. Thus, we have evidence that the superior long-term effects 
of BA above ADM are at least partially related to self-attributions, which are higher in 
BA. 
 The attribution questionnaire we used contained items that referred to ADM or to 
psychological treatment, and therefore might have been difficult to rate by partici-
pants that did not receive, or had previously received, the treatment referred to. We 
therefore redid the analyses after all items that either referred to ADM or psychologi-
cal treatment were deleted. Although now only two factors were found, they were 
similar in content to the two of the four factors of the primary analysis that turned out 
to be mediators, and they mediated condition differences in the same way as in the 
primary analysis. That is, the “lack of belief in coping” factor mediated the condition 
differences at 1-year on the HRSD, with no mediating role for the other factor. The 
“credits to the self” factor partially mediated the condition differences on the BDI, with 
no role for the “lack of belief in coping” factor. This indicates that the main findings of 
the study are not caused by items that were in content condition-specific. We also ex-
plored whether a scale constructed from items that do not refer to psychological 
treatment related to changes from 3 months to 1-year within the ADM condition, and 
found evidence for a negative relationship, reflecting that stronger attributions to 
ADM and weaker attributions to the self and to improved coping are related to poorer 
long-term effects in the ADM condition, replicating similar associations in the Basoglu 
et al. (1994) study. Remarkably, a scale constructed from items that do not refer to 
ADM did not significantly correlate to changes from 3 months to 1 year in the BA con-
dition. This might reflect a restriction of range effect in BA caused by many participants 
in the BA condition having relatively strong beliefs in their own coping and strong at-
tributions to the self, while at the same time having good immediate and follow-up 
effects. This indicates that belief in one’s own coping and crediting the self for improv-
ing are factors that explain differences in long-term effects between AMD and BA, but 
not so much within BA. 
The results of the study showed that clinician-rated depressive symptoms (HRSD) are 
predicted by “belief in coping’’, i.e. belief in the effectiveness of specific behaviours 
and one’s capacities to use these behaviours. On the other hand, self-reported depres-
sive symptoms (BDI) were predicted by feeling good about progress and improvement 
made and attributing this to the self (credits to the self). There are indications that 
interviews more validly assess objectifiable symptom manifestations and self-reports 
better capture symptom experience (Hopwood et al., 2008), and factors like severity of 
depression and neuroticism appear to play a role in discrepancies between the two 
(Carter et al., 2010; Enns et al., 2000). For example, it has been suggested that more 
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severely depressed patients have difficulties in appropriately rating their symptoms 
(Enns et al., 2000). It is unclear what underlies the specific relationships between at-
tribution type and method of depression severity assessment. Speculations might con-
sider the possibility that the relationships are meaningful, in the sense that attribution 
to a concrete cause (i.e. skills) relates to more objectifiable depressive symptoms 
(those that can be rated by an assessor) whereas attribution to a subjective feeling (i.e. 
crediting oneself and liking oneself better for accomplishing improvement) is related to 
a more subjective experience of depressive symptoms. Possibly, behavioural skills spe-
cifically reduce objectifiable depression symptoms, whereas feeling emotionally good 
reduces specifically subjective depression symptoms. Clearly, more research is needed 
to disentangle the associations if they prove to be replicable. 
 Our results on the influence of attribution to the self and belief in own coping is 
consistent with Brewin and Antaki (1982) proposition that patients who attribute their 
improvement to their own efforts will maintain those improvements better than those 
who attribute gains to external attribution such as medication. Our findings are also in 
line with the Basoglu et al. (1994) study, in that patients who attributed their im-
provement to medication and felt less confident in coping without medication had 
more severe withdrawal symptoms and more loss of gains than those who attributed 
their improvement to their own efforts during treatment. Biondi and Picardi (2003) 
findings are also consistent with our results. They found that panic patients with ago-
raphobia who attributed their improvement to the self showed no relapse, whereas 
60% of those who attributed their improvement to the medication relapsed. 
 One can speculate about the relationship between attributing progress to the self 
and one’s own coping, and DeRubeis et al.’s (1990) explanation for the superior long-
term effects of CBT over ADM treatment. They speculated that in CBT patients learn 
skills and strategies in coping with life problems which are not learned in ADM. These 
skills and new strategies may act directly to prevent relapse, but may also lead to in-
creased attributions to own efforts and belief in coping, which might directly guard 
patients against relapse. To what degree attributions or skills, or both, explain the su-
perior long-term effects of CBT over (discontinued) ADM is an important topic for fur-
ther research.  
 A number of limitations should be mentioned with respect to the data presented 
in this study. Since most patients in Iran have only access to ADM, offering a relatively 
new psychological treatment for depression could attract especially those who prefer 
this new treatment available. Most participants in our sample with recurrent MDD had 
previously received medication treatment, due to accessibility of medication treat-
ment for psychological disorder in Iran. Another limitation is that we used a modified 
version of the instrument constructed by Basoglu et al. (1994), adapted to depression 
and to represent not only medication but also psychological treatment, which was not 
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validated in a previous study. A problem with our approach was that not all items re-
ferred to experiences that participants had in their treatment condition. Although the 
instruction to participants to respond in such cases by rating what they believed did 
not seem to have reduced reliability, and an additional analysis based on items that did 
not suffer from this limitation yielded the same results, future research should im-
prove on this. Moreover, there might be other attribution dimensions that are im-
portant, but are not represented in our questionnaire. Thus, the pragmatic approach 
we choose by modifying Basoglu’s questionnaire had its limitations. Given the positive 
evidence we found for attributions playing a role in long-term effects of BA vs. ADM 
future studies might consider to improve the assessment of attributions. Still another 
limitation is that we restricted the analyses to participants with complete data (who 
happened to be all treatment completers), and dropouts were not included. We are 
not aware of bootstrap mediation tests for approaches that can handle dropouts with 
missing data (like mixed regression), but the exclusion of dropouts limits the results to 
those that complete treatment, whereas attributional processes might also play a role 
in those who dropout from treatment and/or a treatment study. Lastly, although we 
speculated that the new skills acquired in BA may lead to relatively stronger beliefs in 
skills and stronger crediting the self for improvement, we could not test this possibility. 
Also, whether or not attributions are essential for the long-term effects of BA, or just a 
reflection (or even an “epiphenomenon”) of increased and effective skill use after BA 
could not be tested with our data. 
 In conclusion, our study found that long-term effects are predicted by attribution-
al factors. Attribution of effects to medication does not seem to play a role, but attrib-
ution to increased coping capacities and giving credits to the self appear essential. In 
the long-term (at 1 year follow-up), the difference between BA and ADM (with BA > 
ADM) is at least partially mediated by attributions. Moreover, we have evidence that 
the superior long-term effects of BA over ADM at least related to self-attributions, 
which are higher in BA. One interpretation waiting for further study is that offering BA 
to depressed patients help them learn new skills and strategies in coping with prob-
lematic life events, that lead to increased attribution to skills and higher credits to the 
self, that in turn guard them against a relapse into the difficult condition in their life. 
Future studies should investigate the effects of attributions for BA and ADM in other 
clinical settings and cultures. 
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Chapter 6 
General Discussion 
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The current dissertation aimed to compare the effectiveness of behavioural activation 
(BA) and treatment as usual (antidepressant medication (ADM)) for Major Depressive 
Disorder (MDD) in routine clinical practice in Iran. Depression relates to an extensive 
domain of mental health problems specified by the lack of a positive affect (a loss of 
interest and enjoyment in ordinary things and experiences), low mood and a range of 
related emotional, cognitive, physical and behavioural symptoms (Lewinsohn et al., 
2000). In addition to the subjective suffering experienced by those who are depressed, 
the influence on social and occupational functioning, physical health and mortality is 
large. Depressive disorders bring about a greater decrease in health state than major 
chronic physical illnesses like angina, arthritis, asthma, and diabetes (Moussavi et al., 
2007). 
 BA treatment is based on the behavioural component of cognitive behavioural 
therapy (CBT) for treating major depression (Beck et al., 1979). In BA treatment, inter-
ventions are strictly behavioural and specific cognitive techniques are prohibited. BA 
therapists focus on participants’ behaviours and the environmental context in which 
these behaviours occur. Using activity charts to schedule participant’s activities, acting 
according to goals and not to feelings, and monitoring the relationship between activi-
ty and mood are some important techniques in BA treatment. Finding and breaking 
down the pattern of avoidance is vital in BA. BA therapists consider rumination as be-
haviour and address it with behavioural techniques rather than exploring or challeng-
ing the contents of ruminative thoughts. 
 Jacobson et al. (1996) conducted the first RCT on BA, and found that BA was as 
effective as a full CBT package in treating depression. In the subsequent study by the 
same research group, Dimidjian et al. (2006) compared BA with CBT and ADM. The 
results showed that BA was as effective as ADM, and even outperformed CBT in partic-
ipants with severe depression. A study by Ekers et al. (2011) compared BA (delivered 
by nurse practitioners) with treatment as usual in a routine clinical setting and found 
BA to be superior to treatment as usual. 
 The studies in the current dissertation focused on the effectiveness of BA com-
pared to ADM, the effects of comorbidity of personality disorder on depression treat-
ment, the effects of patients’ preference/attitudes towards psychotherapy and ADM, 
and the influence of patients’ attributions of the immediate effects of depression 
treatment on long-term effectiveness of BA and ADM. The main study examined 
whether BA is more effective than ADM in the treatment of MDD (chapter 2). The sec-
ond study concerned the influence of comorbid personality disorder on the effects of 
BA vs. ADM for MDD (chapter 3). Chapter 4 tested the influence of patients’ prefer-
ence/attitude towards psychotherapy and ADM on the treatment of MDD. The fourth 
and the final study was about the influence of patients’ attributions of the immediate 
effects of depression treatment on long-term effectiveness of BA and ADM (chapter 5). 
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This discussion section is organized as follows. The first subsection revolves around the 
question how BA compares to ADM as treatment for depressed people, and in which 
treatment dropout of the patients is less. The second subsection presents the influ-
ence of comorbid personality disorder on the effects of BA and ADM as treatments for 
MDD. We also discuss whether depressed patients comorbid with personality disorder 
respond to BA and ADM similarly to those without comorbid personality disorder. The 
third subsection describes the results of the influence of patients’ preference/attitude 
towards psychotherapy and ADM on the treatment of MDD. This subsection also re-
views whether those patients who received ADM and who at the same time had a low 
preference for or negative attitude towards ADM had a higher chance to drop out of 
treatment than those without such a preference/attitude. The fourth subsection pre-
sents the findings of the influence of patients’ attributions of the immediate effects of 
depression treatment on long-term effectiveness of BA and ADM. We discuss whether 
attribution of treatment effects to the self predicts long-term effects of depression 
treatment and whether attribution of treatment effects to the self mediates the long-
term differences between BA and ADM. Following discussion of the four main issues 
addressed in this thesis, the general conclusions are presented, followed by a discus-
sion of the limitations of the studies. Next, the Iranian context in which the study took 
place, and what it means for the study, and for the effectiveness and suitability of BA 
in particular, is discussed. After that implementation possibilities in Iran are discussed. 
Lastly, future prospects, as well as general clinical and societal implications are dis-
cussed. 
Effectiveness of behavioural activation or antidepressant medication for depressed 
people 
Our study compared BA to ADM and the results showed that BA was superior to ADM 
and even more so in the more severely depressed patients. BA targets the avoidance 
patterns and rumination in depressed people and may have led to the reduction of 
depressive symptoms. The lower treatment dropout from BA than from ADM suggests 
that BA was more acceptable for participants than ADM. The reason for this perhaps 
was that seeing a psychologist is more acceptable than seeing a psychiatrist, which in 
Iran is viewed as indicative of mental illness. Among those who completed the study at 
week 13, remission and response rates for BA were higher than for ADM. After 1–year 
(at 49 weeks) follow-up, 87 out of 100 participants completed assessment and remis-
sion and response rates were higher for BA than for ADM as well. 
 From a BA viewpoint, the likely reason for relapsing after discontinuation of medi-
cation is that depressed patients who are treated with antidepressant and then re-
lapsed, did not change their coping skills. Patterns of avoidance, environmental pun-
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ishment, lack of reinforcement, and depressive rumination might still exist, although 
their effects on mood might have been temporarily reduced by using antidepressants. 
In contrast, BA equips individuals with healthy behavioural skills and thus the probabil-
ity of relapse is reduced. As BA had less dropouts and was also more effective than 
medication, it might offer a viable alternative to medication, especially for those par-
ticipants who prefer non-pharmacological treatment. In a country like Iran, accessible 
treatment for most of the depressed patients is medication. Offering psychological 
treatment like BA attracted more people and it should be considered as a limitation of 
our study. Our results are in line with the findings of three earlier trials (Jacobson et al., 
1996; Dimidjian et al., 2006; Ekers et al., 2011).  
 BA’s relatively simple techniques and strategies can be learned by non-expert 
mental health professionals (Ekers, 2011) and conducted in all clinical settings. The 
finding of our study suggests that other mental health professionals with minimum 
training could disseminate BA techniques. Taken together with the superior effects in 
the subgroup of patients with more severe depression, it pleads for dissemination in 
other routine clinical setting around the globe. 
The influence of comorbid personality disorder on the effects of behavioural 
activation vs. antidepressant medication for major depressive disorder 
Our second study investigated the influence of comorbid personality disorder on the 
effects of BA vs. ADM for MDD. The findings of the study showed that participants with 
comorbid PD had higher scores on BDI and HRSD at baseline and throughout the study 
than participants without comorbid PD. In the acute phase of treatment, both groups 
responded equally well to the short treatment (3 months treatment). After one-year 
follow-up, this parallel development over time was still apparent. Non-significant 
three-way interactions indicate that PD did not moderate the difference between 
treatment conditions. We also repeated the analyses for PD-trait sum score and the 
findings were the same: PD-traits were associated with higher depressive symptom 
scores from baseline on throughout the study, but not with a reduced treatment ef-
fect. However, those participants with comorbid PD had higher dropout of the treat-
ment than those without PD. 
 From the exploration of the effects of the three cluster scores (A-B-C cluster), we 
did not find evidence for moderating effects of cluster scores on treatment differ-
ences. Furthermore, we found that cluster-C PD-traits were associated with generally 
higher levels of depression over the trial, whereas cluster-A and B traits did not have 
this association. For the BDI, we found that cluster-A PD-traits were associated with a 
poorer treatment response over time, for both BA and ADM. These results should be 
interpreted with caution because they were not found on the HRSD. Our results devi-
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ate from those found by Fournier et al. (2008) that Cluster-B PD-pathology was re-
sponsible for the moderation of treatment effects.  
 The findings are consistent with Mulder (2002), Kool et al. (2005), and De Bolle et 
al. (2010). They concluded that the general PD pathology does not have an effect on 
treatment outcome. The results are in contrast to Newton-Howes’s review (2006). 
However, baseline severity was not taken into account in this meta-analysis, so it can-
not be excluded that that the PD effects on depression scores found at follow-up in 
fact reflect differences already present at baseline (Dreessen & Arntz, 1998). 
The influence of patients’ preference/attitude towards psychotherapy and 
antidepressant medication on the treatment of major depressive disorder 
Our third study investigated the influence of patients’ preference/attitude towards 
psychotherapy and ADM on the treatment of MDD. More studies were conducted 
about the influence of patients’ preferences on outcome and dropout for ADM but less 
for psychological treatment. The results of our study showed that participants with a 
lower ADM preference/attitude score had a higher chance to drop out from the ADM 
treatment condition. Those participants with a higher psychological prefer-
ence/attitude score had also a higher chance to drop out from ADM condition. Drop-
out from BA condition was not affected by preference/attitude. Thus, those who pre-
ferred psychological treatment but received ADM had a higher chance to drop out 
from treatment, but the equivalent mismatch was not associated with dropout from 
BA. Three-way preference/attitude psychological treatment × time (squared) × condi-
tion interactions for HRSD showed that preference/attitude psychological treatment 
moderated the difference between treatment conditions after three-months acute 
treatment but this difference disappeared after one-year follow-up. 
 When controlled for treatment preference/attitude, the main outcomes of our 
RCT maintained stable. Dropout from ADM was higher than in the BA condition and 
after controlling for ADM preference/attitude this effect remained significant. Our 
findings on the influence of preference on dropout are in line with Van Schaik et al. 
(2004), Schulberg et al. (1996), and Raue et al. (2009). Our study found that the differ-
ences between BA and ADM in outcome as assessed with the HRSD was moderated by 
preference are consistent with four previous studies reporting the influence of prefer-
ence on outcome (Kocsis et al., 2009; Mergl et al., 2011; Patricia et al., 2005; 
Steidtmann et al., 2012), but in contrast to the seven studies that did not find such 
influences (Bedi et al., 2000; Dunlop et al., 2012; Kwan et al., 2010; Laykin et al., 2007; 
Raue et al., 2009; Van et al., 2009; Ward et al., 2000). 
 In this study, most participants preferred psychological treatment over ADM. One 
explanation for this preference is having had a disappointing previous experience with 
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ADM before entering the study. Another explanation is that providing the relatively 
new psychological treatment attracted more participants with low ADM preference 
and/or high BA preference to the study. 
 
In conclusion, our study found that those participants who received ADM and at the 
same time had a low preference for or negative attitude towards ADM had a higher 
chance to drop out of than those participants without such a preference/attitude. The 
fact that dropout from BA was not influenced by preference/attitude pleads for its 
high acceptability. Overall, taking into account participants’ preference/attitude might 
improve treatment retention and initial response. Investigating the effect of prefer-
ence/attitude for BA and ADM in other clinical settings is recommended for future 
studies. 
The influence of patients’ attributions of the immediate effects of depression 
treatment on long-term effectiveness of behavioural activation and antidepressant 
medication 
Previous studies so far concentrated on the influence of attributions to medication for 
anxiety disorders. Our study investigated the effects of patients’ attributions after 
acute treatment on the long-term outcome of antidepressants and psychological 
treatment (BA). The findings of the study showed that BA and ADM treatment condi-
tions affected attribution types differentially. Participants in ADM condition indicated 
relatively stronger belief in medication and to stronger indifference compared to BA, 
while those in BA condition displayed relatively stronger belief in own coping capabili-
ties and stronger crediting the self for reducing depression symptoms. Participants in 
BA learnt strategies and skills that helped them to cope with problems and the direct 
experience that one’s own actions lead to overcoming problems and consequential 
improvement in mood probably resulted in a stronger belief in coping and stronger 
crediting the self for improvement.  
 The findings of the study indicated that objectifiable depressive symptoms (HRSD) 
were predicted by “belief in coping’’, that is, belief in the effectiveness of given behav-
iours and one’s capabilities to use these behaviours. Therefore, this belief was associ-
ated with a more objective variable (behaviour). However, subjective symptoms (BDI) 
were predicted by feeling good for the improvement made and attributing this gain to 
the self (credits to the self). Perhaps then the results of the study indicate that behav-
ioural skills specifically reduce objective depressive symptoms, while feeling emotion-
ally good lessen subjective depression symptoms. 
 Long-term effects are predicted by attributional factors. In the study, attribution 
of effects to medication does not appear to have a role, but attribution to coping ca-
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pabilities and giving credits to the self seems fundamental. In the long term (at 1 year 
follow-up), the difference between BA and ADM treatment conditions is at least par-
tially mediated by attributions. Therefore, we can infer that the superior long-term 
effects of BA over ADM are at least partially associated with self-attributions, which 
are higher in BA. 
 Our findings on the influence of attribution to the self and belief in one’s own cop-
ing is in line with Brewin and Antaki (1982) suggestion that participants who attribute 
their gains to their own efforts will maintain those gains better than those who attrib-
ute improvement to external attribution such as medication. The results of the study is 
also consistent with Basoglu et al. (1994) study, in that participants who attributed 
their improvement to medication and felt less confident in coping without medication 
had more severe withdrawal symptoms than those who attributed their gains to their 
own efforts. 
 In conclusion, our study found that attribution to increased coping capabilities and 
giving credits to the self seem essential, while attribution of effects to medication does 
not appear to have such a role. The difference between BA and ADM treatment condi-
tions in the long run (at 1 year follow-up) is at least partially mediated by attributions 
(BA > ADM).  
General conclusion 
Overall, from the findings of the four studies in this dissertation we conclude that BA 
treatment could be conducted in clinical settings for those diagnosed with MDD. Our 
study was conducted in a setting where ADM was the standard treatment for MDD 
and most participants had been treated with ADM previously before entering to the 
study. The results confirmed that BA is a viable alternative for ADM. Most participants 
were satisfied with results of the BA treatment. With regard to participating of patients 
comorbid with personality disorder in the study, BA was better in improving symptoms 
in patients but this effect was not influenced for those with comorbid PD. The general 
conclusion is that comorbid PD pathology is related to higher depression severity, es-
pecially for cluster-C PD, but not with less response to treatment. Concerning the pa-
tients’ preference/attitude towards depression treatment, we conclude that patients’ 
preference/attitude influenced dropout from ADM and moderated the short-term dif-
ference in effectiveness between BA and ADM. Concerning the influence of patients’ 
attributions of the immediate effects of depression treatment on long-term effective-
ness of behavioural activation and antidepressant medication, the general conclusion 
is that attribution to increased coping capacities and giving credits to the self appear 
highly important for the long-term effects. The difference between BA and ADM in the 
long-term (after 1-year follow-up) is at least partially mediated by attributions. 
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Limitation of the studies 
A number of limitations should be considered for the studies in this dissertation. First, 
BA therapists were not trained by behavioural activation experts and this might have 
led to suboptimal application of the behavioural activation techniques. The dropout 
rate in ADM treatment condition was relatively high and this could have influenced the 
results. Third, participants in ADM condition after three month of treatment had to 
pay for ADM which might have contributed to discontinuation. Fourth, our prescribed 
medication for ADM participants was sertraline and in the case of non-response, we 
did not change it. However, this was the same for the BA. Fifth, due to financial con-
straint, we did not independently assess treatment integrity and reliability checks of 
the HRSD interviews. Seventh, BA treatment was a relatively new treatment and actu-
ally attracted more participants than ADM which might have biased the sample selec-
tion. Eight, the absence of a control group or placebo condition is another limitation. 
Finally, the majority of our sample was female and although this reflects clinical prac-
tice in Iran, it limits generalizability to male patients. Further studies into non-Western 
male samples are suggested. 
Reflections on the influence of the context of Iranian culture 
As we discussed in chapter 2, most Iranian MDD patients are referred to psychiatrists 
for treatment. Antidepressant medication is the first choice of psychiatrists for treating 
patients with MDD. Most of the patients who entered into our study had previously 
undergone medication treatment. Due to the limited number of psychologists in Iran, 
the most accessible choice for treating psychological disorders is medication. The new 
(at least in Iran) psychological treatment for MDD led to more participants with posi-
tive results than medication. However, this result should be interpreted in the Iranian 
context. Most of the participants had severe avoidance behaviours and the techniques 
and skills taught in BA seemed highly suitable to help these avoidant patients solve 
their problems and equip themselves for the future difficulties. This may be the main 
reason that our BA treatment displayed good results, and why BA did better than 
ADM. Why is avoidance such a prominent problem in Iranian culture? In the view of 
the present author, the traditional culture of Iran teaches children at home or at 
school up to university to be polite and silent in any situation because it is sign of mat-
uration. Iranian children are taught that they do not have the right to protest against 
older people, even in a polite way, or ask others that they change actions or behav-
iours that bother them. As they grow up, Iranian people learn to avoid assertive behav-
iours even though they know that are useful for their life. Thereby Iran people do not 
learn how to cope with situations that call for assertiveness. As a psychologist who 
112 
conducted this study, I learned that most avoidance behaviours of depressed people 
trace back to childhood learning. BA treatment however can detect deficit behavioural 
repertoires, and teach and equip patients with new adaptive behaviours. Thus, the 
results of the present project should especially encourage mental health policy makers 
and mental health professionals in Iran and other similar cultures to consider non-
pharmaceutical treatments for psychological disorders and train more counsellors, 
psychologists and nurses in treatments like BA. Future research can clarify to what 
degree the results of our study depend on the specific Iranian context. 
Dissemination possibilities in Iran 
When I came back to Iran, I presented the results of my study to graduate students of 
the Faculty of Psychology, Science and Research Branch, Azad University, Kurdistan. 
Most of these students expressed their interest in behavioural activation treatment for 
treating MDD. They asked me to teach BA to them. Subsequently, I taught BA to twen-
ty-two M.A graduate students during four days consecutively. All participants in the 
group expressed their interest and willingness to do BA with their MDD patients. The 
likely reason for their interest in BA treatment is the familiarity of the group with cog-
nitive therapy and interpersonal therapy in treatment of depression. Before I taught 
BA skills and techniques, most of them had already discussed the possibility that 
changing beliefs and thoughts is for some depressed patients more difficult than 
changing behaviours. BA treatment was positively received as it matched the idea that 
behavioural change would fit the needs and possibilities of many Iranian patients bet-
ter than cognitive or interpersonal change. The other reason for the positive response 
to BA is that offering BA is simple and doable for inexperienced counsellors and psy-
chologists.  
 After six months, I had a final review session with 18 of the graduate students. 
Approximately 13 of them worked in mental health clinics in several cities in the prov-
ince. They reported that the new BA treatment for MDD patients displayed promising 
results with their patients. In my personal opinion, BA can become a widely accepted 
treatment approach for depression in Iranian mental health care. Learning and imple-
menting BA skills and techniques is for most mental health professionals in Iran (in-
cluding psychologists and counsellors) simpler than cognitive therapy, which is the 
widely accepted treatment for depression. However, more studies are needed to see 
whether BA can be implemented on a larger scale in Iran. The important challenge that 
lies ahead is teaching and training mental health professionals in the skills and tech-
niques of BA. 
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Future prospects 
Our results in this dissertation that BA was superior to ADM and more effective in the 
more severely depressed participants, should be replicated by other groups and in 
other settings. The effectiveness and cost-effectiveness of BA, ADM, and other psycho-
logical treatments such as cognitive therapy, in subsequent trials would be recom-
mended. The other important issue is related to mechanisms of change that are re-
sponsible for the superior effects of BA which needs further investigation to under-
stand the causal pathways that lead to recovery with BA and ADM. 
 As to the second study in this dissertation, it is recommended that further studies 
include more depressed patients comorbid with PD to investigate the effects of specif-
ic PDs on effects of BA or other psychological treatments, since our study had a small 
number of PD patients. As for the third study future studies might use the prefer-
ence/attitude questionnaire in other patients and in different clinical settings. Our 
study was one of the first psychotherapy studies conducted in Iran, and offered a rela-
tively new treatment (BA) that probably attracted more patients with a specific prefer-
ence, which might have created a selection bias. For the fourth study, we used a modi-
fied version of the instrument constructed by Basoglu et al. (1994), adapted to depres-
sion and to not only represent medication but also psychological treatment, which was 
not validated in a previous study. It is likely that there are other important attribution 
dimensions that were not represented in our questionnaire. Future research is needed 
to investigate this questionnaire in other clinical settings. 
Clinical and societal implications 
The results of our study suggest that Behavioural Activation is a simple and effective 
treatment for depression that can be easily disseminated to routine clinical settings. 
Therapists with a minimum of training and supervision delivered BA and it is encourag-
ing for all mental health professionals in the field that results were so positive. BA 
treatment showed superior effects in the subgroup of participants with more severe 
depression, which pleads for its dissemination also in clinical settings where more se-
verely depressed patients are seen. Various mental health professionals, including 
counsellors, psychologists and psychiatric nurses, can deliver this relatively simple 
treatment. Most patients diagnosed with MDD in Iran will receive antidepressant med-
ications after their first referral to a general practitioner or psychiatrist. The findings of 
our study demonstrated that BA treatment is at least as effective as ADM and ac-
ceptable for depressed patients, even for those that are severely depressed. As to the 
cost-effectiveness of BA over ADM, we did not do a formal economic evaluation in the 
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study, but we calculated the total direct costs for BA and ADM. The results favoured 
BA. 
 The results of this dissertation are interested not only for academic community 
but also for all mental health professionals that help depressed patients regularly. The 
skills and techniques taught in BA treatment can be learned and practiced in the short 
term. 
 The findings of this dissertation are relatively new and promising. As it was the 
second study around the world other than Washington University that developed BA 
treatment assessed the effectiveness of BA treatment for depressed patients and dis-
played good results. 
In sum, we conclude that BA treatment can be one of the most effective and cost-
effective treatments for MDD, relatively easy to disseminate, and with a potentially 
great societal impact. 
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Impact of depression on quality of life, health, and society 
Depression is considered by the World Health Organization (WHO) to be the second 
greatest cause of disability in the world (Murray and Lopez, 1997; Mathers CD, Stein C, 
Ma Fat D, et al, 2002; WHO, 2004). Depression is described as a chronic disorder and 
follows a pattern of relapse and remission that is related to illness burdens that falls 
into two broad categories (Klerman and Weissman, 1992). The first is the burden of 
illness experienced by the depressed patients, including discomfort, pain or distress, or 
problems in conducting the activities of daily life. The second is the extensive econom-
ic burden that consists of the costs of providing social and health care, loss of produc-
tivity and time off work, the burden on caregivers, and loss of wages. Moreover, de-
pression has been regarded as a condition that is “chronic and recurrent in nature, 
impairs family life, reduces social adjustment, and is a burden on the community” 
(Klerman and Weissman, 1992). 
 Depression is associated with an extensive domain of mental health problems and 
interferes with the experience of positive well-being. Various components of quality of 
life are influenced by depression. It is quite clear that depression is related to impair-
ment and disabilities in role functioning. Depression can impair social functioning and 
thereby have a negative influence on patients’ life. Thus, by reducing psychological 
well-being, impairing role functioning and depriving patients of social support, depres-
sion may lead to a reduced overall quality of life. 
 In addition to the subjective suffering experienced by those who are depressed, 
the impact on social and occupational functioning, physical health and mortality is 
quite evident. Depressive disorders bring about a greater decrease in health state than 
major chronic physical illnesses like angina, arthritis, asthma, and diabetes (Moussavi 
et al, 2007). 
 Therefore, effective treatment (s) for depression that can be conducted by many 
mental health professionals around the globe that is cost-effective and has enduring 
effects for patients is necessary. Moreover, easy implementation and dissemination of 
the treatment for depression is another issue to be considered. Most patients with 
MDD in Iran will have access to antidepressants (ADM) when they see a general practi-
tioner or a psychiatrist for their first visit. Thus, ADM are commonly prescribed for de-
pressed patients. The results of our study indicated that BA treatment is at least as 
effective as ADM and acceptable for depressed patients, even for those patients that 
are severely depressed. However, the most available treatment for depression is still 
ADM, although psychological treatments often have higher acceptability and better 
long-term effects than ADM. 
120 
Access to treatment in various countries in the world and specifically in Iran 
Antidepressant medications are often prescribed for patients with depression. Because 
of the unavailability of psychotherapies, psychological treatments are not offered in 
primary care (Van Schaik et al., 2004). There is a lack of specialist mental health care 
for depression in rural areas, compared to urban areas (Lambert, Agger, & Hartley, 
1999), and especially the availability of psychotherapy is low in rural areas (Fortney, 
Harman, Xu, & Dong, 2009). There are vast differences in availability of psychological 
treatment for mental disorders when Western countries are compared to non-
Western countries. The median rate of psychologists per 100,000 population working 
in the mental health sector by WHO region is 0.04 for Africa, 1.29 for the Americas, 
0.48 for the Eastern Mediterranean, 2.58 for Europe, 0.03 for South East Asia, and 0.00 
for the Western Pacific (WHO Mental Health Atlas, 2011).  
 In Iran, for instance, the usual treatment for depression is ADM and because of 
the lack of enough mental health professionals, psychological treatments are not 
available for most patients. In rural area and even in urban areas in Iran the provision 
of psychological treatments is very limited (WHO-AIMS Report, 2006). Sanandaj for 
example, where the present study was conducted, has a population of more than 
500.000, but there are only five psychologists available for mental health care. In sum, 
equipment of mental health professionals with a relatively simple treatment like BA 
could be beneficial for the improvement of depression and decrease of mental disor-
ders in society.  
What are the results of our study for patients and societies worldwide and 
specifically in Iran? 
The findings of our study indicated that BA is an effective psychological treatment for 
major depressive disorder. The simplicity to implement BA in clinical settings in com-
parison to the complexity of the implementation of cognitive behaviour therapy should 
appeal to the majority of mental health professionals. In our study, BA therapists had a 
minimum of training and supervision in BA and the results of BA were nevertheless 
very positive. After the short-term treatment (three months) BA was more effective 
than antidepressant medication (Sertraline). Moreover, BA treatment had superior 
effects for the subgroup of patients with more severe symptoms of depression, which 
calls for its dissemination in clinical settings where more severely patients are seen by 
clinicians.  
 The results of our study showed that depressed patients with comorbid personali-
ty disorders (PDs) had a higher dropout rate from treatment, even though the superior 
effect of BA was not influenced by comorbid PD. Among patients who preferred psy-
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chotherapy, but received ADM, dropout from treatment was higher compared to those 
who preferred ADM. Thus, preference influenced treatment completion in case of 
ADM. Interestingly, no association between dropout and preference was found in BA. 
This indicates that BA is a highly acceptable treatment, even for those that initially pre-
ferred ADM. Lastly, patients who attributed their improvement more to factors associ-
ated with themselves better maintained effects on the long-term. BA was associated 
with higher attribution of improvement to the self, which helps to prevent relapse. 
These three additional findings: (1) BA is not less effective in patients with comorbid 
PDs; (2) preference for ADM does not influence dropout and effectiveness of BA; and 
(3) BA has a positive effect on attribution of improvement to the self (which is a factor 
in maintenance of success and prevention of relapse); further plead for implementa-
tion of BA around the world. 
 The findings of BA treatment were positive and promising in the treatment of ma-
jor depressive disorder in Iranian context and could be disseminated in other clinical 
settings in Iran and also around the world. BA treatment could be learned and prac-
ticed by a majority of psychologists, counsellors, psychiatrists and psychiatric nurses. 
Health care costs of depression and cost-effectiveness of BA vs ADM 
In Iran, little research about the social and economic burden of depression has been 
conducted. However, behavioural activation treatment might be a very cost-effective 
intervention for depression. Although our study did not include a formal economic 
evaluation, we calculated that the total direct treatment costs for behavioural activa-
tion amounted to €128 per patient, while the whole direct treatment costs for patients 
treated with antidepressant medication were €198 per patient on average, depending 
on the number of follow-up consultations. A simple index shows the difference be-
tween average costs of BA and ADM per patient, and divides this difference by the 
long-term difference (after 1-year follow-up) in recovery rates. This is the incremental 
cost-effectiveness ratio (ICER). With the cost difference estimated as € 128 - € 198 = € -
70 per patient, and difference at 1 year in remission rates is .66-.28 = .38, the ICER is -
70/.38 = -184. This means that for every extra remitted patient at 1 year, Iranian health 
care wins € 184 when BA treatment is provided instead of ADM. A full economic analy-
sis would involve estimates of all depression related costs that patients make, whether 
health care related or not. For instance, health care costs outside the depression 
treatment (e.g., depressed patients going more often to the GP because of psychoso-
matic complaints; absence of study and work; alcohol use; etc.) should also be as-
sessed and compared between treatments. Thus, the present ICER estimate is a very 
simple one, but given the positive clinical effects of BA on short and long term, lower 
costs in BA compared to ADM treatment in other relevant sectors can be estimated. In 
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short, our study indicates that BA, compared to the standard treatment with Ser-
traline, is a cost-effective treatment, being not only more effective and acceptable to 
depressed patients, but probably also less costly for health care and society as a whole. 
General conclusion 
The current dissertation aimed to compare the effectiveness of behavioural activation 
and antidepressant medication for Major Depressive Disorder in routine clinical prac-
tice in Iran. The findings of our study suggest that behavioural activation is a simple 
and effective treatment for depression that can be easily disseminated to routine prac-
tice settings, similar to what has been demonstrated in Western countries. The fact 
that the behavioural activation was delivered effectively by therapists with a minimum 
of training and supervision is very encouraging, and taken together with the superior 
effects in the subgroup of participants with more severe depression, it speaks for its 
timely dissemination to other routine practice settings as well. Depressed patients 
comorbid with PDs were associated with higher dropout. BA was more effective in 
reducing symptoms in patients, but this effect was not influenced by comorbid PD. 
Those patients who preferred psychotherapy, but who received ADM treatment were 
more likely to drop out from ADM. At the same time, no association between dropout 
and preference was found in BA. Those patients who attributed their improvement 
more to factors associated with themselves did better in the long-term, also in terms 
of relapse prevention. Moreover, behavioural activation might be a very cost-effective 
intervention that could be delivered after a short-term training by psychiatrists, psy-
chologists, counsellors and nurses around the world. 
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Depression is associated with an extensive domain of mental health problems such as 
the lack of positive affect (a loss of interest and enjoyment in ordinary things and ex-
periences), low mood, and a range of related emotional, cognitive, physical and behav-
ioural symptoms. Depressed patients not only experience subjective suffering, but also 
encounter physical health, social, and occupational functioning problems. Depression 
causes a greater decrease in health state than chronic physical illnesses like arthritis, 
asthma, and diabetes. 
 The studies in this dissertation focused on the effectiveness of behavioural activa-
tion (BA) and antidepressant medication (ADM) as treatments for Major Depressive 
Disorder (MDD); the effects of comorbidity of personality disorder on depression 
treatment; the effects of patients’ preference/attitudes towards psychotherapy and 
antidepressant medication; and the influence of patients’ attributions of the immedi-
ate effects of depression treatment on long-term effectiveness of behavioural activa-
tion and antidepressant medication. 
 The main study of the dissertation investigated whether behavioural activation is 
more effective than antidepressant medication. The second study examined the influ-
ence of comorbid personality disorder on the effects of behavioural activation and 
antidepressant medication for major depressive disorder. The third study tested the 
influence of patients’ preference/attitude towards psychotherapy and antidepressant 
medication on the treatment of major depressive disorder. The fourth study investi-
gated the influence of patients’ attributions of the immediate effects of depression 
treatment on long-term effectiveness of behavioural and antidepressant medication. 
Attributions are patients’ beliefs about why they improved in therapy. It has been pos-
tulated that patients who attribute gains to their own efforts are more likely to sustain 
those gains compared to those who attribute improvement to external causes such as 
a drug’s activity or a therapist’s charisma. 
 The results of the main study of the dissertation showed that behavioural activa-
tion was superior to antidepressant medication (Sertraline), especially for patients 
with severe depression. Dropout from treatment was lower in behavioural activation 
compared to antidepressant medication and this pleads for the acceptability of behav-
ioural activation above antidepressant medication among depressed patients. After 
three months of treatment and at 1-year follow-up, the remission and response rates 
for the behavioural activation group were higher compared to the antidepressant 
medication group. 
 The findings of the second study, the influence of comorbid personality disorder 
on the effects of behavioural activation vs. antidepressant medication for major de-
pression disorder, indicated that patients with comorbid personality disorder had 
higher scores on the Beck Depression Inventory and the Hamilton Rating Scale for De-
pression at baseline and throughout the study compared to participants without 
128 
comorbid personality disorder. After three months of treatment, both treatment 
groups responded equally well to the treatments and after one-year follow-up, this 
parallel development over time was still apparent. However, participants with comor-
bid personality disorder showed higher treatment dropout compared to those without 
personality disorder. 
 The findings of the third study on the influence of patients’ preference/attitude 
towards psychotherapy and antidepressant medication on the treatment of major de-
pressive disorder showed that participants who received antidepressant medication 
and at the same time had a low preference for or a negative attitude towards antide-
pressant medication had a higher chance to drop out compared to those participants 
without such a preference/attitude. The fact that dropout from behavioural activation 
was not influenced by preference/attitude pleads for its high acceptability. 
 The results of the study on the influence of patients’ attributions of the immediate 
effects of depression treatment on long-term effectiveness of behavioural activation 
and antidepressant medication showed that behavioural activation and antidepressant 
medication affected attribution types differentially. Participants in the behavioural 
activation group showed stronger beliefs in their own capabilities to improve their 
symptoms of depression. More specifically, those who attributed their improvement to 
factors associated with themselves, showed less relapse. 
General Conclusion 
This dissertation aimed to compare the effectiveness of behavioural activation and 
antidepressant medication for major depressive disorder in routine clinical settings in 
Iran. The findings of our study indicated that behavioural activation is an effective 
treatment for major depressive disorder and can be disseminated in routine clinical 
settings. The fact that behavioural activation can be easily taught to mental health pro-
fessionals and the superior effects in the subgroup of people with more severe depres-
sion, plead for timely dissemination to other routine clinical settings as well. Depressed 
participants with comorbid personality pathology had higher treatment dropout. With 
regard to reducing symptoms in participants, behavioural activation was more effec-
tive, but this effect was not influenced by comorbid personality disorder. Those partic-
ipants who preferred psychosocial treatment, but who received at the same time anti-
depressant medication treatment were more likely to drop out from the antidepres-
sant medication group. However, no association between dropout and preference was 
found in the behavioural activation group. Those participants who attributed their im-
provement to factors associated with themselves did better in the long-term, suggest-
ing that these attributions prevent relapse. Importantly, behavioural activation leads 
to stronger attributions of this kind than medication. Lastly, behavioural treatment 
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might turn out to be a very cost-effective intervention that can be delivered by psychi-
atrists, psychologist, and other health professionals after a short-term training. 
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